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ABSTRACT 
GENERATION OF DIVERSE MOLECULAR COMPLEXITY  
FROM CYCLOOCTATETRAENE 
 
 
Mohamed F. El Mansy, B.Sc, M.Sc. 
 
Marquette University, 2014 
 
 
The use of simple hydrocarbons as starting materials for the synthesis of complex 
molecules relies on efficient methods for oxidation, functionalization or rearrangement. 
For example, various researchers have explored cyclopentadiene or cycloheptatriene as 
precursors for the preparation of a wide variety of drug candidates, natural products and 
synthetic products.  The purpose of this research is to explore methods to transform the 
simple hydrocarbon, cyclooctatetraene (COT) into complex target molecules.   
 
Tricarbonyl (cyclooctatetraene)iron, readily prepared from COT, reacts with a 
variety of electrophiles to form (dienyl)iron cations. These steps may be regarded as 
branching pathways in diversity oriented synthesis.  Reaction of these cations with a 
variety of nucleophiles, followed by oxidative decomplexation gave the corresponding 
racemic polyenes.  Further manipulation of the generated polyenes can be effected by 
cycloaddition, oxidation, oxidative cleavage, rearrangement or reduction.   
 
Utilizing these reactions, a variety of stereochemically diverse polyhydroxy 
aminocycloalkanes (“aminocyclitols”) have been prepared.  The inhibitory activity of 
these aminocyclitols against β-glucosidase (from almonds) was reported.  Conversely, 
ring-rearrangement metathesis of the polyenes containing a pendant olefin tether leads to 
a variety of carbocycles and heterocycles by what can be considered folding pathways in 
diversity oriented synthesis.  This strategy has lead to a number of biologically active or 
natural product-line structures from the simple hydrocarbon cyclooctatetraene in a short 
number of steps. 
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I- INTRODUCTION 
I.1. General Introduction: 
The ability of small molecules to interact with biological systems and perturb 
their function has emerged as a powerful tool for the study of complex biological 
systems.
1,2
 Small molecules that modulate crucial cell signaling pathways have been 
identified via the screening of large libraries of diverse small molecules.
3,4
 Traditionally, 
high-throughput screening (HTS) of large libraries of compounds has been employed to 
identify chemical probes of biological function and as a consequence, lead compounds 
for drug development.
5
 HTS can be used in a “chemical genetic” approach with 
phenotypic assays to identify compounds which promote a particular biological effect.
6
  
Although current small molecule libraries can lead to identification of effective 
modulators of certain targets, the focus has primarily been on a relatively narrow region 
of chemical structure space, the so-called ‘drug-like’ compounds.7 To address the 
important need for modulation of so-called “undruggable” targets, diversity-oriented 
synthesis (DOS) has emerged as a promising approach to generating libraries that explore 
untapped or underrepresented regions of chemical structure space.
8
  
In contrast to target-oriented synthesis, which aims to prepare a specific target 
compound, the goal of DOS is the facile preparation of collections of structurally 
complex and diverse compounds from simple starting materials.
9
  
Structural diversity can be achieved via different ways; incorporation of diverse 
building blocks,
10
 incorporation of a variety of functional groups,
11
 synthesis of 
2 
 
stereoisomeric products
12 
and branching reaction pathways that result in structures with 
widely varying connectivity.
13
 
I.2. The development of DOS approach 
The early examples of DOS chemistry were mainly focused on showing the 
ability to synthesize complex molecules within few synthetic steps. This Structural 
complexity can be efficiently generated in diversity-oriented synthesis through the use of 
tandem reactions, processes involving reactions in which the product is a substrate for the 
next step.
14,15
  
A classic example of generating complex molecules was reported by Schreiber 
and coworkers
16
 where they used tandem reactions in an iterative manner is an especially 
powerful concept that enabled the efficient conversion of simple starting materials into 
complex products. For example, The Ugi four component condensation
17,18
 
 
of the amine 
I-1 to give intermediate I-2 followed by intramolecular Diels Alder reaction
19
 generates 
complexity by formation of a alkene within a five-membered ring I-3. After addition of 
two allyl groups to provide I-4, Schreiber and coworkers introduced additional 
complexity through a subsequent ring-opening/ring closing metathesis reaction, thus 
forming a complex product I-5 containing two five membered and two seven-membered 
rings  (Scheme-I-1).
16
 
3 
 
 
Scheme I-1. Tandem Ugi-Diels-Alder-Ring Opening/Closing Metathesis. 
More recent DOS approach is directed to rapidly make complex molecules that 
have useful biological applications or share the structural features with other natural 
products.
20,21
 In an attempt to use DOS chemistry to make natural product like 
compounds, Martin and coworkers reported the synthesis of diverse heterocyclic cyclic 
scaffolds via sequential reactions.
22
 A one-pot multicomponent reaction of o-
bromobenzaldehyde I-6 with allylamine followed by attack of allylzinc nucleophile gave 
allylamine derivative I-7 (Scheme I-2). Ring closing metathesis of I-7 followed by Heck 
cyclization reaction gave the corresponding bridged azabicyclic structure I-8 which has a 
framework similar to that in naturally occurring methylated morphine (also known as 
codeine) which has analgesic, antitussive, antidiarrheal, antihypertensive, anxiolytic, 
antidepressant, sedative and hypnotic properties.
23
  
4 
 
 
Scheme I-2. Sequential ring closing metathesis/Heck cyclization. 
The same research group presented the synthesis of compounds containing 
isopavine skeleton which has interesting biological activities.
24
 Condensation reaction of 
methyl amine with piperonal I-9 followed by reaction with Grignard reagent I-10 then 
diacetoxyacetyl chloride gave amide I-11 which upon treatment with HCl and methanol 
afforded roelactamine I-12 in a good yield (Scheme I-3).
22
 
 
Scheme I-3. Preparation of isopavine containing structure. 
A high –throughput screening campaign of about 12,000 diverse chemical 
compounds containing pure natural products and DOS libraries was conducted to search 
for antimalarial agents with potential new mechanisms using a phenotypic growth 
inhibition assay against the  blood-stage parasite of malaria.
25–27
 This search led to the 
identification of the lead racemic spiroazepineindole
28,29
 I-13 with moderate potency in 
5 
 
both wild type (NF54) and chloroquine resistant (K1) of IC50 in nanomolar scale (Figure 
I-1). 
 
Figure I-1. Discovery of spiroazepineindole I-13. 
This discovery of I-13 initiated structure activity relationship studies to optimize 
its potency and in vivo activity. Yeung and coworkers
30
 reported the synthesis of new 
derivatives which are more potent than I-13. Vilsmeyer−Haack formylation31 of the 
indole followed by condensation with nitroethane gave the corresponding nitroalkenes I-
14 and I-15 (Scheme I-4). Reduction I-14 followed by condensation with 5-chloroisatin 
provided racemic I-16 and I-17. The 1R,3S and 1S,3R enantiomers were then resolved by 
chiral chromatography to give (+)-I-16 and (+)-I-17. 
 
6 
 
  
Scheme I-4. Preparation of isopavine containing structure. 
I.3. Aminocyclicpolyols  
Polyhydroxyl aminocyclic compounds are important synthetic targets and 
attractive candidates for diversity-oriented synthesis. Polyhydroxyl aminocyclohexanes, 
best known as “aminocyclitols” are reported to be glycosidase inhibitors and they are also 
present as aglycon units of numerous aminoglycoside antibiotics, e.g., streptomycin and 
fortimycin, which possess inhibitory activity against various glycosidases.
10
  
The glycosidic bond, shown in (Figure I-2), is the exocyclic ether linkage between 
two sugar units. This bond is known to be very stable towards hydrolysis; in particular, 
the linkage between two sugar residues is known to be the most stable within naturally 
occurring biopolymers which include polypeptides and nucleic acids.  
7 
 
 
Figure I-2. Glycosidic bond between two sugar residues. 
Enzymes that cleave glycosidic bonds are called "glycoside hydrolases" or 
"glycosidases". The mechanisms of the glycosidic bond hydrolysis have been extensively 
studied.
32–34
 Hydrolysis can be achieved with retention of configuration at the anomeric 
carbon as shown in scheme I-5, where the enzyme active site involves two carboxylic 
acidic residues ~ 5.5 Å apart. The hydrolysis starts with one of the acidic residue which 
acts as a general acid catalyst that protonates the glycosidic oxygen followed by bond 
cleavage forming the oxocarbenium ion. Stabilization of the generated oxocarbenium ion 
is achieved by forming a covalent glycosyl–enzyme bond with the other acid residue in 
the enzyme active site. Eventually in the presence of a water molecule attack takes place 
at the anomeric center facilitated by the carboxylate general base.
34 
 
Scheme I-5. Mechanism of the hydrolysis of glycosidic bond with retention of 
configuration at anomeric carbon. 
8 
 
Researchers extensively studied the transition-state of glycosidase inhibitors and 
proposed different intermediate compounds that mimic both exo and endo positively 
charged oxygen intermediate in the enzyme active sites.
34,35
 To mimic the positive charge 
that developed during this mechanism, many researchers showed cycltitols containing 
amine group at pH < 5 will be protonated and form the analogue of the positively charged 
oxygen in the enzyme active site.
36
 
Alternatively, other glycosidases proceed via a different mechanism with 
inversion at the anomeric center as illustrated in figure I-3. In this mechanism the 
hydrolysis starts with enhancing the nucleophilicity of water molecule by an enzymic 
general base. The hydroxyl anion attacks the anomeric center leading to departure of the 
aglycon and is assisted by a general-acid catalytic group on the enzyme active site.
37 
 
Figure I-3. Mechanism of the hydrolysis of glycosidic bond with inversion of 
configuration at the anomeric carbon. 
Due to the importance of aminocyclitols, several attempts to synthesize them and 
their derivatives have been reported. For example synthesis of quercitols 
(deoxyinositols)
38,39 
from inositols where they start from a single optically active cyclitol 
and selectively converting it by deoxygenation
40
 to amine functionality to give two 
9 
 
diastereomeric aminocyclitols. Also carbohydrates have been used to synthesize 
aminocyclitols using Ferrier carbocyclic ring-closure,
41,42 
from oximes through 6-exo 
radical cyclization of carbohydrates,
43
 and from chiral 1,7-octadienes via ring closing 
metathesis have been reported.
44,45
 
I.4. Medicinal chemistry of aminocyclitols 
Aminocyclitols show a variety of biological effects including antibiotic, antiviral, 
anticancer activities.
46
 The aminoglycoside antibiotics are a family of natural products in 
which diaminocyclitols are connected to different sugar units.
47
 The 1,3-diaminocyclitols 
are the most common scaffold in this class of compounds which possess antibacterial 
activity. It was found that most of the 1,3-diaminocyclitols contain 2-deoxystreptamine as 
part of their structures.
48
 Neomycin,
49
  kanamycin,
50
 gentamicin,
51
 tobramycin,
52
 
sisomicin,
53
 verdamicine
54
 and lividomycin
55
 are representative examples of 2-
deoxystreptamine-containing aminoglycosides (Figure I-4). 
10 
 
 
Figure I-4. Representative structures of 2-deoxystreptamine-containing aminoglycosides. 
While 1,3-diaminocyclitols show activity against both gram positive and gram 
negative bacteria, 1,2-diaminocyclitols also show interesting biological activity. 1,2-The 
diaminocyclohexitol oseltamivir, (Tamiflu®) which is a very potent inhibitor of influenza 
neuraminidase.
56
 Llebaria’s research group discovered the new 1,2-diaminocyclitol I-18, 
a β-glucocerebrosidase inhibitor and with potential therapeutic applications for Gaucher 
disease (Figure I-5).
57 
 
11 
 
 
Figure I-5. Representative structures of 1,2-diaminocyclohexitols. 
Aminocyclohexitols have been extensively studied as glycohydrolase inhibitors, 
due to the ability of aminocyclohexitols to mimic the protonation of the exocyclic oxygen 
intermediate in glycosidic bond hydrolysis.
34
  
Similar to 2-deoxystreptamine (Figure I-4) a building unit for 1,3-
diaminocyclitols, valienamine (Figure I-6), was first isolated from the microbial 
degradation of validoxylamine A with Pseudomonas denitrificans,
58,59
 is an essential 
component in many glycosidase inhibitors.
60
 Valiolamine and validamine, which were 
isolated from the fermentation broth of Streptomyces hygroscopicus subsp, inhibit α-
glucosidases and combat bacterial diseases in rice plants.
61
 Hydroxyvalidamine
62 
also 
exhibits glycosidase inhibition activity while validamycin A is used to treat sheath blight 
disease in rice.
63,64
 Acarbose, which was discovered in a target-directed screening from 
the culture broth of Actinoplanes spec,
65
 is currently used for the treatment of type II 
insulin-independent diabetes.
66  
12 
 
 
Figure I-6. Representative examples of valienamine based structures. 
Ogawa and coworkers synthesized dimeric  compounds derived from validamine, 
validamine or valiolamine (Figure I-7), which exhibit trehalase inhibitory activity.
67–69
 
The same group also reported the synthesis of new α-glucosidase inhibitors I-19 in which 
valinamine is linked to a sugar moiety containing a 1,6-anhydrobridge.
70
 
13 
 
 
Figure I-7. Trehalase inhibitors incorporating dimeric aminocyclohexitols and α-
glucosidase inhibitors. 
Due to the potent inhibition that was observed for valioamine against sucrase 
(IC50 = 49 nM),
61
 several medicinal chemistry studies were carried out that led to 
voglibose, a therapeutically useful antidiabetic agent (Figure I-8).
71
 Structurally related 
compounds were synthesized but they showed less potency towards glycosidase 
inhibition.
72 
 
 
14 
 
 
Figure I-8. Volibose, antidiabetic agent. 
Synthesis of β-valienamine and β- validamine also led to the discovery of a new 
series of glygosidases inhibitors. For example, compound I-20 showed to be potent and 
selective GlcCer β-glucosidase inhibitors for both E and Z isomers with IC50 values 0.3 
μM and 0.1 μM respectively.73 Modification of N-substituent in β-valienamine to N-octyl 
to give N-octyl- β-valienamine (NOV) which turned out to be the most potent inhibitor of 
GlcCer β-glucosidase with IC50 = 0.03 μM
74
 and also as pharmacological chaperone for 
Gaucher disease.
75
 Further studies on NOV led to discovery of N-octyl-4-epi-β-
valienamine (NOEV) which was found to be potent inhibitor for lysosomal β-
galactosidase and potential pharmacological chaperone Morquio B disease (Figure I-9).
76
 
15 
 
 
Figure I-9. Examples of GlcCer β-glucosidase and lysosomal β-galactosidase inhibitors. 
I.5. Implementation of an organoiron approach to DOS 
Recently, Donaldson’s group was the first to report the synthesis of a family of 
diverse stereoisomeric aminocyclitols using an organoiron approach.
77
 [(η5-
Cyclohexadienyl)Fe(CO)3]
+
 cation I-22 was easily prepared from 1,3-cyclohexadiene I-
21 
78–80
 followed by nucleophilic attack of potassium phthalimide (KNPhth) at the dienyl 
terminus of the symmetric cation I-22 to give (±)-I-23. Oxidative decomplexation of (±)-
I-23 using CAN/MeOH gave the free diene (±)-I-24 (Scheme I-6).
77 
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Scheme I-6. Synthesis of (Cyclohexadienyl)phthalimide (±) I-24. 
Singlet oxygen cycloaddition of (±)-I-24 resulted in a separable mixture of 
endoperoxides (±)-I-25 and (±) I-26, which upon reduction with thiourea gave (±)-I-27 or 
(±)-I-28 respectively. The OsO4 catalyzed dihydroxylation of (±)-I-28 afforded (±)-I-30 
while for (±)-I-27 dihydroxylation gave (±)-I-29. Epoxidation of (±)-I-27 using meta-
chloroperbenzoic acid produced (±)-I-31 which undergoes epoxide ring opening under 
acidic conditions followed by acetylation to give a mixture of diastereomeric tetraacetates 
(±)-I-32 and (±)-I-33 (Scheme I-7).
77
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Scheme I-7. Synthesis of diverse stereoisomeric  aminocyclitols from endopeoxide 
compounds. 
 The metal-mediated rearrangement
81–83
 of endoperoxide compound (±)-I-25 
using Grubbs’ (II) catalyst through inner sphere radical mechanism yielded the 
corresponding bisepoxide compound (±)-I-34 which on hydrolysis gave (±)-I-30 
(Scheme I-8). Kornblum DeLaMare rearrangement
84
 of (±)-I-25 gave compound (±)-I-36 
as the major product along with a mixture of two other rearrangement regioisomers in 
lesser yield. Reduction of (±)-I-36 under Luche conditions
85
 gave (±)-I-37 followed by 
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osmium catalyzed dihydroxylation then acetylation where a mixture of two 
diastereomeric tetraacetates, (±)-I-38 and (±)-I-39  is obtained.
77
 
 
Scheme I-8. Utilizing rearrangement reactions to generate sterochemically diverse of 
aminocyclitols. 
Brief dihydroxylation of (±) I-24 gave the diol (±)-I-40 which was again treated 
with osmium tetraoxide to provide (±)-I-41, while the epoxidation of (±)-I-40 gave the 
monoepoxide derivative (±)-I-42 (Scheme I-9).  Notably, stereochemical outcome of this 
transformation follows Henbest’s model86 in which the allylic hydroxyl group directs 
peroxide mediated epoxidation onto the same face of the olefin. Epoxide ring opening of 
(±)-I-42 followed by acetylation gave (±)-I-43.
77
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Scheme I-9. Synthesis of aminocyclitols using dihydroxylation and epoxidation 
reactions. 
I.6. Exploring the expanded homologs of aminocyclitols   
 The interesting biological activity of aminocyclitols, motivated chemists to 
explore the preparation of expanded aminocyclic polyols. The synthesis of the 7-
membered carbocycles (I-44, I-45, I-46, I-47) shown in Figure I-10 has been reported by 
the groups of Casiraghi
87 
and Landais.
88 
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Figure I-10. Partial list of recently synthesized seven-membered carbasugars. 
Johnson et a
89
l reported the synthesis of aminoheptatriols I-54 and ent-I-54 
starting from cycloheptatriene I-48 which was oxidized to tropone I-49 according to the 
literature
90
 (Scheme I-10). Reduction of tropone with sodium borohydride, 
diacetoxylation utilizing procedure developed by Backval1,
91
 protection of the alcohol as 
mesylate followed by displacement of mesylate using NaN3 to give azide derivative I-50. 
Chemoselective reduction by hydrogenolysis of I-50 to unsaturated amine  I-51 using 
Lindelar catalyst
92,93
 then protection of the resultant amine as carbamate derivative I-52. 
Enzymatic asymmetric acetylation of I-52 with Amano P-30 lipase in presence of 
isopropenyl acetate gave the corresponding monoacetate derivative I-53 in very high 
enantiomeric excess (>98% ee). Conversion of I-53 to the corresponding enatiomers of 
protected diols followed by hydroboration-oxidation to give the desired products I-54 and 
ent-I-54. 
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Scheme I-10. Synthesis of aminoheptatriols from cycloheptatriene. 
Casiraghi reported aldol-type condensation catalyzed by Lewis acid between 
aldehyde I-55 (prepared from (+)-tartrate) and pyrrole derivative I-56 afforded the 
unsaturated lactam I-57 as a single diastereomer (Scheme I-11). Nickel catalysed 1,4 
reduction of the α,β-unsaturated lactam followed by protection of the hydroxyl group 
gave I-58. Exchange of the N-protecting group then selective deprotection followed by 
Swern oxidation afforded the aldehyde I-60. Intramolecular aldol condensation of I-60 
followed by protecting the resultant hydroxyl group as a silyl ether gave compound I-61 
as a single diastereoisomer. Swapping the protection of N-protecting group from a benzyl 
to a t-butylcarbonate group followed by reductive cleavage of the amide bond and acid 
hydrolysis afforded the aminocycloheptitol I-63.
94
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Scheme I-11. Synthesis of aminocycloheptitol I-63 from (+)-tartrate. 
Casiraghi’s group also reported the synthesis of densely hydroxylated 
cycloheptane amino acids I-71 and I-72 via succession of a vinylogous Mukaiyama aldol 
reaction (VMAR)
95
 by reaction of pyrrole-based dienoxy silane I-64 and (S)-protected 
glyceraldehyde (S) I-65 using SnCl4 as Lewis acid gave I-66 as a single diastereoisomer 
(Scheme I-12). Installation of a second polyol appendage at the α-position of the lactam 
moiety was achieved via Morita-Baylis-Hillman reaction
96
 upon treatment with both (S) 
and (R) glyceraldehyde derivatives leading to the major products I-67 and I-68 
respectively. Several steps involving reduction of the double bond using hydrogenation in 
presence of palladium as a catalyst, protection of the hydroxyl group, exchange of the N-
23 
 
protecting group to an acetyl followed by diol cleavage afforded the dialdehydes I-67 and 
I-70. Separate intramolecular pinacol coupling of either I-69 or I-70 followed by 
hydrolysis and deprotection provided amino acids polyols I-71 or I-72 respectively.
87
 
 
Scheme I-12. Synthesis of I-49 and I-50 from pyrrole-based dienoxy silane. 
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The Landais’s research group managed to desymmetrize 7-
(dimethyl)phenylsilylcycloheptatriene and through consecutive dihydroxylation and acyl-
nitrosocycloaddition to synthesize new aminocycloheptitols. They converted tropylium 
fluoroborate I-73 into cycloheptatriene I-74 using a bis-silyl zinc reagent (Scheme I-13). 
Sharpless asymmetric dihydroxylation using a modified AD-mix containing quinuclidine 
as the chiral ligand followed by protection of the diol with acetyl groups to give I-76. 
Diels-Alder cycloaddition of the diene I-76 with an acyl-nitroso as adienophile afforded 
three isomers I-77, I-78 and I-79. Hydrogenation of the major cycloaddition adduct I-77 
then C-Si oxidation under Felming conditions
97
 followed by acetylation of the resultant 
hydroxyl group yielded I-82. N-O reductive cleavage using Mo(CO)6 of I-82 followed by 
deprotection of the amine group gave the final product I-85.
88
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Scheme I-13. Synthesis of I-63 from commercially available tropylium fluoroborate. 
I.7. Eight-membered ring aminocyclitols 
Andriuzzi and others
98
 reported the synthesis of aminocyclooctitols starting from 
3,4-o-methylethylidene-L-ido-bisepoxide I-86.
99
 
 
Double epoxide ring opening of I-86 
using excess of lithium divinylcyanocuprate
100
 led to the formation of the free diol 
compound I-87 (Scheme I-14). Silylation of I-87 gave the corresponding protected 
compound I-88. Ring closing metathesis using Grubbs’ I catalyst afforded the 
corresponding cyclooctenes I-89. Hydroboration of I-89 followed by in situ oxidation
101
 
to give I-90. Reductive amination of I-90 followed by hydrolysis gave the 
aminocyclooctitol I-91. 
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Scheme I-14. Synthesis of aminocyclooctitol I-91 from L-ido-bisepoxide. 
In the same study
98
 they used D-manno bisepoxide I-92 as starting material. 
Similarly, double epoxide ring opening, protection, ring closing metathesis, 
hydroboration then oxidation followed by reductive amination and finally deprotection 
resulted in aminocyclooctitol 1-97 (Scheme I-15). 
 
Scheme I-15. Synthesis of aminocyclooctitol I-97 from D-manno bisepoxide. 
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In the same year the same research group reported the synthesis of new 
aminocyclooctitols.
102
 Catalytic dihydroxylation of compounds I-89and I-95 gave cis diol 
compounds I-98 and I-99 respectively (Scheme I-16). Treatment of I-98 and I-99 with 
thionyl chloride in the presence of triethyl amine followed by oxidation with sodium 
periodate in the presence of ruthenium trichloride gave the corresponding cyclic sulfates 
I-100 and I-101. Nucleophilic opening of these sulfates followed by acidic hydrolysis 
gave the corresponding azido alcohols I-102 and I-103. Reduction of the azide 
functionality in both I-102 and I-103, using hydrogen in the presence of palladium black 
generated the desired amino derivatives which upon hydrolysis provided the 
aminocyclooctitols I-104 and I-105.  
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Scheme I-16. Synthesis of aminocyclooctitol I-104 and I-105. 
I.6. Bicyclic cyclitols 
A survey of the literature identified only a few examples for bicyclic cyclitols, all 
of which contain a 6-membered ring fused either to a 3- or 4-membered ring. Balci’s 
group accomplished the synthesis of a new class of bicyclic compounds named as bis-
homoconduritol D, E and F.
103
  Starting from cyclooctatetraene I-106 (Scheme I-17), 
29 
 
dibromide I-107 was prepared followed by singlet oxygen cycloaddition, endoperoxide 
reduction using thiourea and subsequent acetylation to give the diacetate I-107. Syn 
dihydroxylation and acetyl protection followed by Zn-reductive elimination reaction and 
eventually deprotection afforded bis-homoconduritol D. The bicyclic diacetate compound 
I-107 underwent epoxidation followed by Zn-reductive elimination of the dibromide, 
acetylation and finally deprotection to give bis-homoconduritol F. To obtain bis-
homoconduritol E, chlorination was used instead of bromination because it was presumed 
that the endo-oriented bromine atom in I-107 determines the stereoselectvity of 
hydroxylation and epoxidation reactions. In a similar fashion to the synthesis of bis-
homoconduritol D, bis-homoconduritol E was prepared in a 1:1 ratio.
103
  
 
Scheme I-17. Synthesis of bis-homoconduritol D, E and F. 
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Bennet and coworkers 
104
 reported the synthesis of two bicyclic aminocyclitols; 
one of these was a potent inhibitor of α-galactosidase (Scheme I-18). They started the 
synthesis with D-galactose derivative I-108 which can be made in two steps from methyl 
α-D-galactopyranoside. Reduction of hemiacetal I-08, selective protection of the primary 
alcohol as the trityl ether then Swern oxidation followed by Wittig olefination gave olefin 
I-109. Deprotection of the primary alcohol, Swern oxidation followed by Grignard 
reaction with vinylmagnesium bromide gave an equimolar mixture of R and S 
diastereomers. This mixture undergoes ring closure metathesis reaction with Grubbs’ II 
catalyst to give a mixture of cyclohexene diastereomers that were separated using radial 
chromatography.
105
 Conversion of the  minor allylic alcohol R I-111 into an allylazide 
functionality proceeded with inversion of configuration to give allylic azide I-112 along 
with small amount of SN2’ product I-113. Cyclopropanation of I-112 using a 
Furukawa
106
 modification of the Simmons-Smith reaction gave a separable mixture 
cyclopropyl isomers I-114and I-115 with over all yield 88%. Deprotection of the benzyl 
groups by hydrogenation and hydrolysis of the amide groups gave the final bicyclic 
aminocyclitols I-116 and I-117.
104 
 
 
31 
 
 
Scheme I-18. Synthesis of bicyclic aminocyclitols I-116 and I-117. 
I.7. Cyclooctatetraene as a simple starting material 
As part of our long term interest to extend the organoiron approach to the 
preparation of aminocycloheptitols, we considered the use of cyclooctatetraene as a 
starting material. A literature survey showed that many research groups have used 
cyclooctatetraene I-105, which is a simple  hydrocarbon readily made from acetylene by 
Ni-catalyzed cyclotetramerization.
107–109
 Different complex molecules, for example 
aminocyclohexitols,
110
 bis-homoconduritols (vide supra),
103 
bis-homoinositol,
111
 and 
cyclooctitols
112
 (Figure I-11) have been synthesized from cyclooctatetraene I-106. 
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Figure I-11. Synthesis of cyclooctatetraene and target recently prepared from this 
hydrocarbon.  
The complexation of iron pentacarbonyl with cyclooctatetraene I-106 gives 
tricarbonyl(cyclooctatetraene)iron I-118 [(COT)Fe(CO)3] in a quantitative yield (Scheme 
I-19).
113
 The number of publications that report on reactions of I-118 are very small. For 
instance, upon treatment of I-118 with a Lewis acid (AlCl3) it rearranges to form a -
alkyl- -allyl complex I-119 which undergoes decomplexation followed by carbonyl 
insertion in the presence of a high pressure of CO to give barbaralone I-120.
114
 Paquette 
and coworkers showed that reaction of I-118 with tetracyanoethylene afforded bicyclic 
-alkyl- -allyl complex I-121 which undergoes oxidative decomplexation using ceric 
ammonium nitrate (CAN) and further rearranges to form tricyclo[5.2.1.0
4,10
]deca-2,5-
diene I-122. Hydrolysis of the tetranitrile I-122 using conc. HCl gave the acid lactone I-
123 followed by reaction of lead tetraacetate and iodine while irradiated with 250-W 
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tungsten lamp to give I-124. Mild hydrolysis and dehydroiodination of I-124 gave a 
carboxylic acid which upon reaction with diazomethane afforded the methyl ester I-125. 
The third double bond was introduced by dehydration of  I-125 followed by 
saponification using KOH gave the final product (-)-triquinacene-2-carboxylic acid I-
126.
115–117
 
 
Scheme I-19. Preparation of (COT)Fe(CO)3 and previous synthetic applications. 
Interestingly enough, I-118 behaves differently with different electrophiles.  The 
electrophilic iminium cation which is generated from the Vilsmeyer-Haack formylation 
reaction
31
 of the dimethyl formamide with phosphorus oxychloride is attacked by the 
electron rich complex I-118 to give I-127 (Scheme I-20).
118
 In a similar fashion 
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tropylium cation reacts with I-118 in the presence of one equivalent of pyridine to give 
styrylcycloheptatriene complex I-87. Reaction of complex I-118 with H
+
 or p-
nitrophenyldiazonium ion gave [5.1.0] bicyclic structures (I-129, I-130) and reaction of 
I-118 with cyclopropenyl cation afforded polycyclic structures (I-131 a,b) while with 
acylium cation electrophiles gave [3.2.1] bicyclic compounds (I-132a,b).
119–124
 
 
Scheme I-20. Reactions of I-118 with electrophiles to generate cationic and neutral 
compounds.  
A mechanistic rationale for the formation of these rearranged structures has been 
proposed by Connelly and co-workers. Upon the addition of an electrophile to a non-
coordinated olefin of I-118 produces cation I-134 (Scheme I-21); which further 
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rearranges into a cyclopropylcarbinyl cation of structure I-135. In case of H
+
 or p-
nitrophenyl
+
, the bicyclo[5.1.0]octadienyl cation I-135 was stable and isolable (i.e. 
products I-129/ I-130).
120–122
  
 
Scheme I-21. Generic attack of electrophile on (COT)Fe(CO)3. 
If the electrophile is an acylium cation, the acyl group present at C7 of I-135 
weakens  the adjacent cyclopropane bond leading to a [1,4]-shift to relieve the strain of 
the cyclopropane ring and to form the bicyclo[3.2.1]octadienyl cation I-132a,b (Scheme 
I-22).
123,124 
If the electrophile is the tropylium cation, I-135 undergoes a [3,3] Cope 
rearrangement to generate the norcaradiene intermediate I-136; in order to re-attain the 
aromaticity it loses one proton to give the styrylcycloheptatriene complex I-137.
119
 
Finally, for cyclopropenyl cation as electrophile, I-134 rearranges to a 
bicyclo[6.3.0]nonatetraenyl cation I-138 followed by transformation into a tricyclic 
cation I-131a,b through an intramolecular bond formation. 
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Scheme I-22. Proposed mechanism for the generation of the skeletal rearranged products. 
Donaldson’s group reported the synthesis of (±)-cis-2-(2’-
carboxycyclopropyl)glycine I-142 through the nucleophilic attack of phthalimide anion 
on the cationic compound I-129b at the terminal carbon to give complex  I-139, followed 
by oxidative decomplexation to give the free diene I-140. Catalytic Sharpless oxidation 
using sodium periodate as oxidant in excess amount and esterification yielded I-141. 
Hydrolysis of I-141 followed by free base generation provided the desired final product 
(±)-cis-2-(2’-carboxycyclopropyl)glycine I-142 (Scheme I-23).125 
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Scheme I-23. Synthesis of (±)-cis-2-(2’-carboxycyclopropyl)glycine from I-129b.  
The nucleophilic attack of triphenyl phosphine on I-132b gave the corresponding 
triphenylphosphonium cation I-143 while reaction of I-132b with lithium 
dimethylmalonate gave compound I-144 (Scheme I-24). Methyl nucleophile also attacks 
I-132b which undergoes oxidative decomplexation to give I-145. Nucleophilic attack of 
hydride anion gave the olefin I-146. In a similar fashion phthalimide anion attacks I-132b 
to give the corresponding phthalimide derivative I-147 followed by decomplexation to 
give the free diene I-147. Chemoselective double bond hydrogenation then cleavage of 
the remaining double bond and finally Fisher esterification afforded I-149.
126
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Scheme I-24. Reactivity of I-132b with various nucleophiles and synthesis of protected 
amino acid analog I-149. 
In order to create more structural diversity of cyclooctatetraene, recently 
Donaldson’s research group studied the reactivity of compounds I-128, I-129b and I-
132b towards allylmalonate nucleophile. Nucleophilic attack of allylmalonate on cation 
I-132b followed by oxidative decomplexation afforded I-150. Ring rearrangement 
metathesis reaction of I-150 with Grubbs’ 1st generation catalyst gave I-151 (Scheme I-
25).
127
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Scheme I-25. Ring rearrangement metathesis reaction of I-150. 
Reaction of I-129b with allylmalonate nucleophile then decomplexation using 
CAN gives (±) I-152. Treatment with Grubbs’ 1st generation catalyst produces ring 
rearrangement product (±) I-153 (Scheme I-26).
128
 
 
Scheme I-26. Ring rearrangement metathesis reaction of (±) I-152. 
Finally reaction of I-28 with tetrafluoroboric acid gave the corresponding cation 
I-154 which reacts with allylmalonate nucleophile followed by oxidative decomplexation 
to generate free tetraene compound (±) I-155. Ring closure metathesis reaction with 
Grubbs’ I catalyst gives bicyclic triene intermediate (±) I-156 that undergoes olefin 
isomerization to produce the final compound (±) I-157 as shown in scheme I-27.
129
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Scheme I-27. Ring rearrangement metathesis reaction of (±) I-155. 
In this introduction part we showed some representative examples of the different 
synthetic approaches for making aminocyclitols where the major limitation in all these 
methods is the limited number of aminocyclitols which can be obtained using each 
synthetic route. Another disadvantage is the use of starting materials which in certain 
cases are expensive or difficult to make. 
 In this work we aim to further generate molecular complexity and structural 
diversity from cyclooctatetraene and to provide more examples of aminocycloheptitols. It 
is also planned to access the here-to-fore unknown bicycle[5.1.0] aminopolyols as a new 
class of compounds using organoiron chemistry. These latter compounds will be tested 
for their inhibition towards a commercially available glucosidase. 
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II- RESULTS AND DISCUSSION 
II.1. Generation of diverse molecular complexity using dienyliron approach 
 Electrophilic addition of the phenacylium cation (generated from reaction of 
aluminum chloride and phenacyl chloride) to tricarbonyl(cyclooctatetraene)iron I-118 
according to prior literature led to the formation of (dienyl)iron cation I-132b.
123
 
Reaction of this cation (±)-I-132b with the potassium salt of (allyl)tosylamine followed 
by oxidative decomplexation using cerium ammonium nitrate gave 
benzoylbicyclooctadienyl-N-tosylamine (±)-II-1 (Scheme II-1). The 
1
H NMR spectrum 
of the free ligand shows a signal characteristic for the methyl protons of the tosyl group at 
δ  2.43 ppm (3H) and the diastereotopic methylene protons of the N-tosyl allylamine 
appeared at δ 3.98 ppm (1H) and 4.13 ppm (1H) along with 9 aromatic protons. In the 13C 
NMR spectrum of (±)-II-1, characteristic peaks for the sulfonamide appear at δ 143.6 
ppm and for the ketone at δ 199.4 ppm. 
 
Scheme II-1. Preparation of free ligand (±)-II-1. 
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 The reaction of (±)-II-1 with Grubbs’ 1st generation catalyst led to the ring 
rearrangement metathesis (RRM) product (±)-II-2 (eqn. II-1). The NMR spectral data for 
(±)-II-2 supports the proposed structure, particularly the signal at δ 3.39-3.46 ppm which 
is characteristic for the allylic proton of the cyclopentene ring and the protons at range of 
δ 4.02-4.10 ppm (2H) which are characteristic for the dihydropyrrole ring at position 5.130 
 
 The synthesis of bicyclo-N-tosyl allylamine (±)-II-4 was achieved by reaction 
of cyclooctatetraene I-106 with iron pentacarbonyl to afford tricarbonyl ligated iron 
complex I-118 (Scheme II-2). This complex I-118 underwent ligand exchange with 
triphenylphosphine to give the corresponding monosubsitituted triphenylphosphine iron 
complex II-3 which was treated with a cold solution of aqueous tetrafluoroboric acid in 
acetic anhydride to afford bicyclooctadienyl iron cation I-129b. The NMR spectral data 
and melting points for II-3 and I-129b were consistent with the literature values.
125
  This 
freshly prepared cation I-129b, was allowed to react with the potassium salt of N-tosyl 
allylamine
131
 in water-saturated ether; the crude product underwent oxidative 
decomplexation after treatment with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone to give 
bicyclooctadienyl-N-allylamine derivative (±)-II-4. The structural assignments for (±)-II-
4 were based on its 
1
H NMR spectral data. The characteristic signals for the 
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diastereotopic methylene protons of the N-tosyl allylamine appear at δ  3.75 ppm (1 H) 
and 3.95 ppm (1H) and the methyl protons of the tosyl group at δ 2.35 ppm (3H), along 
with the methylene protons of the cyclopropane ring at 0.77  and 1.15 ppm (1H each). 
 
Scheme II-2. Synthesis of the bicyclic free ligand (±)-II-4.  
 Reaction of the free ligand (±)-II-4 with Grubbs’ I catalyst gave only the self-
metathesis dimer (±)-II-5 as a mixture of diastereomers instead of the expected ring 
rearrangement product (±)-II-6 (Scheme II-3). The structure of the dimer (±)-II-5 was 
assigned on the basis of its NMR spectral data, absence of signals corresponding to a 
mono-substituted olefin and the appearance of a narrow multiplet at δ 5.80–5.85 (2H) 
corresponding to the new 1,2-disubstituted double bond. In addition, the presence of a 
signal at δ 130.5 ppm in the 13C NMR spectrum of dimer (±)-II-5 (instead of a signal at 
ca. δ 117–119 ppm) indicated the presence of the self-metathesis olefin.  
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Scheme II-3. Formation of dimer (±)-II-5 via metathesis reaction of (±)-II-4.  
 The difference in reactivity between (±)-I-152 and (±)-II-4 toward G-I catalyst 
may be rationalized on the basis of the allylmalonate group of (±)-I-152 compared to the 
(allyl)tosylamine group of (±)-II-4. Two possible explanation for this different behavior; 
Throp-Ingold effect
132
 where increasing the size of the two germinal substituents on a 
tetrahedral center increases both the rate and equilibrium constants of cyclization 
reactions.  In this case the rate of attaching the ruthenium metal to the allylmalonate 
compound is faster than it for (allyl)tosylamine  derivative. The other explanation is 
proposed by Hoye and co-workers whom have previously noted that the allylmalonate 
group is particularly effective as an activator for initiating relay ring closing metathesis 
(RRCM).
133
 These authors suggested that the rate-determining step in some RRCM 
reactions is the decomplexation of the product olefin (i.e. a cyclopentene ring), and that 
this decomplexation was more rapid for a cyclopentene ring with a sterically bulky 
dicarboxylate substitution pattern which encounters a steric repulsion with ruthenium 
ligand sphere. In the present case initiation generates the Ru-carbene A (Scheme 4). Two 
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pathways are available to this intermediate: either reversible intramolecular equilibration 
to afford intermediate E, or irreversible self-metathesis dimerization. According to 
Hoye’s proposal, the rate of decomplexation of D [X = C(CO2Me)2] is rapid (i.e. koff is 
fast), and thus E reacts with (±)-I-152  to give the ring rearranged product  I-153 and 
regenerate intermediate A. Conversely, intermediate D [X = NTs] undergoes 
decomplexation at a slower rate leading to the eventual irreversible self metathesis and 
concomitant formation of ethylene via the methylene carbene complex 
[(Cy3P)Cl2Ru=CH2].  
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Scheme II-4. Mechanistic rational for the reactivity difference of  (±)-I-152and (±)-II-4 
toward G-I catalyst.  
 Reaction of (cyclooctatetraene)Fe(CO)3 I-118 with tropylium tetrafluoroborate 
in presence of pyridine as a base provided styrylcycloheptatriene complex (±)-I-128 
(Scheme II-5). The reported yield in the literature was only modest (41%).
 134 
The yield 
of this product could be improved by using one equivalent of pyridine and running the 
reaction for 8 hours, which increased the yield to (75%).  Treatment of (±)-I-128 with 
tetrafluoroboric acid gave the corresponding cation (±)-II-7; the NMR spectral data for 
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(±)-I-128   and (±)-II-7 are consistent with the literature values.
129
 Nucleophilic attack of 
the potassium salt of tosyl allylamine at this cation led to styryl-cycloheptadienyl tosyl 
allylamine complex (±)-II-8; which undergoes oxidative decomplexation using cerium 
ammonium nitrate to give styryl cycloheptadienyl tosyl allylamine (±)-II-9. The 
1
H NMR 
spectra of the free ligand (±)-II-9 contained signals characteristic for the styryl olefinic 
proton at δ 6.39 (d, 1H), methyl protons of the tosyl group at δ 2.42  ppm (3H) and 
diastereotopic methylene protons of the N-tosyl allylamine at δ 3.73 (1H) and δ 3.85 ppm 
(1H). 
 
 
Scheme II-5. Preparation of styryl cycloheptadienyl tosyl allylamine (±)-II-9.   
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 The substrate (±)-II-9 has a number of potential sites for olefin metathesis. 
Exposure of free ligand (±)-II-9 to Grubbs’ first generation catalyst gave a complex 
mixture of products; use of Grubbs’ second generation catalyst led to a ring-closed 
product. This product was found to isomerizes to give 2-azabicyclo[4.4.1]undeca-5,7,9-
triene (±)-II-10 (Scheme II-6). The structural assignment for this isomer is based on its 
NMR spectral data. In particular, the 
1
H NMR of (±)-II-10 integrates to 19 Hs; five of 
which are olefinic. Furthermore, the 
13
C NMR spectrum of (±)-II-10 consisted of 15 
signals with seven aryl/alkenyl methine carbons and three quaternary aryl/alkenyl 
carbons. 
 
Scheme II-6. Formation of ring closure product (±)-II-10. 
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II.2. Synthesis of racemic and optically active aminocycloheptitols  
 As had reported by a previous graduate student
129
 in our group, 
styrenylcycloheptadiene derivative (±)-II-11 was prepared by nucleophilic attack of 
phthalimide anion at C-1 of the cation (±)-II-7 to afford the corresponding 
phthalimidocycloheptadiene complex which undergoes oxidative decomplexation to give 
phthalimidocycloheptadiene free ligand (±)-II-11 (eqn. II-2).  
  
 Cycloaddition of (±)-II-11 with singlet oxygen gave (±)-II-12 as a single 
diastereomer (Scheme II-7). Cycloaddition occurs on the diene face opposite to the syn-
C
1
/C
6
 substituents. Similar facial selectivity was also observed for substituted 
cycloheptadiene systems by the groups of Pearson and Seitz.
54
 Initial attempts to reduce 
the generated endoperoxide (±)-II-12 were done using thiourea but the yield was low 
with a long reaction time.
129
 The yield and reproducibility of the reduction reaction was 
improved using activated zinc and glacial acetic acid to afford the diol derivative (±)-II-
13. Acetylation of (±)-II-13 in acetic anhydride and p-toluenesulfonyl chloride in 
catalytic amount provided the diacetate derivative (±)-II-14. The relative 
stereochemistries of (±)-II-12, (±)-II-13, and (±)-II-14 were assigned based on their 
1
H 
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NMR spectral data. In particular the signal for H-5’ of (±)-II-12 appears at  2.11 (q, J = 
10.1 Hz)ppm, while the comparable signal for H-5’ of (±)-II-13 and (±)-II-14 appear at  
2.73 (td, J = 11.8, 14.0 Hz) and 2.85 (q, J=12.8 Hz) ppm respectively. The relative 
upfield shift for H-5’ of (±)-II-12 (compared to H-5’ of (±)-II-13/(±)-II-14) may be 
attributed to the anisotropic effects of the proximal C6-C7 olefin. In addition, the signal 
for H-4 of (±)-II-14 appears as a broad triplet at  4.42 ppm (J = 10.8 Hz); these two 
large coupling constants are due to axial-axial couplings to both H-5’ and H-3, thus 
indicating that H-3 occupies an axial orientation in (±)-II-14. 
 
Scheme II-7. Singlet oxygen cycloaddition of (±)-II-11 followed by reduction. 
 Truncation of the styrenyl group present on (±)-II-11 into a hydroxymethyl 
substituent was achieved in the following fashion (eqn. II-3). Sharpless asymmetric 
dihydroxylation of (±)-II-11 with commercially available AD-mix β135 gave a mixture of 
diastereomeric diols. The dihydroxylation exclusively took place on the styrene double 
bond in a stereofacial fashion leaving the diene olefins intact because it favors the 
reaction with trans double bonds more than cis double bonds. Notably, the “binding 
pocket” of the phthalazine ligands in the AD-mix is well suited to accommodate olefins 
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with flat, aromatic substituents. Phthalazine ligands  are also recommended for the 1,l- 
and 1,2-trans-disubstituted as well as the trisubstituted classes of olefins.
135
 Singlet 
oxygen cycloaddition to the diol mixture gave a mixture of diastereromeric endoperoxide 
diols, which undergo diol cleavage with lead tetraacetate to give a single racemic 
endoperoxide aldehyde (±)-II-15. The presence of the aldehyde group was confirmed by 
a singlet in 
1
H NMR spectrum for one proton at  9.65 ppm while in the 
13
C NMR 
spectrum an aldehydic carbonyl was observed at  199.0 ppm.  
 
 Reduction of only the aldehyde functionality in the presence of the 
endoperoxide proved to be challenging, however this was eventually accomplished by 
using NaBH3CN/AcOH to afford (±)-II-16 in quantitative yield (Scheme II-8). Protection 
of (±)-II-16 via reaction with t-butylchlorodiphenylsilane gave the corresponding silyl 
ether (±)-II-17. Reduction of the endoperoxide moiety with zinc and glacial acetic acid 
gave the diol (±)-II-18. The relative stereochemistry of II-15 to II-18 were assigned by 
comparison of their 
1
H NMR spectral data with that for II-12 to II-14. In particular the 
signals for H-3’ of II-15, II-16 and II-17 appear relatively upfield at  2.11, 1.84 and 
1.78 ppm respectively. The signal for H-4 of II-18 appears as doublet of doublet of 
doublets at  4.14 ppm (J=2.4, 10.0 and 12.4 Hz); the two larger coupling constants are 
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due to axial-axial couplings to H-5’ and H-3. Dihydroxylation of (±)-II-18 with catalytic 
OsO4 led to a mixture of diastereomeric tetraols (±)-II-19 and (±)-II-20 (ca. 6:1). The 
relative stereochemistry of the major compound (±)-II-19 was tentatively assigned on the 
basis of facial selectivity noted by Kishi, et al. ,
136,137
 for dihydroxylation of an allylic 
alcohol opposite to the adjacent hydroxyl groups. In this fashion, the racemic protected 
cycloheptitol was prepared from (cyclooctatetraene)Fe(CO)3 (±)-I-77 in 11 steps and 
17% overall yield. 
 
Scheme II-8. Synthesis of final tetraols (±)-II-19 and (±)-II-20. 
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 In Kishi's empirical model, the substrate reacts in a conformation that 
minimizes steric repulsion of the oxygen lone pairs with OsO4 the reagent comes in from 
the face opposite the oxygen substituent (Figure II-1).
136,137
  
 
Figure II-1. Kishi’s model for osymlation reaction. 
 In an attempt to obtain optically active tetraols, successful separation of the 
diastereomeric mixture of endoperoxide diols (+)-II-21 and (+)-II-22 using column 
chromatography was shown to be feasible on > 1 g scale (Scheme II-9).  
 The absolute stereochemistry of (+)-II-21 and (+)-II-22 was assigned by a 
former graduate student in our group.
129
 Asymmetric dihydroxylation of (±)-II-11 gave a 
mixture of diastereomers which was separable by preparative thin layer chromatography. 
Diels-Alder reaction of N-phenyl-1,3,5-triaza-2,4-dione (PTAD) with the less polar 
cycloheptadiene diastereomer (-)-II-23 gave adduct (+)-II-25 which undergoes protection 
with 3,5-dinitrobenzoyl chloride to give (+)-II-26 (Scheme II-9). The relative 
stereochemistry of all chiral centers of (+)-II-26 were assigned based on its single crystal 
X-ray diffraction analysis.
129 
 Singlet oxygen cycloaddition of the isolated dienediol (-)-
II-23 gave a compound which was identical with (+)-II-21. 
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Scheme II-9. Assignment of the stereocenters configurations of (-)-II-21 and (+)-II-22. 
 Separate diol cleavage of optically enriched endoperoxide diols (+)-II-21 and 
(+)-II-22 gave the aldehydes (+)-II-15 and (-)-II-15 respectively (Scheme II-10). 
Reduction of (+)-II-15 and (-)-II-15 to the corresponding alcohols (+)-II-16 and (-)-II-16 
was achieved by activated zinc in glacial acetic acid, followed by protection using t-
butyldiphenylsilyl chloride to give (+)-II-17 and (-)-II-17. Reduction of the endoperoxide 
moiety gave optically active diols (+)-II-18 and (-)-II-18. Dihydroxylation of each 
optically enriched diol afforded the optically enriched tetraols (+)-II-19 and (-)-II-19. 
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Scheme II-10. Preparation of optically active tetraols (-)-II-19 and (+)-II-19. 
 While asymmetric dihydroxylation of styrene is known to proceed with high 
enantioselectivity,
135
 an independent method of assaying the optical purity of the 
endoperoxide alcohols (+)-II-16 and (-)-II-16 was sought. To this end the (S)(-)-α-
methoxy-α-trifluoromethylphenylacetyl of both (+)-II-16 and (-)-II-16 were prepared (II-
27 and II-28 respectively, Scheme II-11). Portions of the 
1
H NMR spectra of II-27 and 
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II-28 are similar (but not identical) to that obtained for racemic alcohol (±)-II-16. The 
main point of differences were found to be the diastereotopic alkoxy methylene signals 
which appear at  3.38-3.47 and 3.60-3.66 ppm for II-16 and are found downfield for II-
27 (  4.27 and 4.39 ppm) as well as for II-28 (  4.27-4.38).  Also, one olefinic peak for 
II-27 appears at  6.22 ppm while for II-28 it shows at  6.31 ppm (Figure II-2). The 
clean baseline separation of these signals allowed for establishment of a lower limit for 
the diastereomeric excess by integration. Using this method each was determined to be ≥ 
94% de and thus the enantiomeric excess of the optically active II-15 to II-19 and 
diastereomers (+)-II-21 and (-)-II-22 to be ≥ 94% ee. 
 
Scheme II-11. Preparation of Mosher’s esters II-27 and II-28. 
 
 
 
 
57 
 
 
 
Figure II-2. a) Partial 
1
H NMR spectra of II-27 in (CD3)2CO (scale in  ppm). b) Partial 
1
H NMR spectra of II-28 in (CD3)2CO (scale in  ppm). 
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II.3. Preparation of bicyclo[5.1.0]octane derivatives of cyclitols  
 The preparation of the bicyclooctadienyl phthalimide (±)-II-29 was 
accomplished by nucleophilic attack of potassium phthalimide on the bicyclic cation I-
129b. The purification of the resultant complex was found to be challenging due to its 
relative instability in solutions and/or to exposure to typical chromatographic adsorbents 
(Al2O3, SiO2) which promotes the elimination reaction to go back to (±)-I-118.
125
 For this 
reason, oxidative decomplexation of the crude complex using 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (instead of CAN which was reported in literature
125
) led to good 
isolated yield of the corresponding bicyclic phthalimide compound (±)-II-29 (eqn. II-4). 
The NMR spectral data of (±)-II-29 was consistent with the literature values.
125
 
 
 With this bicyclic free ligand (±)-II-29 in our hands, routes to a diverse series 
of polyols were explored. Exhaustive dihydroxylation using excess of N-
methylmorpholine-N-oxide and catalytic amount of OsO4 resulted in two separable 
diastereomers (±)-II-30 and (±)-II-31 respectively (eqn. II-5).  
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 The assignment of the relative stereochemistry for (±)-II-30 was based on its 
1
H NMR spectral data; in particular the coupling constant between H
2
 and H
3
 is large 
(10.6 Hz) indicating that those two protons exhibit a trans diaxial orientation. Protons H
3
 
and H
4
 must be cis to each other because dihydroxylation takes place in a syn fashion. 
The coupling constant for H
4
 and H
5
 is small (2.2 Hz) showing that they possess cis 
orientation and again H
6
 and H
5
 must be same side. The 
13
C NMR spectrum of (±)-II-30 
showed a separate signal for each of the six aromatic carbons. It is proposed that these 
carbons are magnetically non-equivalent due to restricted rotation of the phthalimide 
group as a result of the hydrogen bond formation as shown in (Figure II-3).  
 
Figure II-3. Structural assignment of (±)-II-30. 
60 
 
 This assignment was consistent with the structure obtained from single crystal 
X-ray diffraction analysis (Figure II-4) where all OH groups are in same side and trans to 
the phthalimide group. 
 
Figure II-4. X-ray crystal structure of (±)-II-30. 
 In similar fashion, the relative stereochemistry of (±)-II-31 was assigned on 
the basis of its 
1
H NMR spectral data; the large coupling constant between the H
2
 and H
3
 
(11.2 Hz) is consistent with their trans diaxial orientation. This was confirmed by single 
crystal X-ray diffraction analysis (Figure II-5). 
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Figure II-5. X-ray crystal structure of (±)-II-31. 
 When (±)-II-29 was treated with one equivalent of methylmorpholine-N-oxide 
in the presence of a catalytic amount of OsO4, two regioisomeric diols were obtained, a 
major product (±)-II-32 and a minor one (±)-II-33 (eqn. II-6).  
 
 The structures of the two regioisomers were assigned by comparison of their 
1
H NMR spectral data. The major product (±)-II-32 arises due to reaction of the more 
electron rich double bond remote to the phthalimide group and close to cyclopropane 
ring. The chemical shift for the H
2
 proton of (±)-II-32 (  = 5.68 ppm) is shifted more 
downfield than it is for (±)-II-33 (  = 5.25 ppm) indicating the proximity of this proton to 
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the double bond in (±)-II-32. The relative stereochemistry of (±)-II-33 was assigned due 
to the large coupling constant (10.6 Hz) between H
2
 and H
3
 which indicates a trans-
diaxial orientation for these two protons (Figure II-6). 
 
Figure II-6. Structural assignments of (±)-II-33. 
 Epoxidation of the major regioisomer (±)-II-32 was carried out using 
trifluoroperacetic acid to give the corresponding epoxydiol compound (±)-II-34 (eqn. II-
7). The 
1
H NMR spectrum shows an absence of signals for olefinic protons and new 
peaks appeared at the range of at  3-5 ppm. The relative stereochemistry of (±)-II-34 
was assigned tentatively based on the precedent
86 
that epoxidation is assisted by hydrogen 
bonding between the allylic alcohol and the peracid reagent.  
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 Epoxide hydrolysis was carried out in a mild condition using deionized water 
in the  presence of a catalytic amount of CBr4
138
 to afford tetraol compound (±)-II-35 
(eqn. II-8).  
 
 The relative stereochemistry of (±)-II-35 was assigned on the basis of its 
1
H 
NMR spectral data; a small coupling constant between H
2
 and H
3
 (2.2 Hz) indicated a cis 
orientation of these two protons.  
 The stereochemical outcome of the epoxide hydrolysis is controlled by Fürst-
Plattner rule which also known as the trans-diaxial effect
139
 in which epoxidation of 
substituted cyclohexene give the corresponding epoxy product where R substituent locks 
the conformation of the epoxycyclohexene in the pseudo-equatorial position (Scheme II-
12). Two potential  sites for epoxide ring opening, position 1 where it ends up having 
twisted boat product and this  path is disfavored because it about 5 Kcal/mol higher than 
opening at position 2 which gives chair form product leading to the formation of trans-
diaxial products.  
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Scheme II-12.Mechanism and stereochemistry of epoxycyclohexene hydrolysis. 
 Since epoxide ring opening takes place in an anti fashion,
139
 the two hydroxyl 
group at C3 and C4 must be trans to each other (Figure II-7). 
 
Figure II-7. Epoxide ring opening product (±)-II-35. 
 The reaction of (±)-II-29 with one equivalent of   meta-chloroperoxybenzoic 
acid led to a separable mixture of mono-epoxide (±)-II-36 and enone (±)-II-37 (eqn. II-
9). Evidence of epoxidation of only a single olefin in (±)-II-36 was found in its NMR 
spectral data; in the 
1
H NMR spectrum only two olefinic signals were observed and two 
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new peaks appeared at   3 ppm corresponding to the oxirane hydrogens. In the 
13
C 
NMR spectrum of (±)-II-36 there are only two sp
2
 olefinic carbons compared to (±)-II-29 
and two new sp
3
 C-O peaks appear for (±)-II-36 at  52.8 and 54.9 ppm. The relative 
stereochemistry of (±)-II-36 was assigned by single crystal X-ray diffraction analysis 
(Figure II-8) where the epoxide ring shows to be trans to the phthalimide group. On the 
other hand, the 
1
H NMR spectrum of the enone (±)-II-37 showed two new peaks at  
2.93 and 3.10 ppm corresponding to the α-keto methylene with a large coupling constant 
(J = 15.2 Hz) indicating a geminal relationship. Moreover, there were two fewer olefinic 
peaks in the 
13
C NMR spectrum of (±)-II-37 compared to (±)-II-36. This also was 
supported by the 
13
C NMR spectral data of (±)-II-37 where a new signals for a CH2 
signal and a C=O were observed at  41.5 and 198.9 ppm respectively. 
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Figure II-8. X-ray crystal structure of (±)-II-36. 
 The proposed mechanism for formation of (±)-II-37 is shown in (Scheme II-
13); under acidic conditions (±)-II-36 gets protonated. Oxirane ring opening occurs at the 
bond adjacent to the cyclopropane ring to give a carbocation intermediate followed by 
1,2-hydride shift to afford an oxycarbenium cation which deprotonated to provide (±)-II-
37.  
 
Scheme II-13. Mechanism of enone (±)-II-37 formation.  
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 Dihydroxylation of (±)-II-36 using a catalytic amount of OsO4 and N-
methylmorpholine-N-oxide gave (±)-II-38 in a good yield (Scheme II-14). The structure 
of (±)-II-38 was assigned on the basis of single crystal X-ray diffraction analysis where 
the newly installed OH groups are on the same side as the peroxide ring and opposite to 
the phthalimide group (Figure 6). Peroxide ring opening of (±)-II-38 was carried out in 
water using carbon tetrabromide as a catalyst to afford the corresponding bicyclic tetraol 
(±)-II-39. The structure of (±)-II-39 was assigned based on its 
1
H NMR spectral data; in 
particular the large coupling constant between H
2
-H
3
 (J = 11.0 Hz) and between H
5
-H
6
 (J 
= 9.6 Hz) are consistent with a trans-diaxial relationship for each pair of protons (Figure 
II-10). 
 
Scheme II-14. Formation of bicyclic tetraol (±)-II-39.    
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Figure II-9. X-ray crystal structure of (±)-II-38.  
  The stereochemistry observed in tetraol (±)-II-39 represents epoxide ring 
opening of (±)-II-38 by exclusive cleavage of the C13-O5 bond (vs C12-O5 bond; 
arbitrary X-ray structure numbering). This might be rationalized on the basis of a greater 
stabilization of the partial positive charge on the protonated carbon adjacent to the 
cyclopropane ring.  
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Figure II-10. Structural assignments of (±)-II-39. 
 Reaction of (±)-II-29 with an excess of meta-chloroperoxybenzoic acid led to 
the formation of bis-epoxide compound (±)-II-40 (eqn. II-10).  
 
 The structure of (±)-II-40 was assigned based on its 
1
H NMR spectral data; no 
olefinic proton signals were observed and instead, four new peaks showed up at   3 
ppm. This also was observed in the 
13
C NMR spectrum where four new signals appeared 
in the range of 50-60 ppm. The relative stereochemistry of (±)-II-40 was assigned based 
on single crystal X-ray diffraction showing the two epoxide rings are anti to the 
phthalimide group (Figure II-11). 
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Figure II-11. X-ray crystal structure of (±)-II-40. 
 This bisepoxide compound (±)-II-40 underwent epoxide ring opening using 
water and CBr4 in a catalytic amount to give bicyclic tetraol (±)-II-41 and the 8-
membered ring tetraol (±)-II-42 (eqn. II-11).  
 
 The assignment of stereochemistry of (±)-II-41 was based on its 
1
H NMR 
spectral data; in particular the coupling constant between H
2
 and H
3
 is small (2.2 Hz) 
indicating that they possess a cis orientation since the H
2
 proton adjacent to the bulky 
phthalimide is axial, the H
3
 proton must be equatorial. In contrast, the relatively large 
coupling constant for H
5
-H
6
 reveals that these two protons must have a trans-diaxial 
relationship. Since epoxide ring openings are known to occur in an anti fashion, the H
3
-
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H
4
 and H
5
-H
6
 relative stereochemistry is assigned as indicated (Figure II-12). It is 
interesting to note that opening of the C4-C5 oxirane occurs by cleavage of the C5-O2 
bond, which is adjacent to the cyclopropane ring. As in the case of the epoxide ring 
opening of (±)-II-38, this may be due to the stabilizing effect of the adjacent three-
membered ring on the partial positive charge in the protonated oxirane. 
 
Figure II-12. The assignment of stereochemistry of (±)-II-41. 
 Examination of the 
1
H NMR spectral data for (±)-II-42 revealed an absence of 
cyclopropane ring protons, the presence of the two olefinic protons and two new geminal 
aliphatic protons. The structure of (±)-II-42, including the relative stereochemistry was 
assigned based on single crystal X-ray diffraction (Figure II-13). 
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Figure II-13. X-ray crystal structure of (±)-II-42. 
 The proposed mechanism for ring expansion to afford (±)-II-42 is rationalized 
through two different pathways (Scheme II-15). In path A, hydrolysis of the epoxide at 
C3,C4 takes place first to give epoxydiol compound (±)-II-43 which under protonation of 
C5,C6 epoxide gave the intermediate (±)-II-44. A concerted SN2’ type mechanism with 
attack of the weak nucleophile water at the cyclopropane ring carbon of (±)-II-44 opens 
the cyclopropane ring with inversion and relieves the strain to end up with octene-tetraol 
compound (±)-II-42. While in path B, initial concerted SN2’ attack of a water molecule 
on the protonated intermediate (±)-II-45 gives epoxycyclooctene (±)-II-46 that 
undergoes epoxide ring opening to give (±)-II-42.   
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Scheme II-15. Ring expansion mechanism and formation of (±)-II-42. 
 Cycloaddition of (±)-II-29 with singlet oxygen gave (±)-II-47 as a single 
diastereomer (Scheme II-16). The relative stereochemistry of (±)-II-47 was tentatively 
assigned on the basis of the stereochemistry observed for the cycloaddition of (±)-II-29 
with nitrosobenzene.
140
 This tentative assignment was eventually corroborated by further 
chemical reaction including X-ray crystal structure of one derivative. Reduction of (±)-II-
47 was carried out using activated zinc and glacial acetic acid to afford the diol derivative 
(±)-II-48 in a good yield. The relative stereochemistry of (±)-II-48 was assigned on the 
basis of its NMR spectral data; in particular the large coupling constant between H
2
 and 
H
3
 (10.8) Hz indicating these two protons are trans diaxial with respect to each other. 
Based on this the endoperoxide ring in (±)-II-47 must be trans to the phthalimide group. 
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Scheme II-16. Singlet oxygen cycloaddition of (±)-II-29 followed by endoperoxide ring 
opening. 
 Dihydroxylation of (±)-II-48 using a catalytic amount of OsO4 and N-
methylmorpholine-N-oxide gave (±)-II-49 in a good yield (eqn. II-12).  
 
 The structural assignment of (±)-II-49 was based on its 
1
H NMR spectral data; 
in particular the large coupling constants between H
2
 and H
3
 (10.2 Hz) and between H
3
-
H
4
 (10.0 Hz) indicate the trans-diaxial orientations of these three protons. Since 
dihydroxylation takes place in a syn fashion then H
4
 and H
5
 are cis with respect to each 
other (Figure II-14). This was confirmed by having small coupling constant between H
4
 
and H
5
 (2.7 Hz). This assignment is consistent with the Kishi model
136,137
 for osmium 
dihydroxylation of allylic alcohols. 
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Figure II-14. Structural assignment of (±)-II-49. 
 Photochemical rearrangement of (±)-II-47 was carried out in benzene as a 
solvent and using a medium-pressure mercury lamp to give the bisepoxide compound 
(±)-II-40 which was identified by comparison to a sample previously made (vide supra) 
(eqn. II-13). 
 
 Kornblum–DeLaMare rearrangement84 of (±)-II-47 in the presence of Et3N as a 
base afforded primarily one regioisomer; (±)-II-50 along with a very small amount of 
(±)-II-51 (eqn. II-14). The structural assignment of (±)-II-50 was based on its 
1
H NMR 
spectral data; in particular the signal for the H
2
 proton appears at  4.95 has a large 
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coupling constant (J = 10.2 Hz) indicating a trans-diaxial orientation with the proton next 
to it (H
3
). 
 
 Reduction of α,β-unsaturated ketone (±)-II-50 under Luche conditions85 
provided trans enediol (±)-II-52 (eqn. II-15). The stereochemistry of the OH group at C6 
was assigned in order to be unique compared to (±)-II-48. 
 
 Dihydroxylation of (±)-II-52 using a catalytic amount of OsO4 and N-
methylmorpholine-N-oxide gave a separable mixture of two diastereomers (±)-II-53 and 
(±)-II-39 (eqn. II-16). Product (±)-II-39 was assigned by comparison of its NMR spectral 
data with that previously obtained.  
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 The other tetraol product was tentatively assigned structure (±)-II-53 in order 
to have a unique structure arising from a syn-dihydroxylation. This tentative assignment 
was corroborated by its 
1
H NMR spectral data; large couplings constant between H
2
 and 
H
3
 (11.0 Hz) and between H
3
 and H
4 
(9.8 Hz) indicating a trans-diaxial orientation of 
these three protons. The small coupling constant between H
4
 and H
5
 (1.4 Hz), is 
consistent with an axial-equatorial stereochemical relationship between these protons 
(Figure II-15).  
 
Figure II-15. Structural assignment of (±)-II-53. 
 Epoxidation of (±)-II-47 using trifluoroperacetic acid gave a unique 
epoxyendoperoxide structure (±)-II-54 in a very high yield (eqn. II-17). 
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 The relative stereochemistry of (±)-II-54 was assigned based on single crystal 
X-ray diffraction showing the endoperoxide ring and the epoxy ring are syn with respect 
to each other (Figure II-16). 
 
Figure II-16. X-ray crystal structure of (±)-II-54. 
 Reduction of epoxyendoperoxide compound (±)-II-54 using zinc in glacial 
acetic acid gave epoxydiol (±)-II-55 (Scheme II-17). Hydrolysis of (±)-II-55 in water and 
catalytic amount of CBr4
138
 gave the bicyclic tetraol (±)-II-56. 
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Scheme II-17. Synthesis of (±)-II-56. 
 The structural assignment of (±)-II-56 was based on its 
1
H NMR spectral data; 
large coupling constants between H
1
 and H
2
 (10.8 Hz), H
3
 and H
4
 (9.0 Hz) and H
4
 and H
5
 
(J = 8.8 Hz) indicating a trans-diaxial orientation of these four protons (Figure II-17).  
 
Figure II-17. Structural assignment of (±)-II-56. 
 This structural assignment for (±)-II-56 was corroborated by single crystal X-
ray diffraction (Figure II-18).This structural assignment also confirmed the structural 
assignment for the hydroxyl groups of epoxydiol (±)-II-55. 
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Figure II-18. X-ray crystal structure of (±)-II-56. 
 Epoxidation of (±)-II-48 using trifluoroperacetic acid gave the corresponding 
epoxydiol (±)-II-57 (eqn. II-18). The relative stereochemistry of (±)-II-57 was assigned 
in order to be unique compared to (±)-II-55. This tentative stereochemical assignment 
was eventually corroborated by single crystal X-ray diffraction that shows the epoxide 
ring is opposite to the installed diol (Figure II-19). 
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Figure II-19. X-ray crystal structure of (±)-II-57. 
 Epoxide ring opening under the standard conditions using deionized water and 
CBr4 afforded the corresponding unsaturated aldehyde (±)-II-58 (eqn. II-19). 
 
 The structural assignment of (±)-II-58 was based on its 
1
H NMR spectral data; 
in particular the peak at  9.54 shows one aldehydic proton. The large coupling constant 
(8.2 Hz) between the H4 and H5 is indicative of their trans-diaxial orientation. This 
assignment was corroborated by single crystal X-ray diffraction analysis that shows ring 
contraction with exocyclic aldehyde group (Figure II-20). 
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Figure II-20. X-ray crystal structure of (±)-II-58. 
 The proposed ring contraction mechanism is initiated by protonating the 
epoxide oxygen making it a good electron sink to give intermediate (±)-II-59 (Scheme II-
18). The nearly antiperiplanar alignment of (±)-II-59 between C3-C4 bond and C5-O2 
bond (X-ray crystallographic numbering, Figure II-19) triggers σ σ* type interaction 
between the filled bonding orbital between C3-C4 bond and the antibonding orbital of 
C5-O2 bond ( Figure II-19) giving oxocarbenium intermediate (±)-II-60 which upon 
deprotonation leads to the aldehyde diol compound (±)-II-61. To extend the conjugation 
and to attain more stability, dehydration takes place to give the corresponding α,β-
unsaturated aldehyde (±)-II-58. Similar ring contraction reactions have been reported by 
different research groups where they observed ring contraction from epoxycyclohexanol 
to 2-hydroxycyclopentenal
141–143
. 
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Scheme II-18. Ring contraction mechanism and formation of (±)-II-58. 
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II.4. Evaluation of potential β-glycosidase inhibitors 
 β-Glucosidase is an enzyme which cleaves the β linkage between the β-D-
glucoside and an attached substituent, for the purposes of this assay, the substrate is p- β-
D-glucoside, since the p-nitrophenolate anion may be quantified spectrophotometrically 
(Equation II-20). This system was selected for the initial assay as both the enzyme 
(isolated from almonds) and substrate are commercially available at reasonable cost. 
Depending on the results from this assay, a determination would be made if further 
assays against other glucosidases enzyme was warranted on cost and time basis.  The 
enzymatic activity is determined spectrophotometrically by monitoring the release of p-
nitrophenol/ p-nitrophenolate anion from the substrate in sodium acetate buffer (pH 4.8, 
37 
o
C) by measuring the absorbance at 405 nm. Assays will be conducted under 
conditions where the amount of p-nitrophenol released is linear with both time and 
protein concentrations. 
 
 The assay was validated by measuring the initial rate of reaction at a variety of 
different enzyme concentrations. An increase in the initial reaction rate was observed 
with each increase in enzyme concentration. The linear region was then selected which 
shows increase in reaction rate with time for each enzyme concentration (Figure II-21).  
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The initial rates were plotted against enzyme concentration to produce a validation curve 
Figure II-22). 
 
 
 
 
 
 
Figure II-21. Linear relationship between initial reaction rate for each enzyme and time. 
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Figure II-22. β-glucosidase validation curve.  
 Once the linear rate of the hydrolysis versus protein concentration was 
established, an assay was run using the known β-glucosidase xylitol.144 The inhibitory 
effect measured at 100mM xylitol concentration was similar to that reported by Kelemen 
and Whelan (43% inhibition). With this assay validation complete, the assay was 
performed by preparing serial dilution of each potential enzyme and the 50% inhibitory 
concentration for each compound was determined.  The results are summarized in Table 
II-1. The error limitations listed were determined by a non-linear least square fit. For 
nearly all the phthalimido polyols examined, except II-49, the error limitations were on 
the same order as the IC50 values. This indicates that the inhibitory activities of these 
compounds is negligible. Only for II-49 was the error ~15%, which demonstrated an 
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acceptable reliability.  The IC50 for II-49 indicates it has limited inhibitory action at 
approximately 1 mM.  
Compound Inhibition 
II-30 IC50 = 1.7 mM ± 1.2 mM 
II-31 IC50 = 160 µM ± 60 µM 
II-35 IC50 = 42 µM ± 48 µM 
II-39 IC50 = 1.9 mM ± 3.2 mM 
II-41 IC50 =  43 µM ± 34 µM 
II-49  
IC50 =  0.91 µM ± 0.14 mM 
II-53 IC50 = 1.9 mM ± 3.2 mM 
II-56 IC50 = 75 µM  ± 83 µM 
 
Table II-1. The inhibition of the generated phthalimide tetraols. 
 The most likely reason that none of the phthalimido polyols exhibit significant 
β-glucosidase inhibitory activity is that at the pH of the assay, these compounds are 
neutral (i.e. the phthalimido group is not protonated). So it was important to cleave the 
phthalimide group. Different attempts were made to cleave the phthalimido group to 
generate aminocyclitols. Attempted acid hydrolysis lead to products which lacked 
cyclopropane ring in their 
1
H NMR spectra. The exact nature of these ring opened 
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products was not established. Basic hydrolysis also was not ideal way to cleave the 
phthalimido group as we observed elimination products along with the desired 
compound. Use of anion exchange resins
145
 gave a mixture of compounds also with very 
low overall yield. Ganem’s research group146 reported the deprotection of phthalimides 
using partial reduction of phthalimide by NaBH4 in acidic medium followed by reflux. 
Unfortunately this did not produce the free amines for these compounds . n-
Butylamine
147
  and methylamine
148
 also were used to deprotect the aminocyclitols but 
these procedures gave a mixture of products in addition to un reacted starting material left 
over.  Finally, the cleavage of the phthalimido tetraols was carried out using hydrazine 
hydrate in ethanol to give the corresponding aminobicyclicoctitols and the 2,3-dihydro-
1,4-phthalazinedione II-62 (Scheme II-19). Attempts to separate these reaction mixtures 
either by normal or reverse phase chromatography, met with failure. For this reason the 
crude residue was washed multiple times with diethyl ether and dried under vacuum. In 
order to determine if further experimentation tp produce pure aminopolyols was 
warrented (on the basis of significant inhibitory activity) the mixture of the aminopolyol 
and phthalhydroazide were assayed  against β-glucosidase using the standard protocol.144 
The assay results for these mixtures (Figure II-23) indicated an activation of the enzyme 
at higher concentration instead of inhibition. Separate assay of the 2,3-dihydro-1,4-
phthalazinedione II-62 against β-glucosidase revealed that this increase in enzyme 
activity could be attributed to the hydrazinolysis by-product, and not to any specific 
aminobicyclooctitol. Since the aminobicyclooctitiols did not exhibit any significant 
against β-glucosidase activity, further assay against other commercially available 
enzymes was abandoned. 
89 
 
 
 
Scheme II-19. Deprotection of the phthalimidetetraols. 
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Figure II-23. The activity of the bicyclooctitols/phthalhydrazide mixtures against β-
glucosidase from almond. 
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III- SUMMARY 
 The hydrocarbon cyclooctatetraene I-106 [COT] is formed by the Ni-catalyzed 
cyclotetramerization of acetylene.  The use of COT I-106 as a starting material for 
synthesis has experience a rebirth in the last 6 years, as exemplified by its use in the 
synthesis of bis-homocon-duritols, bis-homoinositol, pentacycloanammoxic acid methyl 
ester, and the polyene segment of roxiticin.  Complexation of I-106 readily generates 
(COT)Fe(CO)3 I-118, the reaction of which with electrophiles gives rise to a wide variety 
of cationic iron complexes via skeletal rearrangements II-7, I-129b and I-132b (Scheme 
III-1). 
 
Scheme III-1. Preparation of different variety of cationic iron complexes. 
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III.1. Skeletal diversity via ring-rearrangement metathesis 
 Within the general build/couple/pair or functional group pairing strategy for 
diversity oriented synthesis (DOS), folding pathways allow for the transformation of 
different substrates into different scaffolds using a common reagent.  Toward this end, 
reaction of cations II-7, I-129b and I-132b with (allyl)tosylamine nucleophiles, followed 
by oxidative decomplexation and reaction with Grubbs’ 1st or 2nd generation catalyst gave 
a diverse group of polycyclic products II-2,  II-5and  II-10 either via ring-rearrangement 
metathesis or RCM (Scheme III-2).  
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Scheme III-2. Skeletal diversity from COT via ring rearrangement metathesis. 
III.2. Preparation of racemic and optically active aminocycloheptitols 
 Addition of potassium phthalimide to (6-styrylcycloheptadienyl)Fe(CO)3+ 
cation II-7 followed by decomplexation gave (6-styryl-2,4-cycloheptadien-1-
yl)phthalimide (Scheme III-3).  Sharpless asymmetric dihydroxylation gave a mixture of 
diastereomeric glycols, which were separable only by prep TLC.  Cycloaddition of the 
mixture of diastereomeric diendiols with singlet oxygen gave a mixture of two 
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diastereomeric endoperoxides (+)-II-21 and (+)-II-22 which were separable by column 
chromatography on a 1 gram scale. Each of the individual endoperoxides were further 
transformed into the enantiomeric protected aminocycloheptitols (>94% ee each).The 
racemic mixture was prepared without separating (+)-II-21 and (+)-II-22 and carry the 
synthesis as shown in scheme III-3. 
 
Scheme III-3. Asymmetric preparation aminocycloheptitilos from COT. 
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III.3. Novel synthesis of bicyclic aminopolyols 
 Nucleophilic attack of phthalimide on cation I-129 gave the phethalimide 
derivative, which undergoes oxidative decomplexation using DDQ to give the free 
bicyclic diene (±)-II-29 (Scheme III-4). Dihydroxylation or tetrahydroxylation of (±)-II-
29, using a controlled amount of NMO reoxidant gave a separable mixture of dienediols 
or tetraols respectively.  Reaction of (±)-II-29 with one or two equivalents of mCPBA 
gave a mono- or bis-epoxide respectively.  Singlet oxygen cycloaddition gave single endo 
peroxide (±)-II-47, which upon further photolysis gave a bis-epoxide diastereomeric to 
that obtained from the reaction with mCPBA. 
 
Scheme III-4. Oxidation of bicyclo[5.1.0]octadiene (±)-II-29. 
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 Further elaboration of the tricyclic endoperoxide can be effected by Kornblum-
DeLeMare rearrangement, by O-O bond reduction or by epoxidation (Scheme III-5).  
These products can be further manipulated to generate diastereomeric tetraols, or 
diastereomeric epoxydiols. 
 
Scheme III-5. Elaboration of tricyclic endoperoxide.  
 Hydrolysis of the epoxydiols or bis-epoxides generally proceeds via anti 
addition to give further diastereomeric tetraols (Scheme III-6).  One notable exception is 
hydrolysis of the epoxydiol (±)-II-57 which gave the 2-formyl-bicyclo[4.1.0]hept-2-ene 
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(±)-II-58.This outcome was attributed to a stereoelectronic effect due to alignment of the 
C-C bond in II-57 nearly antiperiplaner with one of the epoxide C-O bonds. 
 
Scheme III-6. Epoxydiols and bisepoxides hydrolyses. 
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IV- CONCLUSIONS AND RECOMMENDATIONS 
In this work we have developed a new approach of making aminocycloheptitiols 
and bicyclic aminocyclooctitiols using organoiron chemistry. The advantages of this 
method over the other existing methods are using one simple and cheap hydrocarbon 
starting material to target these molecules and this method give the access to many 
stereochemical isomers. We have reported also the possibility of obtaining the optically 
enriched aminocycloheptitols using this approach with high enantiomeric excess (>94%). 
Ring rearrangement metathesis reaction was employed to generate molecular complexity 
and to make diverse structure from cyclooctatetraene (Scheme IV-1). This reactivity 
could be exploited in the future for natural products synthesis. 
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Scheme IV-1. Generation of molecular diversity from cyclooctatetraene. 
We produced eight bicyclic aminocyclooctitol isomers out of 16 possible ones. 
The hydrolysis of epoxide functionality adjacent to cyclopropane functionality in 
bicycle[5.1.0]octanes proceeded via selective cleavage of the C-O bond in proximity to 
the three-membered ring. This was attributed to stabilization of the cyclopropane ring on 
partial positive charges at one adjacent carbon. A quantification of this effect could be 
explored by computational analysis at the DFT/B3LYP level.  We encountered 
purification problems for the hydrolysis of the phthalimido group. The reaction of  
alternative nitrogen-based nucleophiles in reaction with I-129b might lead to systems 
more amenable to clean deprotection / separation . Docking the aminobicyclooctitiols in 
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crystallographically characterized enzyme active sites would be useful tool to see the 
different types of interactions between the ligand and the amino acid residues in the 
active site of the enzyme.   
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V- EXPERIMENTAL 
General methods: All reactions involving moisture- or air-sensitive reagents were 
carried out under a nitrogen atmosphere in oven-dried glassware with anhydrous solvents. 
THF and diethyl ether were distilled from sodium/benzophenone. Purifications by 
chromatography were carried out by using flash silica gel (32–63 m). NMR spectra were 
recorded on either a Varian Mercury+ 300 MHz or a Varian UnityInova 400 MHz 
instrument. CDCl3, CD3OD, and [D6]acetone were purchased from Cambridge Isotope 
Laboratories. 
1
H NMR spectra were calibrated to d=7.27 ppm for residual CHCl3, d=3.31 
ppm for CD2HOD, or d=2.05 ppm for [D5]acetone. 
13
C NMR spectra were calibrated 
from the central peak at d=77.23 ppm for CDCl3, d=49.15 ppm for CD3OD, or d=29.92 
ppm for [D6]acetone. Coupling constants are reported in Hz. 
 
Tricarbonyl(η4-cyclooctatetraene)iron(0) (I-118): To a 500 mL round bottomed flask 
was added cyclooctatetraene I-106 (5.0 mL, 48 mmol) dissolved in benzene   (200 mL). 
Iron pentacarbonyl (14 mL, 96 mmol) was added followed by the addition of 
trimethylamine N-oxide dihydrate (21.33 g, 191.9 mmol). The reaction mixture was 
heated at reflux for 2 h then filtered and concentrated. The solid residue was washed 
several times with benzene and the washings were filtered and concentrated. The deep-
brownish residue was purified through column chromatography (SiO2, hexane-ethyl 
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acetate = 20:1) to give I-118 as deep brown crystals (9.83 g, 100%). mp 82 – 86 oC (lit.39, 
92 – 93.5oC); IR (KBr, cm-1) 2043, 1960; 1H NMR (300 MHz, CDCl3)  5.25 (s, 8H); 
13
C 
NMR (75 MHz, CDCl3)  100.1, 212.5. The NMR spectral data were consistent with the 
literature values.
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(2-4:6-7-η-8-Benzoylbicyclo[3.2.1]octadienylium)tricarbonyliron 
hexafluorophosphate: I-132b. Anhydrous AlCl3, (3.3 g, 25 mmol) was added to dry 
dichloromethane (60 mL). Freshly distilled acetyl chloride (4.50 mL, 63.5 mmol) was 
added from a syringe. The resulting deep red solution was added dropwise to a stirred 
solution of [Fe(C8H8)(CO)3] I-118 (6.00 g, 25.0 mmol) in dichloromethane (60 mL) at 0 
o
C over a 20 min period. Stirring was continued for another 10 min at 0 
o
C, and the 
reaction mixture then hydrolyzed with ice-cold 5% hydrochloric acid solution (75 mL). 
Diethyl ether (60 mL) was added and the organic phase separated, then washed with 
water (3 x 50 mL). The combined aqueous fractions were extracted several times with 
diethyl ether and the golden yellow aqueous solution cooled to 0 
o
C. Addition of 15% 
aqueous ammonium hexafluorophosphate solution (50 mL) gave a pale yellow precipitate 
which was collected and washed with diethyl ether, then dried in vacuo to give the 
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product. Further purification by dissolving in the minimum volume of acetone and 
reprecipitating with diethyl ether gave a pale yellow precipitate (9.0 g, 74 %). This 
product was used without further characterization.
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N-(8-Benzoylbicyclo[3.2.1]octa-3,6-dien-2-yl)-4-methyl-N-2-propen-1-yl-
benzenesulfonamide:(±)-II-1.  To a solution of I-132b (0.20 g, 0.40 mmol) in 
acetonitrile (15 mL) under N2, was added the potassium salt of tosyl allylamine (0.250 g, 
1.00 mmol).  The mixture was stirred at room temperature for 3 h, at which time 
monitoring by TLC indicated the disappearance of I-132b.  The reaction mixture was 
filtered under vacuum and the filter bed washed with acetonitrile.  To the combined 
filtrates was added cerium ammonium nitrate (0.42 g, 0.77 mmol).  The mixture was 
stirred under nitrogen for 2 h, and then filtered through a short column of silica gel, using 
CH2Cl2 to complete the elution.  The combined filtrates were concentrated and the 
residue purified by column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to give 
(±)-II-1 (0.117g, 70%) as a colorless solid.  mp 137-138 
o
C; IR (CH2Cl2) 1676, 1330, 
1157 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  2.43 (s, 3H), 3.11 (br s, 1H), 3.22 (dd, J = 3.0, 
6.6 Hz, 1H), 3.88 (s, 1H), 3.98 (dd, J = 6.4, 16.8 Hz, 1H), 4.13 (br dd, J = 5.0, 16.8 Hz, 
1H), 4.27-4.30 (m, 1H), 5.04-5.11 (m, 2H), 5.23 (dd, J = 1.2, 17.6 Hz, 1H), 5.86-5.93 (m, 
2H), 6.18 (dd, J = 3.2, 5.6 Hz, 1H), 6.39 (ddd, J = 2.5, 6.4, 9.2 Hz, 1H), 7.30 (d, J = 7.6 
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Hz, 2H), 7.45 (t, J = 7.8 Hz, 2H), 7.55 (tt, J = 1.6, 7.6 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 
7.89 (dd, J = 1.6, 8.4 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  21.7, 42.9, 47.3, 48.9, 
55.3, 57.2, 117.5, 124.6, 127.3, 128.5, 128.8, 129.9, 130.0, 133.1, 135.9, 136.2, 137.9, 
138.5, 140.4, 143.6, 199.4. Anal. Calcd for C25H25NO3S·½ H2O: C, 70.07; H, 6.11.  
Found:  C, 70.29; H, 5.90. 
 
2-(5-Benzoyl-4-ethenyl-2-cyclopenten-1-yl)-2,5-dihydro-1-[(4-
methylphenyl)sulfonyl]-1H-pyrrole:(±)-II-2. To a solution of (±)-II-1 (45 mg, 0.11 
mmol) in freshly distilled dichloromethane (25 mL), under N2, was added Grubbs’ 1st 
generation catalyst (5 mg, 0.006 mmol, 5 mol %).  The reaction progress was monitored 
by 
1
H NMR spectroscopy, which revealed that no starting material was left after 90 min.  
The reaction mixture was concentrated under reduced pressure and the residue was 
purified by column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to give (±)-II-2 
(36 mg, 80%) as a colorless oil. IR (CH2Cl2) 1678, 1340, 1162 cm
-1
; 
1
H NMR (400 MHz, 
CDCl3)  2.37 (s, 3H), 3.39-3.46 (br m, 1H), 3.76 (tdd, J = 2.4, 4.8, 15.2 Hz, 1H), 3.80-
3.85 (m, 1H), 4.02-4.10 (m, 2H), 4.63-4.68 (m, 1H), 4.93 (d, J = 16.8 Hz, 1H), 5.01 (dd, J 
= 1.4, 9.4 Hz, 1H), 5.54 (qd, J = 2.0, 6.2 Hz, 1H), 5.59 (td, J = 2.2, 6.0 Hz, 1H), 5.65-5.70 
(m, 2H), 5.91 (ddd, J = 8.8, 10.2, 17.0 Hz, 1H), 7.22 (t, J = 8.0 Hz, 2H), 7.46 (t, J = 7.4 
105 
 
Hz, 2H), 7.56 (br t, J = 7.6 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 8.00 (dd, J = 2.0, 7.6 Hz, 
2H); 
13
C NMR (100 MHz, CDCl3)  21.7, 52.1, 55.0, 56.0, 56.3, 69.5, 115.9, 126.7, 
127.7, 128.6, 128.7, 129.2, 129.8, 129.9, 133.1, 133.9, 134.5, 137.4, 140.3, 143.7, 202.3. 
HRMS (ESI): m/z calcd for C25H25NO3S: [M+Na
+
]; 442.1453, found 442.1451. 
 
Dicarbonyl(cyclooctatetraene)(triphenylphosphine)-iron: II-3. To a solution of 
tricarbonyl(cyclooctatetraene)iron I-118 (2.50 g, 10.0 mmol) and triphenylphosphine 
(4.00 g, 15.1 mmol) in acetone (90 mL) was added anhydrous trimethylamine N-oxide 
(1.34 g, 17.5 mmol) in one portion. Effervescence was observed upon the addition. The 
reaction was stirred at room temperature under a blanket of N2 and was monitored by 
TLC. After 60 min, additional triphenylphosphine (1.00 g, 3.77 mmol) and TMANO 
(0.36 g, 4.7 mmol) were added. After another 30 min, a final portion of TMANO (0.36 g, 
4.7 mmol) was added. After being stirred for a total of 2 h and 30 min, the reaction 
mixture was passed through a short bed of silica and the filter bed was washed with 
reagent acetone until the washings were colorless. The filtrates were concentrated, and 
the resulting red solid was adsorbed to silica using acetone. The material was purified by 
column chromatography (SiO2, hexanes-ethyl acetate = 20:1 to 4:1 gradient) to give the 
product  as a red solid (4.46 g, 93%): mp 169-171 °C; IR (KBr) 3053, 1969, 1913, 1481, 
1433 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  4.95 (d, JHP = 1.5 Hz, 8H), 7.37-7.43 (m, 9H), 
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7.47-7.57 (m, 6H); 
13
C NMR (100 MHz, CDCl3)  99.4, 128.4 (d, JCP = 9.5 Hz), 130.0 (d, 
JCP = 1.7 Hz), 133.3 (d, JCP = 10.4 Hz), 135.9 (d, JCP = 39.2 Hz), 217.6 (d, JCP =14.1 Hz). 
The NMR spectral data was consistent with the literature values.
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Dicarbonyl(bicyclo[5.1.0]octadienyl)(triphenylphosphine)iron(1+) 
Tetrafluoroborate: I-129b. To an ice-cold solution of iron complex II-3 (4.00 g, 8.36 
mmol) in Ac2O (37 mL) was carefully added a cold solution of aqueous tetrafluoroboric 
acid (60 wt %, 7.8 mL) in Ac2O (19 mL). After several minutes of stirring, the orange 
solution was added dropwise to a large excess of ether (1300 mL). The resulting 
precipitate was collected by vacuum filtration, washed with ether, and dried in vacuo to 
give I-129b as an orange powder (4.34 g, 92%): mp >133 °C dec; IR (KBr) 3075, 2025, 
1984, 1481, 1437 cm
-1
; 
1
H NMR (400 MHz, CD3OD)  1.09-1.19 (m, 1H), 1.24-1.34 (m, 
1H), 2.20-2.34 (br m, 1H), 2.34-2.48 (br m, 1H), 3.63-3.79 (br m, 1H), 4.91-5.06 (br m, 
1H), 5.30-5.43 (br m, 1H), 5.43-5.55 (br m, 1H), 7.45-7.68 (m, 15H), 7.71 (br t, J = 5.9 
Hz, 1H); The NMR spectral data was consistent with the literature values.
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 N-(Bicyclo[5.1.0]octa-3,5-dien-2-yl)-4-methyl-N-2-propen-1-yl-
benzenesulfonamide:(±)-II-4. To a stirring  suspension of cation I-129b (1.00 g, 1.77 
mmol) in water-saturated ether (60 mL) was added the potassium salt of N-tosyl 
allylamine (2.76 g, 11.1 mmol). After 30 min the orange ethereal layer was decanted 
from any solid and additional moist ether (60 mL) was added to the solid and the mixture 
stirred for 10 min.  This was repeated until the mother liquor was colorless. The collected 
ethereal layers were combined and concentrated to give a yellow solid (1.10 g, 90%): mp 
108-109 
o
C.  To a stirring solution of the intermediate complex (0.30 g, 0.44 mmol) in 
dry acetonitrile (20 mL) was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.11 g, 
0.48 mmol). After 1 h, the starting material had been consumed as indicated by TLC 
monitoring. The reaction mixture was passed through a short column of silica gel and the 
column flushed with CH2Cl2 until no further product appeared by TLC monitoring.  
These fractions were combined and concentrated, and the residue was purified by column 
chromatography (SiO2, hexanes–ethyl acetate = 4:1) to give (±)-II-4 (81 mg, 58%) as a 
pale yellow oil. IR (CH2Cl2) 1346, 1162 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  0.77 (dt, J = 
4.5, 8.4 Hz, 1H), 1.11-1.19 (m, 1H), 1.71 (dt, J = 4.8, 5.6 Hz, 1H), 1.79 (q, J = 8.4 Hz, 
1H), 2.35 (s, 3H), 3.75 (dd, J = 6.2, 16.2 Hz, 1H), 3.95 (dd, J = 5.8, 16.2 Hz, 1H), 4.96 
(br d, J = 11.6 Hz, 1H), 5.07 (dd, J = 2.0, 10.4 Hz, 1H), 5.08-5.12 (br s, 1H), 5.21 (dd, J = 
1.6, 18.8 Hz, 1H), 5.44 (dd, J = 6.0, 11.6 Hz, 1H), 5.60 (ddd, J = 2.8, 6.4, 11.6 Hz, 1H), 
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5.93 (tdd, J = 6.2, 10.0, 17.2 Hz, 1H), 6.10 (dd, J = 7.2, 12.0 Hz, 1H), 7.25 and 7.70 
(ABq, J = 8.4 Hz, 4H total); 
13
C NMR (100 MHz, CDCl3)  8.4, 14.8, 21.7, 44.1, 48.1, 
57.6, 117.1, 122.6, 126.6, 127.5, 127.9, 129.8, 135.3, 136.1, 137.7, 143.3. HRMS (ESI): 
m/z calcd for C18H21NO2SNa: [M+Na
+
]; 338.1191, found 338.1180. 
 
Self metathesis dimer:(±)-II-5. To a solution of (±)-II-4 (248 mg, 0.786 mmol) in 
freshly distilled CH2Cl2 (100 mL) under N2 was added Grubbs’ 1st generation catalyst 
(39 mg, 0.047 mmol, 6 mol%). The mixture was heated at reflux and the reaction 
progress was monitored by NMR spectroscopy. After 6 h additional Grubbs’ I (39 mg, 
0.047 mmol, 6 mol %) was added and heating continued for 12 h.  A final portion of 
Grubbs’ catalyst (20 mg, 0.024 mmol, 3 mol %) was added and heating continued for 12 
h. The reaction mixture was concentrated and purified by column chromatography (SiO2, 
hexanes–ethyl acetate = 7:3) to afford a mixture of diastereomeric dimers (±)-II-5 (180 
mg, 76%) as a colorless solid.  mp 162-163 
o
C; IR (CH2Cl2) 1336, 1161 cm
-1
; 
1
H NMR 
(400 MHz, CDCl3)  0.81-0.87 (m, 2H), 1.12-1.22 (m, 2H), 1.73-1.85 (m, 4H), 2.42 (s, 
6H), 3.73 (dd, J = 2.4, 16.0 Hz, 2H), 3.92 (br d, J = 14.8 Hz, 2H), 4.94 (dt, J = 2.8, 12.0 
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Hz, 2H), 5.05-5.10 (br s, 2H), 5.46 (dd, J = 6.2, 11.4 Hz, 2H), 5.61 (dtd, J = 2.8, 6.0, 12.0 
Hz, 2H), 5.83 (q, J = 3.2 Hz, 2H), 6.14 (dd, J = 7.4, 11.4 Hz, 2H), 7.29 and 7.72 (ABq, J 
= 8.0 Hz, 8H total); 
13
C NMR (100 MHz, CDCl3)  8.2, 14.7, 21.7, 44.1, 46.9, 57.6, 
122.6, 126.7, 127.5, 127.7, 129.9, 130.5, 135.3, 137.5, 143.4. Anal. Calcd for 
C34H38N2O4S2: C, 67.75; H, 6.35.  Found:  C, 67.29; H, 5.92. 
 
Tricarbonyl(
4–7-styrylcyclohepta-1,3,5-triene)iron:(±)-I-128. To a 1 L round-
bottomed flask, (cyclooctatetraene)Fe(CO)3 I-118 (10.0 g, 40.9 mmol) was dissolved in 
dry acetone (50 mL) at -23 
0
C under N2. Dry pyridine (3 mL, 40.9 mmol)
129
 was added 
and mixture stirred for 5 min. A solution/suspension of tropylium tetrafluoroborate (8.73 
g, 49.1 mmol) in dry acetone (400 mL) was added and the reaction mixture was stirred 
for 8 h maintaining the temperature at -23 
0
C. The reaction mixture was warmed to room 
temperature and stirred overnight. The clear reddish solution was concentrated under 
reduced pressure and dried. To the solid residue was added ether (200 mL) and the slurry 
stirred for 2 h and filtered. The above process was repeated three times with the solid 
residue. The combined filtrate was concentrated and applied to a column of silica. Elution 
(100% hexane) gave a bright yellow solid (±)-I-128  (10.42 g, 75%). mp  43 – 47 0C; 1H 
NMR (300 MHz, CDCl3)  3.10-3.03 (m, 1H), 3.34-3.21 (m, 2H), 5.18-5.10 (m, 1H), 
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5.43-5.33 (m, 2H), 5.92-5.82 (m, 2H), 6.46 (d, J = 16.0 Hz, 1H), 7.37-7.19 (m, 5H); 
13
C 
NMR (75 MHz, CDCl3)  46.9, 55.8, 64.9, 87.6, 95.3, 126.4, 127.6, 128.1, 128.9, 129.1, 
130.4, 134.2, 137.6   211.3. The NMR spectral data was consistent with the literature 
values.
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Tricarbonyl(η5-7-styrylcyclohepta-2,4-dien-1-yl)iron(+1) tetrafluoroborate:(±)-II-7. 
To a 250 mL round bottomed flask, (7-styrenyl-1,3,5-cycloheptatriene)Fe(CO)3 (±)-I-87  
(8.0 g, 24 mmol) was dissolved in  acetic anhydride (150 mL) at 0 
0
C with stirring. An 
ice-cold solution of fluoroboric acid (60 wt%, 23.40 mL, 240.0 mmol) in acetic 
anhydride (25 mL) was added dropwise to the stirring mixture. After 20 min of stirring a 
yellow-gray precipitate began to form. The reaction mixture was added dropwise into a 
large excess of ether (3.5 L). The solid yellow cation was isolated by filtration and dried 
under high vacuum (8.88 g, 88%). IR (KBr) 2112, 2067, 760, 697 cm
-1
; 
1
H NMR (300 
MHz, d6-acetone)  1.41 (m, 1H), 2.68 (m, 1H), 4.25 (m, J = 8.0 Hz, 1H), 5.16 (m, 2H), 
5.93 (dd, J = 16.0, 8.3 Hz, 1H), 6.29 (m, 1H), 6.62 (m, J = 16.0 Hz, 1H), 7.33 (m, 5H), 
7.47 (tq, J = 6.1, 1.2 Hz, 1H). The NMR spectral data was consistent with the literature 
values.
113
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N-(6-styryl-2,4-cycloheptadien-1-yl)-4-methyl-N-2-propen-1-yl-
benzenesulfonamide:(±)-II-8. To a solution of (±)-II-7 (0.10 g, 0.24 mmol) in 
acetonitrile (10 mL), under N2, was added the potassium salt of tosyl allylamine (0.140 g, 
0.562 mmol).  The mixture was stirred for 2 h, at which time TLC indicated the 
disappearance of (±)-II-7.  The reaction mixture was dried under reduced pressure and 
the solid residue was purified by column chromatography (SiO2, hexanes–ethyl acetate = 
4:1) to give the product (0.113 g, 86%) as a yellow foam. mp 47-48 
o
C; IR (CH2Cl2) 
2047, 1965, 1338, 1157 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  1.14 (q, J = 12.4 Hz, 1H), 
1.55 (br d, J = 13.2 Hz, 1H), 1.91 (d, J = 7.2 Hz, 1H), 2.40 (s, 3H), 2.82-2.92 (m, 2H), 
3.68 (dd, J = 6.0, 16.8 Hz, 1H), 3.93 (dd, J = 5.2, 16.8 Hz, 1H), 4.38 (dd, J = 3.6, 12.0 Hz, 
1H), 5.14 (d, J = 10.4 Hz, 1H), 5.22-5.33 (m, 3H), 5.80-5.94 (m, 2H), 6.33 (d, J=15.2 Hz, 
1H), 7.20-7.38 (m, 7H), 7.77 (d, J = 8.0 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  21.6, 
36.4, 44.0, 46.2, 57.1, 58.6, 61.5, 88.3, 88.6, 117.0, 126.3, 127.3, 127.6, 128.8, 129.1, 
130.1, 135.2, 136.5, 137.1, 137.9, 143.8. 
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N-(6-styryl-2,4-cycloheptadien-1-yl)-4-methyl-N-2-propen-1-yl-
benzenesulfonamide:(±)-II-9. To the prior complex (±)-II-8 (0.277 g, 0.509 mmol) in 
acetonitrile (15 mL), under N2, was added cerium ammonium nitrate (0.470 g, 0.858 
mmol). The mixture was stirred at room temperature for 1 h, at which time TLC indicated 
complete disappearance of the starting material. The reaction mixture was filtered 
through a short column of silica gel, which was washed with CH2Cl2 until the entire 
product was eluted.  These fractions were combined, concentrated, and the residue was 
purified by column chromatography (SiO2, hexanes–ethyl acetate = 17:3) to give (±)-II-9 
(0.106 g, 51%) as a faint yellow oil. IR (CH2Cl2) 1336, 1162 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3)  1.96 (br d, J = 12.6 Hz, 1H), 2.08 (td, J = 10.9, 12.6 Hz, 1H), 2.42 (s, 3H), 3.30-
3.42 (m, 1H), 3.73 (dd, J = 6.0, 16.5 Hz, 1H), 3.85 (dd, J = 6.0, 16.5 Hz, 1H), 4.85-4.94 
(m, 1H), 5.13 (dd, J = 0.9, 8.7 Hz, 1H), 5.23 (dd, J = 1.5, 16.8 Hz, 1H), 5.39 (br d, J = 
11.1 Hz, 1H), 5.64-5.75 (m, 3H), 5.91 (tdd, J = 6.0, 10.5, 17.1 Hz, 1H), 6.11 (dd, J = 8.4, 
15.9 Hz, 1H), 6.39 (d, J = 15.9 Hz, 1H), 7.20-7.38 (m, 7H), 7.77 (d, J = 8.0 Hz, 2H); 
13
C 
NMR (75 MHz, CDCl3)  21.7, 39.0, 43.2, 47.9, 59.1, 117.6, 123.9, 125.1, 126.3, 127.4, 
127.5, 128.8, 129.8, 129.9, 132.6, 134.4, 136.1, 137.3, 137.6, 137.9, 143.5. HRMS (ESI): 
m/z calcd for C25H27NO2SNa: [M+Na
+
]; 428.1660, found 428.1657. 
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N-Toluenesulfonyl-2-azabicyclo[4.4.1]undeca-5,7,9-triene: (±)-II-10. To a solution of 
(±)-II-9 (60 mg, 0.15 mmol) in freshly distilled dichloromethane (20 mL), was added 
Grubbs’ 2nd generation catalyst (7 mg, 0.008 mmol, 5 mol %). The reaction mixture was 
stirred under N2 and the reaction progress was monitored by 
1
H NMR spectroscopy. After 
4 h all signals for the starting material disappeared. The reaction mixture was 
concentrated under a flow of N2, and the residue purified by column chromatography 
(SiO2, hexanes–ethyl acetate = 4:1) to afford (±)-II-10 as a colorless oil (37 mg, 82%). 
1
H 
NMR (400 MHz, CDCl3)  2.43 (s, 3H), 2.81 (ddd, J = 1.2, 8.8, 14.4 Hz, 1H), 2.97-2.99 
(narrow m, 2H), 3.06 (ddd, J = 1.2, 3.6, 14.4 Hz, 1H), 4.06-4.09 (narrow m, 2H), 4.59 (td, 
J = 4.0, 8.4 Hz, 1H), 5.56-5.60 (narrow m, 2H), 6.20-6.24 (m, 1H), 6.30 (qd, J = 1.2, 5.4 
Hz, 1H), 6.43 (qd, J = 2.0, 5.4 Hz, 1H), 7.31 and 7.73 (ABq, JAB = 8.2 Hz, 4H total); 
13
C 
NMR (100 MHz, CDCl3)  21.7, 38.0, 44.6, 55.9, 67.6, 125.0, 127.6, 129.5, 130.0, 130.1, 
131.9, 132.6, 134.8, 143.7, 144.5.  This compound decomposed upon standing and thus a 
satisfactory HRMS was not obtained. 
 
 
114 
 
 
(6-Styrenyl-2,4-cyclohepta-1-yl)phthalimide: (±)-II-11.  In 250 mL round bottom flask 
cation (±)-II-7 (1.000 g, 2.375 mmol) was added freshly distilled CH2Cl2 (100 mL). To 
this suspension was added potassium phthalimide (0.659 g, 3.356 mmol). The whole 
mixture was stirred at room temperature under N2 for 3 h and then quenched by adding 
water (50 mL). The mixture was extracted several times with CH2Cl2, the combined 
extracts were dried (Na2SO4) and concentrated to give a pale yellow crude solid (1.257 
g). This crude material was dissolved in methanol (50 mL) and stirred under N2 at room 
temperature for 10 min, then solid cerium ammonium nitrate (IV) (3.42 g, 6.24 mmol) 
was added and the mixture was stirred for 2 h. The solvent was evaporated and water (50 
mL) was added to the solid residue. The product was extracted several times with 
CH2Cl2; the combined extracts were dried (Na2SO4) and concentrated. The residue was 
purified by column chromatography (SiO2, hexane-ethyl acetate = 3:1) to afford a light 
white solid (±)-II-11 (648 mg, 81%). mp 107-108 
0
C; 
1
H NMR (300 MHz, CDCl3)  2.05 
(br d, J = 13.2 Hz, 1H), 2.86 (td, J = 11.1, 13.2 Hz, 1H), 3.56-3.58 (m, 1H), 5.29 (d, J = 
10.5 Hz, 1H), 5.78-5.89 (m, 4H), 6.18 (dd, J = 8.4, 15.9 Hz, 1H), 6.48 (d, J = 15.9 Hz, 
1H), 7.21-7.35 (m, 5H), 7.72 (dd, J = 3.1, 5.4 Hz, 2H), 7.87 (dd, J = 3.1, 5.4 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3)  38.2, 44.0, 50.5, 123.3, 123.9, 124.0, 126.2, 127.3, 128.6, 
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129.8, 132.0, 132.2, 133.6, 134.1, 136.9, 137.2, 167.7. elemental analysis calcd (%) for 
C23H19NO2: C 80.92, H 5.61; found: C 80.61, H 5.67. 
 
2-Phthalimido-4-(2’-styrenyl)-6,7-dioxabicyclo[3.2.2]non-8-ene: (±)-II-12.   To a 50 
mL two-necked round bottom flask equipped with a condenser, was charged with (±)-II-
11   (1.00 g, 2.93 mmol) in dry chloroform (40 mL) and tetraphenylporphine (TPP) (36 
mg, 3 mol %). The resulting deep purple solution was irradiated with a 100-W halogen 
lamp, while ultra pure O2 was bubbled through the solution and stirred at 0 
o
C for 8 h. 
The mixture was concentrated and the residue was purified by column chromatography 
(SiO2, hexane: ethyl acetate= 1:1) to give the endoperoxide (±)-II-12   (923 mg, 91%) as 
a colorless solid, mp 180-181 
o
C. 
1
H NMR (400 MHz, CDCl3)  1.77 (br d, J = 9.6 Hz, 
1H), 2.11 (q, J = 10.1 Hz, 1H), 3.01 (q, J = 3.3 Hz, 1H), 4.79 (m, 2H), 4.84 (dd, J = 3.1, 
9.9 Hz, 1H), 5.98 (dd, J = 6.3, 11.1 Hz, 1H), 6.43-6.51 (m, 2H), 6.89 (dd, J = 6.3, 6.1 Hz, 
1H), 7.21-7.33 (m, 5H), 7.75 (dd, J = 3.6, 5.6 Hz, 2H), 7.86 (dd, J = 3.5, 5.6 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 29.8, 45.8, 52.0, 80.4, 81.1, 123.6, 123.8, 126.4, 127.9, 128.7, 
128.8, 130.8, 131.8, 131.9, 134.5, 136.8, 167.8. Anal. Calcd for C23H19 NO4: C, 73.98; H 
5.13. Found: C, 73.87; H, 5.27. 
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4-Phthalimido-6-(2’-styryl)-3,7-dihydroxycycloheptene: (±)-II-13. To a solution of 
(±)-II-12 (50 mg, 0.15 mmol) in CH2Cl2 (1 mL) was added activated zinc dust (50 mg). 
To the resulting suspension was added a solution of glacial acetic acid (0.02 mL, 0.34 
mmol) in CH2Cl2 (2 mL) in 3 portions over 30 min. The reaction mixture was stirred at 
room temperature for 15 min, after which the mixture was loaded onto a column 
chromatography (SiO2, hexanes-ethyl acetate = 2:3) to give (±)-II-13 (47 mg, 92%) as a 
colorless solid; mp 225-227 
o
C; 
1
H NMR (400 MHz, CD3OD)  1.95 (td, J = 2.8, 14.0 
Hz, 1H), 2.47 (dq, J = 2.8, 10.1 Hz, 1H), 2.70 (td, J = 11.8, 14.0 Hz, 1H),  4.25-4.10 (m, 
2H),  4.99-4.93 (m, 1H), 5.70 (td, J = 2.8, 12.6 Hz, 1H), 5.80 (td, J = 2.8, 12.6 Hz, 1H), 
6.19 (dd, J = 9.0, 16.4 Hz, 1H), 6.46 (d, J = 16.4 Hz, 1H), 7.16 (t, J = 7.4, 1H), 7.25 (t, J = 
7.6 Hz, 2H),  7.37 (d, J = 7.6 Hz, 2H),  7.88-7.75 (m, 4H); 
1
H NMR (400 MHz, d6-
acetone)  2.01 (td, J = 2.8, 14.0 Hz, 1H), 2.53-2.42 (m, 1H),  2.73 (td, J = 11.8, 14.4 Hz, 
1H), 3.99 (d, J = 4.8 Hz, 1H), 4.16 (ddd, J = 3.2, 10.4, 12.4 Hz, 1H), 4.31-4.25 (m, 1H),  
4.53 (d, J = 5.6 Hz, 1H), 4.99-4.93 (m, 1H), 5.73 (td, J = 2.8, 12.4 Hz, 1H), 5.82 (td, J = 
2.7, 12.8 Hz, 1H), 6.28 (dd, J = 8.8, 16.0 Hz, 1H), 6.50 (d, J = 16.0 Hz, 1H), 7.18 (tt, J = 
1.6, 7.4 Hz, 1H), 7.28 (t, J = 7.2 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.82 (s, 4H); 
13
C NMR  
(75 MHz, d6-acetone)  37.7,  50.5, 55.5, 70.2,  73.5,  123.7, 127.1,  127.9,  129.2,  131.9,  
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133.3,  134.4, 134.5, 134.8,  137.4,  138.6, 168.9. HRMS (ESI): m/z calcd for 
C23H21NO4: [M+Na
+
]; 398.1363, found 398.1358.  
 
(1S*,2S*,5S*,6S*) N-(2,5-Diacetoxy-6-styryl-3-cyclohepten-1(S*)-yl)phthalimide: 
(±)-II-14.  To a mixture of diol (±)-II-13 (400 mg, 1.11 mmol) and p-toluenesulfonyl 
chloride (21 mg, 0.1 mmol) was added acetic anhydride (5 mL). The resulting suspension 
was heated at reflux under N2 for 1 h. The reaction mixture was concentrated and the 
residue was purified by column chromatography (SiO2, hexanaes–ethyl acetate = 3:2) to 
afford (±)-II-14 (406 mg, 82%) as a colorless solid: mp  65-66 
o
C; 
1
H NMR (400 MHz, 
CDCl3)   1.75 (s, 3H), 1.87 (s, 3H), 2.01 (br d, J = 14.4 Hz, 1H), 2.63 (br q, J = 9.6 Hz, 
1H), 2.85 (q, J = 12.8 Hz, 1H), 4.42 (t, J = 10.8 Hz, 1H), 5.57-5.49 (br m, 2H), 5.70 (br d, 
J = 13.2 Hz, 1H), 5.86 (dd, J = 9.4, 15.6 Hz, 1H), 6.02 (br d, J = 10.4 Hz, 1H), 6.34 (d, J 
= 15.6 Hz, 1H), 7.25-7.10 (m, 5H), 7.80-7.63 (m, 4H); 
13
C NMR (100 MHz, CDCl3)  
20.9, 21.2, 36.2,  47.6, 51.4, 72.1, 74.1, 123.6, 126.4, 127.7, 128.8, 130.2, 130.3, 131.6, 
131.9, 132.7, 134.4, 137.0, 167.9, 169.6,  170.3. Anal. Calcd for C27H25 NO6: C, 70.58; H 
5.48. Found: C, 70.28; H, 5.45. 
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rac-2-Formyl-4-phthalimido-6,7-dioxabicyclo[3.2.2]non-8-ene: (±)-II-15.  To a 
mixture of (±)-II-11 (1.00 g, 2.93 mmol) in a mixture of t-BuOH (20 mL), ethyl acetate 
(5 mL) and water (25 mL, was added at room temperature methanesulfonamide (60 mg, 
0.59 mmol).  The mixture was cooled to 0 
o
C with an ice bath and then solid AD-mix β 
(4.325 g) was added.  The reaction mixture was stirred for 34 h at 0 
o
C, after which 
monitoring by TLC indicated the disappearance of starting material.  The reaction was 
quenched with water (20 mL). The mixture was transferred to separatory funnel, and the 
top, organic layer was decanted.  The aqueous layer was extracted several times with 
ethyl acetate and the combined organic layers were dried (Na2SO4), concentrated and the 
residue purified by column chromatography (SiO2, hexanes:ethyl acetate = 2:3) to afford 
a 1:1 mixture of diastereomeric diols (1.050 g, 96%) as a colorless foam. This material 
was used in the next step without further characterization.  To a solution of 
diastereomeric diols (1.00 g, 2.67 mmol) in CHCl3 (30 mL) was added 
tetraphenylporphine (15 mg).  The deep purple solution was irradiated for a 5 h period 
with a commercially 100-W halogen lamp, while ultra pure O2 was bubbled through the 
solution. The organic solvent was removed to afford a mixture of diastereomeric 
endoperoxide diols, (+)-II-21 and (+)-II-22 which were used in the next step without 
further purification (1.005 g).  To a solution of (+)-II-21 / (+)-II-22 (500 mg, 1.29 mmol) 
in dry CH2Cl2 (25 mL) at –78 
o
C was added solid Pb(OAc)4 (544 mg, 1.23 mmol).  The 
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mixture was stirred for 30 min, and then quenched with water.  The mixture was 
extracted several times with CH2Cl2, and the combined extracts were dried (Na2SO4) and 
concentrated.  Purification of the residue by column chromatography (SiO2, 
hexanes:ethyl acetate = 3:2) gave (±)-II-15 (244 mg, 63%) as a colorless solid: mp  179-
180 
o
C; 
1
H NMR (400 MHz, CDCl3)  2.05-1.97 (m, 1H), 2.11 (q, J = 13.0 Hz, 1H), 3.16 
(dd, J = 5.0, 13.0 Hz, 1H), 4.86-4.80 (m, 2H), 5.26 (d, J = 7.2 Hz, 1H), 6.43 (dd, J = 7.2, 
9.3 Hz, 1H), 6.77 (dd, J = 7.2, 9.3 Hz, 1H), 7.88-7.78 (m, 4H), 9.65 (s, 1H); 
13
C NMR 
(100 MHz, CDCl3)  23.9 , 52.1, 54.3, 75.4, 80.0, 123.7,  124.6,  129.8,  131.7,  134.6,  
167.7,  199.0 ppm; HRMS (ESI): m/z calcd for C16H13NO5+Na+: 322.0686 [M+Na
+
]; 
found: 322.0685. 
       
Singlet oxygen cycloaddition of diastereomeric diol mixture: To a stirred solution of 
the diastereomeric mixture of diols (1.300 g, 3.467 mmol) in 35 ml CHCl3 was added 
tetraphenylporphine (TPP) (25 mg, 0.041 mmol). The deep purple solution was irradiated 
with a 100-W halogen lamp, while ultra pure O2 was bubbled through the solution and 
stirred at room temperature for 6 h. The mixture was concentrated and the residue was 
purified by column chromatography (SiO2, hexanes:ethyl acetate 3:2) to give (+)-II-21 as 
a white foam (671 mg, 48 %) followed by (+)-II-22 as a white foam (626 mg, 44%). 
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(Less polar) 4-(1’R,2’R-Dihydroxy-2’-phenylethyl)-2-phthalimido-6S,7R-
dioxabicyclo[3.2.2]non-8-ene: (+)-II-21. mp 97-98 
oC; [α]D
20 
= + 41.17 (c=0.0011, 
CH2Cl2); 
1
H NMR (300 MHz, CDCl3)  1.60 (br d, J = 12.6 Hz, 1H), 2.10-2.03 (m, 1H), 
2.29 (dd, J = 5.7, 12.6 Hz, 1H), 2.48 (d, J = 4.8 Hz, 1H), 2.68 (d, J = 3.9 Hz, 1H),  3.43-
3.39 (narrow m, 1H), 4.73-4.68 (m, 3H), 5.18 (d, J = 7.2 Hz, 1H),  6.41 (dd, J = 7.5, 8.4 
Hz, 1H), 6.71 (dd, J = 7.2, 9.1 Hz, 1H), 7.39-7.26 (m, 5H), 7.85-7.71 (m, 4H); 
13
C NMR 
 (75 MHz, CDCl3) 27.6, 43.8, 52.2, 74.0, 76.9, 78.1, 79.8, 123.6, 125.8, 126.5, 128.4, 
128.8, 128.9, 131.8, 134.5, 141.0, 167.8; HRMS (ESI): m/z calcd for C23H21NO6+Na
+
: 
430.1261 [M+Na
+
]; found: 430.1254. 
(More polar) 4-(1’R,2’R-Dihydroxy-2’-phenylethyl)-2-phthalimido-6R,7S-
dioxabicyclo[3.2.2]non-8-ene: (+)-II-22.  mp 90-92
oC. [α]D
20 
= +33 (c=0.0011, CH2Cl2); 
1
H NMR (300 MHz, CDCl3)  1.65 (td, J = 4.0, 12.8 Hz, 1H), 2.07-1.98 (m, 1H), 2.23 (q, 
J = 12.6 Hz, 1H), 3.25-3.10 (br s, 2H), 3.80-3.75 (narrow m, 1H), 4.49 (dd, J = 2.4, 6.9 
Hz, 1H), 4.58 (dd, J = 4.4, 12.8 Hz, 1H), 4.70 (d, J = 7.2 Hz, 2H), 6.47 (dd, J = 8.0, 8.8 
Hz, 1H), 6.65 (dd, J = 7.6, 8.8 Hz, 1H),  7.40-7.25 (m, 5H),  7.90-7.70 (m, 4H); 
13
C NMR 
  (75 MHz, CDCl3) 23.4, 44.0, 52.4, 75.1, 77.0, 79.7, 81.4, 123.5, 126.5,  126.6, 127.3, 
128.7, 129.0, 131.8,  134.4, 140.7, 167.0. HRMS (ESI): m/z calcd for C23H21NO6+Na
+
 
[M+Na
+
]; found: 430.1252.  
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2R-Formyl-4S-phthalimido-6,7-dioxabicyclo[3.2.2]non-8-ene: (+)-II-15.  To a 
solution of the less polar endoperoxide diol (+)-II-21 (650 mg, 1.60 mmol) dissolved in 
dry CH2Cl2 (30 mL) was added solid Pb(OAc)4 (1.061 g, 2.396 mmol).  The reaction 
mixture was stirred for 15 min, and then quenched with water, and the mixture was 
extracted several times with CH2Cl2.  The combined extracts were dried (Na2SO4) and 
concentrated, and the residue was purified by column chromatography (SiO2, hexanes-
ethyl acetate = 3:2) to afford (+)-II-15 (439 mg, 93%) as a colorless solid.  m.p. 55-57 
o
C; [ ]D
20
 = +88 (c 0.0011, CH2Cl2); the NMR spectral data for (+)-II-15 was identical to 
that for the racemic material (±)-II-15. 
 
2S-Formyl-4R-phthalimido-6,7-dioxabicyclo[3.2.2]non-8-ene: (-)-II-15. The diol 
cleavage of (+)-II-22 (0.668, 1.641 mmol) was carried out in a fashion similar to the 
cleavage of (+)-II-21 to afford the optically active aldehyde (-)-II-15 (371 mg, 75%). mp 
95-97 
o
C; [ ]D
20
 = -102 (c 0.00102, CH2Cl2).  The NMR spectral data for (-)-II-15 was 
identical with that for the racemic compound (±)-II-15. 
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4-Hydroxymethyl-2-phthalimido-8,9-dioxabicyclo[3.2.2]non-6-ene: (±)-II-16.  To a 
mixture of THF (10 mL) and glacial acetic acid (2 mL) was added (±)-II-15 (50.0 mg, 
0.167 mmol) and the mixture was stirred for 5 min. Solid NaBH3CN (16 mg, 0.254 
mmol) was added, and monitoring of the reaction by TLC indicated complete 
disappearance of starting material after 1 h.  The solvent was evaporated and the residue 
was purified by column chromatography (SiO2, hexanes:ethyl acetate = 2:3) to afford (±)-
II-16 (51 mg, quant.) as a colorless solid: mp = 139-141
o
C; 
1
H NMR (400 MHz, CDCl3) 
 1.53 (br s, 1H), 1.61 (td, J = 4.4, 12.8 Hz, 1H), 1.84 (q, J = 12.8 Hz, 1H), 2.40-2.31 (m, 
1H), 3.47-3.38 (m, 1H), 3.66-3.60 (m, 1H), 4.81-4.73 (m, 2H), 4.98 (d, J = 7.2 Hz, 1H), 
6.45 (dd, J = 6.8, 9.8 Hz, 1H), 6.77 (dd, J = 7.2, 9.8 Hz, 1H), 7.90-7.72 (m, 4H); 
13
C 
NMR (100 MHz, d6-acetone)  26.6, 44.7,  52.3, 64.2, 78.3, 80.0, 123.6, 124.9, 129.7, 
131.9, 134.5, 167.8. HRMS (ESI): m/z calcd for  C16H15NO5: [M+Na
+
]; 324.0842, found  
324.0839. 
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4(S)-Hydroxymethyl-2(S)-phthalimido-8,9-dioxabicyclo[3.2.2]non-6-ene: (+)-II-16.  
The reduction of (+)-II-15 (400 mg, 1.34 mmol) was carried out in a fashion similar to 
the reduction of (±)-102, to afford the optically active primary alcohol (+)-II-16 (329 mg, 
82%). mp 163-166 
o
C; [ ]D
20
 = +119 (c 0.00176, CH2Cl2).  The NMR spectral data for 
(+)-II-16 was identical with that for the racemic compound (±)-II-16. 
 
4(R)-Hydroxymethyl-2(R)-phthalimido-8,9-dioxabicyclo[3.2.2]non-6-ene: (-)-II-16.  
The reduction of (-)-II-15 (360 mg, 1.204 mmol) was carried out in a fashion similar to 
the reduction of (±)-II-15, to afford the optically active primary alcohol (-)-II-16 (281 
mg, 78%). mp 167-169 
o
C; [ ]D
20
 = -95 (c 0.00082, CH2Cl2).  The NMR spectral data for 
(-)-II-16 was identical with that for the racemic compound (±)-II-16. 
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4-(t-Butyldiphenylsilyloxy)methyl-2-phthalimido-8,9-dioxabicyclo[3.2.2]non-6-ene: 
(±)-II-17.  To a solution of (±)-II-16 (40.0 mg, 0.133 mmol) in freshly distilled CH2Cl2 
(5 mL) cooled to 0 
o
C, was added imidazole (18 mg, 0.3 mmol), followed by dropwise 
addition of t-butylchlorodiphenylsilane (44 mg, 0.2 mmol) over a period of 15 min at 0 
o
C.  After stirring at room temperature for 3 h, monitoring of the reaction mixture by TLC 
indicated complete disappearance of starting material.  The mixture was quenched with 
water and extracted several times with CH2Cl2.  The combined extracts were 
concentrated and the residue was purified by column chromatography (SiO2, 
hexanes:ethyl acetate = 4:1) to give (±)-II-17 (65 mg, 91%) as a colorless foam; mp  44-
46 
o
C; 
1
H NMR (400 MHz, CDCl3)  1.06 (s, 9H), 1.47 (td, J = 4.8, 12.8 Hz, 1H), 1.78 
(q, J = 12.7 Hz, 1H), 2.50-2.38 (m, 1H), 3.36 (dd, J = 8.6, 10.6, 1H), 3.60 (dd, J = 5.0, 
10.4 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.75 (dd, J = 4.8, 12.8 Hz, 1H), 5.01 (d, J = 7.2 
Hz, 1H), 6.25 (ddd, J= 0.8, 7.2, 9.2 Hz, 1H), 6.71 (ddd, J = 1.2, 7.2, 9.6 Hz, 1H), 7.48-
7.37 (m, 6H), 7.65-7.60 (m, 4H), 7.87-7.70 (m, 4H); 
13
C NMR (100 MHz, CDCl3)  19.4, 
26.3, 27.0, 44.5, 52.4, 65.0, 78.6, 80.0, 123.5, 125.0, 128.0, 129.4, 130.0, 131.9, 133.3, 
134.4, 135.7, 167.7. HRMS (ESI): m/z calcd for C32H33NO5Si: [M+Na
+
]; 562.2020, 
found 562.2009. 
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4S-(t-Butyldiphenylsilyloxy)methyl-2S-phthalimido-8,9-dioxabicyclo[3.2.2]non-6-
ene: (+)-II-17.  Protection of (+)-II-17 (200 mg, 0.664 mmol) with t-butyldiphenylsilyl 
chloride was carried out in a fashion similar to the reaction of (±)-II-16, to afford (+)-104 
(311 mg, 87%). mp 44-47 
o
C; [ ]D
20
 = +48.5 (c 0.00132, CH2Cl2).  The NMR spectral 
data for (+)-II-17 was identical with that for the racemic compound (±)-II-17. 
 
4R-(t-Butyldiphenylsilyloxy)methyl-2R-phthalimido-8,9-dioxabicyclo[3.2.2]non-6-
ene: (-)-II-17.  Protection of (-)-II-16 (200 mg, 0.664 mmol) with t-butyldiphenylsilyl 
chloride was carried out in a fashion similar to the reaction of (±)-II-16, except for 15 hrs 
to afford (-)-II-17 (358 mg, 99%). mp 45-47 
o
C; [ ]D
20
 = -47.5 (c 0.00122, CH2Cl2).  The 
NMR spectral data for (-)-II-17 was identical with that for the racemic compound (±)-II-
17. 
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6-(t-Butyldiphenylsilyloxy)methyl-3,7-dihydroxy-4-phthalimido-cycloheptene (±)-II-
18.  To a solution of (±)-II-17 (55.0 mg, 0.102 mmol) in CH2Cl2 (5 mL) was added 
activated zinc dust (55 mg).  To this suspension was added acetic acid (61 mg, 1.020 
mmol) dissolved in CH2Cl2 (3 mL) dropwise over a 10 min period. The reaction mixture 
was stirred for 15 min at room temperature, the solvent was evaporated, and the residue 
was purified by column chromatography (SiO2, hexanes:ethyl acetate = 2:3) to afford (±)-
II-18 (52 mg, 94%) as a colorless foam: mp = 51-53
o
C; 
1
H NMR (400 MHz, CDCl3)  
1.07 (s, 9H), 1.56 (td, J = 2.4, 14.4 Hz, 1H), 1.87 (d, J = 6.8 Hz, 1H), 2.00-1.90 (br m, 
1H), 2.38 (td, J = 12.0, 14.8 Hz, 1H), 3.69 (dd, J = 7.2, 10.2 Hz, 1H), 3.75 (dd, J = 4.0, 
10.2 Hz, 1H), 4.07 (d, J = 2.4 Hz, 1H), 4.14 (ddd, J = 2.4, 10.0, 12.4 Hz, 1H), 4.45 (br d, 
J = 9.6 Hz, 1H),  4.93-4.87 (m, 1H), 5.68 (td, J = 2.6, 12.8 Hz, 1H), 5.80 (td, J = 2.8, 12.8 
Hz, 1H), 7.45-7.34 (m, 6H), 7.85-7.63 (m, 8H); 
13
C NMR (100 MHz, CDCl3)  19.3 , 
27.0, 33.1, 44.8,  55.0,  68.7, 70.2, 74.1,  123.4, 128.06, 128.11,  130.17, 130.23,  132.02, 
132.07, 132.7, 134.2, 135.7, 135.8, 136.3, 168.7. Anal. Calcd for C32H35NO6Si: C, 70.95; 
H 6.51. Found: C, 70.66; H, 6.60. 
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6S-(t-Butyldiphenylsilyloxy)methyl-3S,7R-dihydroxy-4S-phthalimido-cycloheptene: 
(+)-II-18.  The reduction of endoperoxide (+)-II-17 (80 mg, 0.15 mmol) with Zn and 
acetic acid was carried out in a fashion similar to reduction of the racemic endoperoxide 
(±)-II-17, to afford (+)-II-18 (73 mg, 91%). mp  53-55 
o
C; [ ]D
20
 = +17 (c 0.0011, 
CH2Cl2).  The NMR spectral data for (+)-II-18 was identical with that for the racemic 
compound (±)-II-18. 
 
6R-(t-Butyldiphenylsilyloxy)methyl-3R,7S-dihydroxy-4S-phthalimido-cycloheptene: 
(-)-II-18.  The reduction of endoperoxide (-)-II-17 (80 mg, 0.15 mmol) with Zn and 
acetic acid was carried out in a fashion similar to reduction of the racemic endoperoxide 
(±)-II-17, to afford (-)-II-18 (80 mg, 91%). mp 57-59 
o
C; [ ]D
20
 = -11 (c 0.00062, 
CH2Cl2).  The NMR spectral data for (-)-II-18 was identical with that for the racemic 
compound (±)-II-18. 
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6-(t-Butyldiphenylsilyloxy)methyl-2,3,4,5-tetrahydroxy-1-phthalimido-
cycloheptane: (±)-II-19.  To a solution of (±)-II-18 (44 mg, 0.081 mmol) in acetone (5 
mL) was added a solution of N-methylmorpholine N-oxide (14 mg, 0.122 mmol) in water 
(1 mL), followed by a solution of OsO4 (0.05 mL, 0.2 M in toluene, 0.01 mmol). The 
reaction mixture was stirred for 2 h at room temperature under N2.  The solvent was 
evaporated and the residue was purified by column chromatography (SiO2, hexanes:ethyl 
acetate = 1:4) to afford (±)-II-19 (41 mg, 88%) as a colorless foam; mp  86-87 
o
C; 
1
H 
NMR (400 MHz, CD3OD)  1.00 (s, 9H), 1.56 (d, J = 14.0 Hz, 1H), 1.76-1.67 (m, 1H), 
2.61 (td, J = 12.0, 14.4 Hz, 1H), 3.68-3.58 (m, 2H), 3.83 (d, J = 6.8 Hz, 1H), 3.89 (dd, 
J=4.2, 9.8 Hz, 1H), 3.97 (d, J = 4.8 Hz, 1H), 4.11 (dt, J = 1.6, 11.0 Hz, 1H), 4.5 (dd, J = 
7.0, 10.2 Hz, 1H), 7.35-7.22 (m, 6H), 7.65-7.55 (m, 4H), 7.90-7.78 (m, 4H); 
13
C NMR 
(100 MHz, CD3OD)  20.2, 27.5, 29.4,  58.5, 67.9, 72.1,  73.6,  75.8,  78.5, 124.2, 
128.84, 128.88, 130.88, 130.93, 133.5, 135.4, 136.8, 136.9, 169.8. HRMS (ESI): m/z 
calcd for C32H37NO7Si: [M+Na
+
]; 598.2232, found 598.2219. 
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6S-(t-Butyldiphenylsilyloxy)methyl-2R,3S,4R,5S-tetrahydroxy-1S-phthalimido-
cycloheptane: (–)-II-19.  The dihydroxylation of (+)-II-18 (65 mg, 0.12 mmol) with 
catalytic OsO4 was carried out in a fashion to the dihydroxylation of (±)-II-18, to afford 
(–)-II-19 (61 mg, 88%). mp 86-88 oC; [ ]D
20
 = –17 (c 0.0010, MeOH).  The NMR 
spectral data for (–)-II-19 was identical with that for the racemic compound (±)-II-19. 
 
6R-(t-Butyldiphenylsilyloxy)methyl-2S,3R,4S,5R-tetrahydroxy-1S-phthalimido-
cycloheptane: (+)-II-19.  The dihydroxylation of (+)-II-18 (75 mg, 0.138 mmol) with 
catalytic OsO4 was carried out in the same fashion as the dihydroxylation of (±)-II-18, to 
afford (+)-II-19 (70 mg, 88%). mp 74-76 
o
C; [ ]D
20
 = +14 (c 0.00090, MeOH).  The 
NMR spectral data for (+)-II-19 was identical with that for the racemic compound (±)-II-
19. 
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(S)(-)-α-methoxy-α-trifluoromethylphenylacetic ester: II-27. To a solution of optically 
enriched endoperoxide alcohol (+)-II-16 (20 mg, 0.066 mmol) in dry THF  (3 mL) was 
added (S)(-)-α-methoxy-α-trifluoromethylphenylacetic acid (50 mg, 0.21 mmol) followed 
by N,N'-dicyclohexylcarbodiimide (44 mg, 0.21 mmol) and 4-dimethylaminopyridine (5 
mg, 0.004 mmol). The reaction mixture was stirred for 2 h, then concentrated and water 
(5 mL) was added. The mixture was extracted several times with ether, and the combined 
extracts were washed with 10% HCl, and concentrated. The residue was purified by 
column chromatography (SiO2, hexanes:ethyl acetate = 7:3) to give a colorless oil (34 
mg, 100 %); 
1
H NMR (400 MHz, d6-acetone)  1.64 (td, J = 4.4, 12.8 1H), 2.03 (q, J = 
12.7 Hz, 1H), 2.44-2.55 (m, 1H), 3.58 (q, J = 1.2 Hz, 3H), 4.27 (dd, J = 7.0 and 11.2 Hz, 
1H), 4.39 (dd, J = 5.4, 11.2 Hz, 1H), 4.63 (ddd, J = 0.9, 4.5, 12.7 Hz, 1H), 4.72  (br d, J = 
7.2 Hz, 1H), 4.92 (br d, J = 7.2 Hz, 1H), 6.22 (ddd, J = 1.2, 7.2, 9.2 Hz, 1H), 6.65 (ddd, J 
= 0.9, 7.2, 9.2 Hz, 1H), 7.37-7.47 (m, 3H), 7.51-7.56 (m, 2H), 7.85 (s, 4H); 
13
C NMR 
(100 MHz, CDCl3)  26.2 , 41.1, 51.7,  55.7, 66.6, 77.8,  79.8,  121.8,  123.5, 123.7, 
124.6, 127.1, 128.6, 129.8, 130.1, 131.6, 132.0, 134.4, 166.5, 167.5. 
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(S)(-)-α-methoxy-α-trifluoromethylphenylacetic ester: II-28. The esterification of 
optically enriched endoperoxide alcohol (-)-II-16 (20 mg, 0.066 mmol) with (S)(-)-α-
methoxy-α-trifluoromethylphenylacetic acid was carried out in a fashion to the 
esterification of (+)-II-16, to afford II-28 (32 mg, 94%). mp 43-45 
o
C; 
1
H NMR (400 
MHz, d6-acetone)  1.67 (td, J = 4.6, 12.8 Hz, 1H), 1.99 (q, J = 12.8 Hz, 1H), 2.45-2.54 
(m, 1H), 3.55 (s, 3H), 4.38-427 (m, 2H), 4.64 (dd, J = 5.0, 13.2 Hz, 1H), 4.74  (br d, J = 
7.2 Hz, 1H), 4.93 (br d, J = 7.2 Hz, 1H), 6.31 (ddd, J = 0.8, 7.1, 9.1 Hz, 1H), 6.66 (ddd, J 
= 0.9, 7.3, 9.1 Hz, 1H), 7.45-7.51 (m, 3H), 7.53-7.58 (m, 2H), 7.85(br s, 4H); 
13
C NMR 
(100 MHz, CDCl3)  26.2 , 41.1, 51.5,  55.4, 66.5, 77.6, 79.8,  121.7,  123.4, 123.6, 
124.6, 127.2, 128.6, 129.8, 130.2, 131.6, 131.8, 134.3, 166.5, 167.4. 
 
N-(Bicyclo[5.1.0]octa-3,5-dien-2-yl)phthalimide: (±)-II-29. To a stirred suspension of 
cation I-88b (8.00 g, 14.2 mmol) in solution of water saturated-ether (water: ether = 1:5) 
was added potassium phthalimide (20.22 g, 109.3 mmol). This suspension was stirred for 
150 min, the ether layer was decanted and to the residual solid was added ether (100 mL) 
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and the mixture was stirred for 1 h. This step was repeated 3 times. The combined 
ethereal fractions were concentrated at low temperature under vacuum to give a yellow 
foam (10.21 g, >100%) which was used in the next step without purification. To a 
solution of the unpurified complex (9.00 g) dissolved in acetonitrile (100 mL) was added 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (5.10 g, 22.5 mmol). After 2 h, 
monitoring by TLC showed complete disappearance of the complex. The mixture was 
passed through a short column of silica gel and washed with dichloromethane. The 
combined fractions were concentrated and the residue purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 4:1) to give a (±)-II-29 as colorless solid 
(2.66 g, 73%): mp 162-163 
o
C; IR (KBr) 3023, 1765, 1711, 1607, 1381 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3)  0.99 (dddd, J = 0.9, 4.7, 8.5, 8.8 Hz, 1H), 1.22- 1.34 (m, 1H), 1.85-
1.95 (m, 1H), 2.25 (ddd, J = 5.6, 5.6, 5.6 Hz, 1H), 5.43-5.62 (m, 3H), 5.83 (ddd, J = 2.8, 
6.0, 11.5 Hz, 1H), 6.23 (dd, J = 7.5, 11.5 Hz, 1H), 7.69-7.76 (m, 2H), 7.82-7.89 (m, 2H); 
13
C NMR (75 MHz, CDCl3)  9.0, 15.2, 43.8, 49.8, 122.6, 123.4, 126.2, 126.9, 132.1, 
134.1, 135.2, 167.9. The NMR spectral data was consistent with the literature values.
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N-(3R*,4R*,5S*,6S*-tetrahydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-30 and 
N-(3R*,4R*,5R*, 6R*-tetrahydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-31: 
To a stirring solution of the diene (±)-II-29 (300 mg, 1.20 mmol) in acetone (5 ml) was 
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added a solution of N-methylmorpholine-N-oxide (419 mg, 3.59 mmol) in water (1 mL), 
followed by addition of a solution of OsO4 (0.1 mL, 0.2 M in toluene). The mixture was 
stirred for 24 h at room temperature. Solid Na2S2O4 (440 mg) was added to the mixture 
and stirred for 30 min, the mixture was concentrated and the residue was dry loaded onto 
column chromatography for purification (SiO2, CH2Cl2:MeOH = 10:1) to give (±)-II-30 
(187 mg, 49%) followed by (±)-II-31 (79 mg, 21%) both as a colorless solids.  
(±)-II-30: mp 229−230 °C; 1H NMR (400 MHz, CD3OD) δ 0.74−0.89 (m, 2H), 1.19 (ddt, 
J = 2.6, 6.6, 9.2 Hz, 1H), 1.39 (ddt, J = 4.8, 7.0, 9.2 Hz, 1H), 3.54 (t, J = 2.2 Hz, 1H), 
4.10−4.14 (m, 1H), 4.27 (dd, J = 1.8, 11.0 Hz, 1H), 4.44−4.50 (m, 1H), 5.16 (dd, J = 2.6, 
10.6 Hz, 1H), 7.76−7.89 (m, 4H); 13C NMR (100 MHz, CD3OD, “doublets” due to 
slowed rotation of the phthalimide substituent shown in parentheses) δ 6.7, 18.6, 20.7, 
50.7, 68.7, 69.6, 76.0, 80.9, 123.7 (124.1), 133.2 (133.6), 135.1 (135.2), 169.8 (170.2). 
Anal. Calcd for C16H17NO6·0.2H2O: C, 59.51; H, 5.43; N, 4.34. Found: C, 59.56; H, 5.49; 
N, 4.35. 
(±)-II-31 : mp 241−244 °C; 1H NMR (400 MHz, CD3OD) δ 0.63 (dt, J = 5.3, 9.0 Hz, 
1H), 1.02−1.23 (m, 2H), 1.53−1.63 (m, 1H), 4.00 (s, 2H), 4.34 (d, J = 3.5 Hz, 1H), 4.59 
(d, J = 10.6 Hz, 1H), 5.05 (dd, J = 2.9, 11.2 Hz, 1H), 7.75−7.87 (m, 4H); 13C NMR (100 
MHz; CD3OD) δ 7.2, 18.0, 19.7, 51.6, 66.2, 68.6, 75.8, 76.3, 123.9 (br), 133.2 (br), 135.1 
(br), 170.1 (br). Anal. Calcd for C16H17NO6: C, 60.18; H, 5.37. Found: C, 60.18; H, 5.32. 
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N-(5R*,6S*-dihydroxybicyclo[5.1.0]oct-3-en-2S*-yl)phthalimide (±)-II-32 and N-
(3R*,4S*-dihydroxybicyclo[5.1.0]oct-5-en-2S*-yl)phthalimide (±)-II-33. To a solution 
of bicyclic diene (±)-II-29 (300 mg, 1.20 mmol) in acetone (10 mL) was added a solution 
of N-methylmorpholine-N-oxide (0.32 mL, 1.2 mmol, 50% wt in water), followed by a 
solution of OsO4 (0.2 mL, 0.2 M in toluene). The mixture was stirred for 1 h at room 
temperature. The reaction was quenched with NaHSO3 (100 mg) and stirred for 30 min 
then adsorbed onto silica gel for purification (SiO2, hexanes:ethyl acetate gradient = 3:1 
to 3:7) to give the starting material (±)-II-29 (81 mg) followed by (±)-II-32 (138 mg, 
56% based on recovered starting material) and (±)-II-33 (72 mg, 29% based on recovered 
starting material) both as colorless solids. 
(±)-II-32: mp 218-221 
o
C; 
1
H NMR (400 MHz, CDCl3)  0.84 (dq, J = 2.0, 7.2 Hz, 1H), 
1.09 (q, J = 5.6 Hz, 1H), 1.15-1.23 (m, 1H), 1.49 (pentet, J = 7.6 Hz, 1H), 2.20-2.43 (br s, 
2H), 4.11-4.18 (m, 1H), 4.64 (d, J = 6.0 Hz, 1H), 5.44 (qd, J = 2.3, 12.9 Hz, 1H), 5.56, 
(qd, J = 2.3, 12.9 Hz, 1H), 5.68 (quin, J = 2.7 Hz, 1H), 7.69-7.77 (m, 2H), 7.82-7.90 (m, 
2H); 
13
C NMR (100 MHz, CDCl3)  6.9, 16.3, 17.6, 48.4, 71.7, 72.7, 123.3, 127.1, 128.4, 
131.9, 134.0, 167.8. HRMS (FAB): m/z calcd for C16H15NO4: [M+Na
+
]; 308.0893, found 
308.0894. 
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(±)-II-33: mp 219-220 
o
C; 
1
H NMR (400 MHz, CDCl3)  0.90 (q, J = 5.9 Hz, 1H), 1.05 
(dt, J = 4.9, 9.1 Hz, 1H), 1.41 (dq, J = 4.3, 7.0 Hz, 1H), 1.45-1.54 (m, 1H), 1.98 (d, J = 
5.5 Hz, 1H), 2.43 (d, J = 9.0 Hz, 1H), 4.33-4.42 (m, 2H), 5.25 (dd, J = 3.9, 10.6 Hz, 1H), 
5.65 (dd, J = 7.4, 12.1 Hz, 1H), 6.16 (dd, J = 5.9, 12.1 Hz, 1H), 7.67-7.76 (m, 2H), 7.79 -
7.88 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  13.2, 15.7, 19.4, 49.9, 68.5, 70.9, 123.0, 
123.2, 132.0, 133.9, 134.4, 169.0. HRMS (FAB): m/z calcd for C16H15NO4: [M+Na
+
]; 
308.0893, found 308.0894. 
 
N-(5S*,6S*-dihydroxy-3R*,4R*-epoxybicyclo[5.1.0]oct-2S*-yal)phthalimide (±)-II-
34: Preparation of trifluoroperacetic acid: To an ice cold solution of trifluoroacetic 
anhydride (0.70 mL, 4.8 mmol) in CH2Cl2 (5 mL) was added H2O2 (0.33 mL, 4.8 mmol, 
50% wt solution). The mixture was stirred for 5 min in the ice cold bath then at room 
temperature for 1 h. To ice-cold solution of enediol (±)-II-32 (138 mg, 0.484 mmol) in 
CH2Cl2 (5 mL) coled in an ice bathwas added the previously prepared solution 
(CF3CO3H) drop by drop at 0 
o
C. After 10 min the mixture was warmed to room 
temperature and stirred for 1 h and then concentrated. The residue was purified by 
column chromatography (SiO2, hexanes:ethyl acetate = 3:7) to give (±)-II-34 as a 
colorless solid (121 mg, 83%): mp > 250 
o
C;
 1
H NMR (400 MHz, DMSO-d6)  0.84 (dt, J 
= 6.7, 8.6 Hz, 1H), 1.04 (tt, J = 5.9, 8.6 Hz, 1H), 1.20 (q, J = 5.9 Hz, 1 H), 1.61 (dq, J = 
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5.1, 8.6 Hz, 1H), 3.73 (d, J = 5.9 Hz, 1H), 3.98 (t, J = 5.5 Hz,  1H), 4.36 (t, J = 5.9 Hz, 
1H), 4.49 (d, J = 8.2 Hz, 1H), 4.59 (d, J = 5.1 Hz, 1H),  4.82 (t, J = 6.5 Hz, 1H), 4.94 (d, J 
= 5.9 Hz, 1H), 7.81-7.93 (m, 4H); 
13
C NMR (100 MHz, DMSO-d6)  7.6, 14.1, 15.4, 
50.7, 70.2, 72.8, 80.6, 81.9, 123.1, 131.2, 134.6, 168.4. HRMS (FAB): m/z calcd for 
C16H15NO5: [M+Na
+
]; 324.0842, found 324.0846. 
 
N-(3S*,4R8,5S*,6S*-tetrahydroxybicyclo[5.1.0]oct-2S*-yal)phthalimide (±)-II-35: A 
mixture of the epoxy compound (±)-II-34 (120 mg, 0.399 mmol) in THF (5 mL) and 
deionized water (10 mL) was heated until all the solid had dissolved. Carbon 
tetrabromide (26 mg, 0.079 mmol) was added and the mixture was heated at reflux with 
stirring for 7 h. The solvent was evaporated and the residue was purified by column 
chromatography (SiO2, CH2Cl2:MeOH = 19:1 to 9:1 gradient) to give the starting 
material (±)-II-34 (26 mg) followed by (±)-II-35 as a colorless solid (81 mg, 81% based 
on recovered starting material) : mp 202-204 
o
C; 
1
H NMR (400 MHz, CD3OD)  0.81 
(td, J = 5.5,  9.4 Hz, 1H), 1.11 (q, J = 7.8,  16.0 Hz, 1H), 1.28-1.41 (m, 1H),  1.51 (q, J = 
5.9 Hz, 1H), 3.83 (br s, 1H), 4.04 (td, J = 1.6, 5.9 Hz, 1H), 4.07 (dt, J = 1.6, 6.3 Hz, 1H), 
4.63 (d, J = 4.7 Hz, 1H), 5.33 (t, J = 2.2 Hz, 1H), 7.81-7.86 (m, 2H), 7.86-7.92 (m, 2H); 
13
 
C (100 MHz; CD3OD)  9.0, 18.3, 20.1, 50.2, 68.4, 76.4, 77.9, 78.1, 124.3, 133.2, 135.5, 
170.8. HRMS (FAB): m/z calcd for C16H17NO6: [M+Na
+
]; 342.0948, found 342.0950. 
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N-(5R*,6S*-epoxybicyclo[5.1.0]oct-3-en-2S*-yl)phthalimide (±)-II-36 and N-(5-
oxobicyclo[5.1.0]oct-3-en-2S*-yl)phthalimide (±)-II-37: A solution of diene (±)-II-29 
(200 mg, 0.794 mmol) in freshly distilled CH2Cl2 (6 mL) was stirred for 5 min. A 
solution of meta-chloroperoxybenzoic acid (mCPBA) (196 mg, ~ 70% wt, ~ 0.794 mmol) 
in freshly distilled CH2Cl2 (2 mL) was added dropwise. The solution was stirred under N2 
for 5 h, at which time monitoring by TLC showed complete disappearance of starting 
material. The solvent was evaporated and the residue was treated with saturated 
bicarbonate solution (5 mL) with stirring for 30 min. The mixture was extracted several 
times with CH2Cl2, concentrated and purified by column chromatography (SiO2, 
hexanes:ethyl acetate = 7:3) to give (±)-II-37 as a colorless solid (28 mg, 12%) followed 
by (±)-II-36 as a colorless solid (158 mg, 70%). 
7-Phthalimido-2-oxatricyclo[6.1.0
1,3
.0
4,6
]non-8-ene (±)-II-36; mp 196-198 
o
C; 
1
H 
NMR (400 MHz, CDCl3)  0.93 (dq, J = 3.9, 8.2 Hz, 1H), 1.07 (br q, J = 8.2 Hz, 1H), 
1.53-1.65 (m, 2H), 3.19 (t, J = 4.8 Hz, 1H), 3.57 (t, J = 4.8 Hz, 1H), 5.63 (br d, J = 12.0 
Hz, 1H), 5.78 (ddd, J = 2.9, 5.5, 12.0 Hz, 1H), 5.91 (d, J = 2.4 Hz, 1H), 7.70-7.93 (m, 
4H); 
13
C NMR (100 MHz, CDCl3)  8.3, 13.8, 18.8, 47.6, 52.8, 54.9, 123.4, 123.5, 132.2, 
132.8, 134.2, 167.9. HRMS (FAB): m/z calcd for C16H13NO3: [M+Na
+
]; 290.0788, found 
290.0789. 
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7-Phthalimido-8-oxatricyclo[6.1.0
1,3
.0
4,6
]non-2-ene (±)-II-37: mp  122-123 
o
C; 
1
H 
NMR (400 MHz, CDCl3)  0.74 (dt, J = 6.4, 9.0 Hz, 1H), 1.03 (q, J = 5.7 Hz, 1H), 1.21-
1.28 (m, 2H), 2.95 (d, J = 15.2 Hz, 1H), 3.11 (d, J = 15.2 Hz, 1H), 5.61-5.64 (br s, 1H), 
6.11 (ddd, J = 1.8, 3.1, 12.6 Hz, 1H), 6.23 (dd, J = 2.4, 12.6 Hz, 1H), 7.75-7.91 (m, 4H); 
13
C NMR (100 MHz, CDCl3)  4.6, 8.3, 17.8, 41.5, 49.3, 123.7, 132.0, 132.5, 1.4.5, 
141.8, 167.7, 198.9. 
 
N-(5S*,6S*-Epoxy-3R*,4R*-dihydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-
38: To a solution of the epoxy compound (±)-II-36 (100 mg, 0.373 mmol) in acetone (5 
mL), was added a solution of N-methylmorpholine-N-oxide (100 mg, 0.857 mmol) in 
water (1 mL), followed by addition of a solution of OsO4 (0.14 mL, 0.2 M in toluene). 
The mixture was stirred for 4 h at room temperature. Solid Na2S2O4 (60 mg) was added 
to the mixture and stirred for 30 min, the mixture was concentrated and the residue 
purified by column chromatography (SiO2, hexanes:ethyl acetate gradient = 1:1 to 1:4) to 
give (±)-II-38 as a colorless solid (109 mg, 97 %): mp >220 
o
C; 
1
H NMR (400 MHz, 
acetone-d6)  0.85 (dt, J = 4.7, 9.3 Hz, 1H), 0.97 (dt, J = 4.7, 6.9 Hz, 1H), 1.19-1.27 (m, 
1H), 1.56 (br q, J = 8.2 Hz, 1H), 3.19 (d, J = 4.8 Hz, 1H), 3.35 (ddd, J = 0.8, 4.2, 6.6 Hz, 
1H), 3.58 (br d, J = 4.8 Hz, 1H), 4.17 (d, J = 6.6 Hz, 1H), 4.35-4.42 (m, 2H), 5.19 (dd, J = 
5.8, 10.8, 1H), 7.84 (s, 4H); 
13
C NMR (100 MHz, acetone-d6)  5.8, 15.5, 19.5, 51.6, 
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55.1, 57.0, 66.6, 69.3, 122.8, 132.2, 134.0, 168.3. HRMS (FAB): m/z calcd for 
C16H15NO5: [M+Na
+
]; 324.0842, found 324.0843. 
 
N-(3R*,4R*,5S*,6R*-tetrahydroxybicyclo[5.1.0]oct-4-en-2S*-yl)phthalimide(±)-II-
39. The hydrolysis of epoxy compound (±)-II-38 (87 mg, 0.29 mmol) in water (3 mL) 
with carbon tetrabromide (20 mg, 0.058 mmol) as catalyst was carried out in a fashion 
similar to the preparation of (±)-II-34. Recrystalization of the residue from methanol 
gave (±)-II-39 (61 mg, 66 %) as colorless crystals: mp > 230 
o
C; 
1
H NMR (400 MHz, 
CD3OD)  0.67 (dt, J = 6.0, 9.0 Hz, 1H), 0.90 (q, J = 6.4 Hz, 1H), 1.16 (ddt, J = 3.0, 6.6, 
9.6 Hz, 1H), 1.31 (ddt, J = 3.6, 6.8, 9.6 Hz, 1H), 4.06 (s, 1H), 4.26 (dd, J = 3.6, 9.6 Hz, 
1H), 4.30 (d, J = 10.4 Hz, 1H), 5.50 (dd, J = 3.0, 11.0 Hz, 1H), 7.76-7.90 (m, 4H), one 
proton hidden underneath CD3OD peak at 3.31; 
13
C NMR (100 MHz, CD3OD)  4.9, 
18.1, 20.0, 50.9, 68.6, 69.3, 74.1, 78.1, 123.9, 124.2, 133.4, 133.8, 135.3, 135.4, 170.2, 
170.5. Anal. Calcd for C16H17NO6: C, 60.18; H, 5.37. Found: C, 59.65; H, 5.38. 
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N-(3R*,4R*,5S*,6S*-diepoxybicyclo[5.1.0]oct-2S*-yl)ohthalimide (±)-123: To a 
solution of bicyclic diene (±)-II-29 (130 mg, 0.516 mmol) in freshly distilled CH2Cl2 (5 
mL) was added mCPBA (319 mg, ~70% wt, ~1.29 mmol).  The reaction mixture was 
stirred under N2 for 12 h, after which monitoring by TLC indicated the disappearance of 
starting material. The mixture was concentrated and the solid residue was treated with 
saturated aqueous bicarbonate (5 mL) with stirring for 30 min. The mixture was extracted 
several times with ethyl acetate then dried over anhydrous Na2SO4. The combined 
organic layers were concentrated and the crude was recrystallized from benzene to give 
colorless crystals of the bisepoxide (±)-II-40 (137 mg, 93%): mp >250
o
C; 
1
H NMR (400 
MHz, CDCl3)  1.03-1.13 (m, 2H), 1.29 (td, J = 4.3, 5.9 Hz, 1H), 1.46 (tt, J = 5.9, 9.2 Hz, 
1H), 3.31 (dd, J = 2.5, 4.5 Hz, 1H), 3.48 (dd, J = 2.5, 4.1 Hz, 1H), 3.51 (dd, J = 4.5, 5.9 
Hz, 1H), 3.70 (dd, J = 4.3, 5.5 Hz, 1H), 5.16 (d, J = 5.9 Hz, 1H), 7.72-7.80 (m, 2H), 7.84-
7.93 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  10.9, 11.1, 19.7, 47.3, 50.9, 52.0, 53.5, 
58.3, 123.4, 131.9, 134.1, 167.9. Anal. Calcd for C16H13NO4: C, 67.84; H 4.62. Found: C, 
67.44; H, 4.68. 
This compound also was prepared as follows: In Schlenk flask was added endoperoxide 
(±)-II-47  (100 mg, 0.352 mmol) in benzene (5 mL) and irradiated with Hg lamp for 6 h, 
the solvent was evaporated and the residue was washed with diethyl ether, solid 
precipitate was obtained (67 mg, 67%).   
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N-(3R*,4S*,5R*,6R*-tetrahydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-124 and 
N-(1R*,3R*,4R*,5S*-tetrahydroxy-6-cycloocten-2R*-yl)phthalimide (±)-II-42: To a 
solution of bisepoxide (±)-II-40 (90 mg, 0.32 mmol) in THF (5 mL) and deionized water 
(7 mL) was added a catalytic amount of CBr4 (42 mg, 0.13 mmol). The reaction mixture 
was heated at reflux for 8 h.  The mixture was concentrated and the residue was purified 
by column chromatography (SiO2, CH2Cl2:MeOH = 19:1) to give bicyclic tetraol (±)-II-
41 (46 mg, 46%) followed by 8-membered ring tetraol (±)-II-42 (17 mg, 18%) both as 
colorless solids. 
 (±)-II-41 :  mp 218-220
o
C; 
1
H NMR (400 MHz, CD3OD)  0.70 (dt, J = 5.5, 9.0 Hz, 1 
H),  1.03 (q, J = 8.2 Hz, 1H), 1.32 (ddt, J = 3.1, 6.7, 9.8 Hz, 1H), 1.56 (q, J = 5.9 Hz, 1H), 
3.64 (dd, J = 1.6, 9.4 Hz, 1H), 3.99 (dd, J = 2.0, 6.3 Hz, 1H), 4.03 (td, J = 1.6, 6.3 Hz, 
1H), 4.28 (dd, J = 3.5, 9.8 Hz, 1H), 5.16 (t, J = 2.0 Hz, 1H), 7.78-7.95 (m, 4H); 
13
C NMR 
(100 MHz, CD3OD)  6.3, 15.4, 18.3, 49.0, 68.7, 70.8, 73.2, 74.6, 123.1, 132.1, 134.4, 
169.7. Anal. Calcd for C16H17NO6: C, 60.18; H 5.37. Found: C, 59.84; H, 5.29. 
 (±)-II-42: mp 236-238
o
C; 
1
H NMR (400 MHz; CD3OD)  2.3 (td, J = 6.2, 12.5 Hz, 1H), 
2.89 (dt, J = 9.8, 12.5 Hz, 1H), 3.86-393 (m, 1H), 4.08 (dd, J = 1.0, 6.1 Hz, 1H), 4.30 (d, 
J = 6.3 Hz, 1H), 4.88 (d, J = 4.0 Hz, 1H), 4.93 (d, J = 6.3 Hz, 1H), 5.74 (ddt, J = 1.6, 6.7, 
10.6 Hz, 1H), 5.82 (dd, J = 6.3, 11.0 Hz, 1H), 7.77-7.83 (m, 2H), 7.84-7.89 (m, 2H); 
13
C 
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NMR (100 MHz; CD3OD)  33.2, 50.9, 67.4, 74.7, 75.5, 76.1, 122.7, 124.5, 131.9, 133.9, 
136.8, 169.0. HRMS (FAB): m/z calcd for C16H17NO6: [M+Na
+
]; 342.094808, found 
342.094911. 
 
Phthalimido-7,8-dioxatricyclo[4.2.2.0
2,4
]dec-9-ene (±)-II-47 To a stirred solution of the 
diene (±)-II-29 (350 mg, 1.40 mmol) in a test tube dissolved in CCl4 (15 mL) was added 
tetraphenylporphine (TPP) (9 mg, 0.1 mmol). The deep purple solution was irradiated 
with a 100-W halogen lamp, while ultra pure O2 was bubbled through the solution and 
stirred in water bath at room temperature for 7 h. The reaction mixture was concentrated 
and the residue was purified by column chromatography (SiO2, hexanes:ethyl acetate = 
2:3) to give (±)-II-47 as a colorless solid (340 mg, 85 %): mp 159-162 
o
C; 
1
H NMR (400 
MHz, CDCl3)  0.64-0.74 (m, 1H), 1.44 (pent, J = 8.4 Hz, 1H), 1.62-1.71 (m, 2H), 4.45-
4.48 (br s, 1H), 5.26-5.33 (m, 2H), 6.26 (dd, J = 8.2, 9.0 Hz, 1H), 6.55 (dd, J = 8.2, 8.6 
Hz, 1H), 7.70-7.90 (m, 4H); 
13
C (100 MHz, CDCl3)  11.1, 15.4, 17.5, 52.2, 77.4, 77.9, 
123.6, 127.4, 128.7, 132.0, 134.4, 168.4. Anal. Calcd for C16H13NO4: C, 67.84; H, 4.63. 
Found: C, 67.81; H, 4.64. 
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N-(3S*,6S*-Dihydroxybicyclo[5.1.0]oct-4-en-2S*-yl)phthalimide: (±)-II-48 To a 
solution of endoperoxide (±)-II-47 (250 mg, 0.880 mmol) in CH2Cl2 (20 mL) was added 
activated zinc dust (250 mg), followed by dropwise addition of a solution of acetic acid 
(537 mg, 8.80 mmol) in CH2Cl2 (2 mL) over a 10 min period.  The reaction mixture was 
stirred for 2 h at 0 
o
C, and then filtered through a celite column.  The column was washed 
with methanol, and the fractions collected were allowed to slowly evaporate under 
atmospheric pressure and the residue was purified by column chromatography (SiO2, 
hexanes:ethyl acetate = 1:4) to give (±)-II-48 (249 mg, 98 %) as colorless crystals: mp 
217-219 
o
C; 
1
H NMR (600 MHz, CD3OD)  0.81 (dt, J = 5.4, 9.0 Hz, 1H), 0.95 (q, J = 
5.8, 1H), 1.21 (ddt, J = 4.5, 6.3, 9.0 Hz, 1H), 1.35 (tt, J = 5.7, 9.0 Hz, 1H), 4.47 (dt, J = 
1.5, 5.8 Hz, 1H), 4.66 (dd, J = 4.2, 10.8 Hz, 1H), 4.78 (td, J = 3.0, 10.8 Hz, 1H), 5.62 
(ddd, J = 1.2, 3.6, 12.0 Hz, 1H), 5.82 (ddd, J = 2.1, 6.3, 12.0 Hz, 1H), 7.79-7.90 (m, 4H); 
13
C NMR (100 MHz, CD3OD)  9.2, 17.1, 23.2, 53.5, 67.2, 70.6, 124.1, 133.3, 133.5, 
134.4, 135.4, 170.3. HRMS (FAB): m/z calcd for C16H15NO4: [M+Na
+
]; 308.0893, found 
308.0895. 
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N-(3R*,4S*,5R*,6S*-tetrahydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-49: To 
a solution of bicyclic enediol (±)-II-48 (140 mg, 0.489 mmol) in acetone (10 mL) was 
added a solution of N-methylmorpholine-N-oxide (85 mg, 0.73 mmol) in water (2 mL), 
followed by a solution of OsO4 (0.1 mL, 0.2 M in toluene). The mixture was stirred for 1 
h at room temperature under nitrogen. The reaction was quenched with Na2S2O4 (140 
mg) and stirred for 30 min. The mixture was passed through a short column of silica gel 
while was then washed with ethyl acetate. The combined fractions were concentrated and 
the residue purified by column chromatography (SiO2, hexanes:ethyl acetate = 1:4) to 
give (±)-II-49 (133 mg, 85%) as a colorless solid: mp 254-255 
o
C; 
1
H NMR (400 MHz, 
CD3OD)  0.71 (dt, J = 5.5, 9.4 Hz, 1H), 1.11 (ddt, 3.9, 7.0, 9.4 Hz, 1H), 1.17-1.26 (m, 
1H), 1.50 (q, J = 5.9 Hz, 1H), 3.64 (dd, J = 2.7, 9.3 Hz, 1H), 4.05 (dd, J = 2.7, 5.9 Hz, 
1H), 4.31 (t, J = 5.4 Hz, 1H), 4.37 (t, J = 10.0 Hz, 1H), 4.71 (dd, J = 3.8, 10.2 Hz, 1H), 
7.71-7.93 (m, 4H); 
13
C NMR (100 MHz, CD3OD)  6.1, 16.2, 18.9, 53.8, 64.8, 70.3, 
72.0, 74.7, 122.8, 131.8, 133.9, 168.6. Anal. Calcd for C16H17NO6: C, 60.18; H 5.36. 
Found: C, 60.01; H, 5.36. 
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N-(3S*-hydroxy-6-oxobicyclo[5.1.0]oct-4-en-2S*-yl)phthalimide (±)-II-50 and N-
(6S*-hydroxy-3-oxobicyclo[5.1.0]oct-4-en-2S*-yl)phthalimide (±)-II-51: To a solution 
of endoperoxide (±)-II-47 (250mg, 0.880 mmol) in freshly distilled CH2Cl2 (15 mL) at 
0
o
C was added a solution of Et3N (0.25 mL, 1.8 mmol) in CH2Cl2 (5 mL). The reaction 
mixture was stirred for 2 h, the solvent was evaporated and the residue was purified by 
column chromatography (SiO2, CH2Cl2) to give two regioisomers; (±)-II-50 (238 mg, 
95%) followed by (±)-II-51 (5 mg, 2 %) both as colorless solids. 
(±)-II-50: mp 227-228 
o
C; 
1
H NMR (400 MHz, CD3OD)  1.44 (td, J = 5.7, 8.7 Hz, 1 H), 
1.65 (td, J = 5.7, 7.4 Hz, 1H), 1.84 (q, J = 8.6 Hz, 1H), 2.08 (ddt, J = 1.6, 5.5, 8.7 Hz, 
1H), 4.68 (d, J = 10.2 MHz, 1H), 4.95 (dt, J = 2.5, 10.2 Hz, 1H), 5.85 (ddd, J = 2.0, 2.0, 
13.7 Hz, 1H), 6.40 (dd, J = 2.0, 13.7 Hz, 1H), 7.78-7.86 (m, 2H), 7.86-7.92 (m, 2H); 
13
C 
NMR (100 MHz, CD3OD)  12.6, 20.2, 27.2, 52.4, 67.0, 122.9, 126.1, 132.2, 134.1, 
144.0, 167.7, 198.0. Anal. Calcd for C16H13NO4: C, 67.84; H 4.62. Found: C, 67.92; H, 
4.65. 
(±)-II-51: mp 182-183 
o
C; 
1
H NMR (400 MHz, CD3OD)  1.01 (q, J = 5.1 Hz, 1H), 1.25 
(dt, J = 5.1, 7.8 Hz, 1H), 1.61-1.69 (m, 1H), 2.08 (ddt, J = 4.9, 7.5, 10.4 Hz, 1H), 4.48 (td, 
J = 2.9, 9.1 Hz, 1H), 4.52 (d, J = 11.0 Hz, 1H),  6.09 (dd, J = 2.7, 12.2  Hz, 1H), 7.01 (dd, 
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J = 3.1, 12.2 Hz, 1H), 7.77-7.93 (m, 4H); 
13
C NMR (100 MHz; CD3OD)  13.6, 18.2, 
27.5, 64.3, 74.1, 124.5, 129.5, 135.8, 158.2, 194.7. 
 
N-(3S*,6R*-dihydroxybicyclo[5.1.0]oct-4-en-2S*-yl)Phthalimide (±)-II-52: To a 
solution of (±)-II-50 (230 mg, 0.810 mmol) in THF (4 mL) and methanol (7 mL) was 
added CeCl3.7H2O (604 mg, 1.62 mmol) and the mixture stirred for 30 min at room 
temperature until it turned to clear solution. The solution was cooled to -78 
o
C and 
NaBH4 (62 mg, 1.6 mmol) was added portionwise. The mixture was stirred at -78
o
C for 5 
h. The solvent was evaporated and the residue was partitioned between water and ethyl 
acetate. After the solvent was evaporated, examination by NMR spectroscopy showed 
only a single product (±)-II-52 (220 mg, 94%): mp  225-227 
o
C; 
1
H NMR (400 MHz, 
CD3OD)  0.70 (dt, J = 5.9, 8.6 Hz, 1H), 0.96 (q, J = 5.9 Hz, 1H), 1.21 (dt, J = 6.3, 9.4 
Hz, 1H), 1.34-1.42 (m, 1H), 4.49 (d, J = 10.2 Hz, 1H), 4.60 (qd, J = 2.4, 10.2 Hz, 1H), 
4.81-4.84 (m, 1H), 5.47 (qd, J = 2.0, 13.3 Hz, 1H), 5.55 (td, J = 2.3, 13.3 Hz, 1H), 7.78-
7.90 (m, 4H); 
13
C NMR (100 MHz; CD3OD)  2.5, 14.7, 18.3, 52.0, 66.8, 67.5, 122.6, 
128.8, 130.5, 132.0, 133.8, 168.4. HRMS (FAB): m/z calcd for C16H15NO4: [M+Na
+
]; 
308.0893, found 308.0895. 
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N-(3R*,4S*,5R*,6R*-tetrahydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-53 and 
N-(3R*,4R*,5S*,6R*-tetrahydroxybicyclo[5.1.0]oct-4-en-2S*-yl)phthalimide(±)-II-
39: To a solution of (±)-II-52 (300 mg, 1.05 mmol) in acetone (8 mL) was added a 
solution of N-methylmorpholine-N-oxide (184 mg, 1.57 mmol) in water (1 mL), followed 
by a solution of OsO4 (0.5 mL, 0.2 M in toluene). The mixture was stirred for 12 h at 
room temperature. The reaction was quenched with NaHSO3 (250 mg) and stirred for 30 
min, the solved was removed and the residue was purified by column chromatography 
(SiO2, CH2Cl2:MeOH = 2:3) to give (±)-II-53 (93 mg, 28%) followed by (±)-II-39 (117 
mg, 34%) both as colorless solids. Compound (±)-II-39 was identified by comparison of 
its NMR spectral data with that previously obtained. 
(±)-II-53: mp  201-203 
o
C; 
1
H NMR (400 MHz, CD3OD)   0.69 (td, J = 5.5, 9.0 Hz, 
1H), 1.09 (ddt, J = 2.7, 6.3, 9.4 Hz, 1H),  1.14-1.24 (m, 1H), 1.70 (q, J = 6.3 Hz, 1H), 
3.27 (dd, J = 1.6, 9.4 Hz, 1H), 4.10-4.17 (m, 2H), 4.45 (t, J = 10.2, 1H), 4.56 (dd, J = 2.7, 
11.0 Hz, 1H), 7.72-7.91 (m, 4H), CD3OD peak at 3.31; 
13
C NMR (100 MHz, CD3OD)  
8.4, 17.8, 20.2, 55.5, 66.4, 70.1, 76.0, 77.0, 124.0, 124.2, 133.3, 133.8, 135.2, 135.5, 
170.0, 170.1. Anal. Calcd for C16H17NO6: C, 60.18; H 5.36. Found: C, 59.93; H, 5.29. 
Anal. Calcd for C16H17NO6: C, 60.18; H, 5.37. Found: C, 59.93; H, 5.29. 
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Epoxidation of endoperoxide (±)-II-54 : To an ice cold solution of trifluoroacetic 
anhydride (0.50 mL, 3.5 mmol) in CH2Cl2 (5 mL) was added H2O2 (0.25 mL, 3.5 mmol, 
50% wt solution). After stirring for 5 min in the ice cold bath it was then warmed to room 
temperature for 1 h. To a solution of endoperoxide (±)-II-47 (130 mg, 0.458 mmol) in 
CH2Cl2: THF (1:1, 5 mL) cooled in an ice bath was added dropwise the previously 
prepared solution (CF3CO3H). After 10 min the mixture warmed to room temperature and 
stirred for 4 h. The solvent was evaporated using nitrogen gas to give (±)-II-54  as a 
colorless solid (136 mg, 99%): mp  205-206 
o
C; 
1
H NMR (400 MHz, CDCl3)  0.96 (td, J 
= 6.3, 8.8 Hz, 1H), 1.49 (pent, J = 7.9 Hz, 1H), 1.77 (ddt, J = 2.0, 6.8, 8.7 Hz, 1H), 1.91 
(q, J  =  6.1 Hz, 1H), 3.40 (t, J = 4.5 Hz, 1H), 3.85 (t, J = 4.1 Hz, 1H), 4.49 (q, J = 3.5 Hz, 
1H), 5.08 (dt, J = 3.6, 6.8 Hz, 1H), 5.59 (dd, J = 3.5, 7.0 Hz, 1H), 7.73-7.82 (m, 2H), 
7.85-7.93 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  9.5, 15.6, 16.3, 46.8, 47.7, 52.1, 74.5, 
78.8, 123.6, 131.6, 134.5, 168.2. HRMS (FAB): m/z calcd for C16H13NO5: [M+Na
+
]; 
322.0686, found 322.0688. 
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N-(4R*, 5S*-Epoxy-3R*, 6S*-dihydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-
55 : To a solution of (±)-II-54  (110 mg, 0.367 mmol) in CH2Cl2 (5 mL) was added 
activated zinc dust (110 mg), followed by dropwise addition of a solution of acetic acid 
(100 mg, 1.54 mmol) in CH2Cl2 (2 mL) over a 10 min period.  The reaction mixture was 
stirred for 3 h at 0 
o
C, and then filtered through a celite column.  The column was washed 
with methanol, and the fractions collected were allowed to slowly evaporate under 
atmospheric pressure and the residue was purified by column chromatography (SiO2, 
CH2Cl2:MeOH = 19:1) to give (±)-II-55 (63 mg, 63%) as colorless solid: mp 194-195 
o
C; 
1
H NMR (400 MHz, CD3OD)  0.68 (q, J = 6.3 Hz, 1H), 0.78 (td, J = 5.5, 9.2 Hz, 1H), 
1.07 (dddt, J = 0.8, 4.0, 6.7, 9.3 Hz, 1H), 1.15 (ddt, J = 3.5, 6.7, 9.3 Hz, 1H), 3.20-3.25 
(m, 1H), 3.29 ( d, J = 1.2 Hz, 1H), 4.43 (t, J = 3.5 Hz, 1H), 4.54 (dd, J = 0.8, 11 Hz, 1H), 
4.80 (dd, J = 3.5, 11.0 Hz, 1H), 7.73-7.91 (m, 4H); 
13
C NMR (100 MHz, CD3OD)  5.6, 
16.9, 18.2, 50.1, 56.4, 59.4, 64.0, 68.5, 122.6, 131.9, 133.9, 168.6. HRMS (FAB): m/z 
calcd for C16H15NO5: [M+Na
+
]; 324.0842, found 324.0846. 
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N-(3R*,4S*,5S*,6S*-tetrahydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-56: To 
a solution of (±)-II-55 (40 mg, 0.13 mmol) in THF (1 mL) and deionized water (5 mL) 
was added a catalytic amount of CBr4 (9 mg, 0.03 mmol). The reaction mixture was 
heated at reflux for 2 h.  The mixture was concentrated and the residue was purified by 
column chromatography (SiO2, CH2Cl2:MeOH = 9:1) to give (±)-II-56 (39 mg, 92%) as a 
colorless solid; mp 126-128
o
C; 
1
H NMR (400 MHz, CD3OD)  0.80 (td, J = 6.1, 9.1 Hz, 
1H), 0.90 (q, J = 6.3 Hz, 1H), 1.17 (ddt, J = 3.1, 6.3, 9.2 Hz, 1H), 1.33 (tt, J = 6.2, 9.3 Hz, 
1H), 3.45 (d, J = 8.8 Hz, 1H), 3.53 (t, J = 8.8 Hz, 1H), 4.00 (dd, J = 9.0, 10.2 Hz, 1H), 
4.30-4.44 (br m, 1H), 4.79 (dd, J = 2.8, 10.8, Hz, 1H), 7.67-7.91 (m, 4H); 
13
C NMR (100 
MHz, CD3OD)  6.3, 16.7, 17.7, 51.9, 65.7, 68.1, 71.5, 73.2, 122.6, 132.0, 133.8, 168.5. 
Anal. Calcd for C16H17NO6: C, 60.18; H 5.36. Found: C, 59.97; H, 5.36. 
 
N-(4S*, 5R*-Epoxy-3R*, 6S*-dihydroxybicyclo[5.1.0]oct-2S*-yl)phthalimide (±)-II-
57: To an ice cold solution of trifluoroacetic anhydride (0.35 mL, 2.44 mmol) in CH2Cl2 
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(5 mL) was added H2O2 (0.17 mL, 2.4 mmol, 50% wt solution). The mixture was stirred 
and warmed to room temperature for 1 h. To a solution of enediol (±)-II-48 (70 mg, 0.25 
mmol) in CH2Cl2 (2.5 mL) and THF (2.5 mL) cooled in an ice bath was added dropwise 
the previously prepared solution (CF3CO3H). After 10 min the mixture was warmed to 
room temperature and stirred for 3 h. The solvent was concentrated and the residue was 
purified by column chromatography (SiO2, hexanes:ethyl acetate gradient = 2:3 to 3:7) to 
give the starting material (±)-II-48 (9 mg) followed by (±)-II-57 as a colorless solid (53 
mg, 83% based on recovered starting material); mp  205-206 
o
C;
 1
H NMR (400 MHz, 
acetone-d6)  0.86 (td, J = 4.7, 8.8 Hz, 1H), 0.992-1.01 (m, 1H), 1.20-1.29 (m, 1H),  1.34 
(tt, J = 7.2, 9.2 Hz, 1H), 3.03 (dd, J = 4.7, 6.8 Hz, 1H) 3.19-3.32 (m, 2 H), 4.01 (ddd, J = 
4.9, 6.9, 11.7 Hz, 1H), 4.68-4.86 (m, 3H), 7.85 (br s, 4 H);
 13
C NMR (100 MHz, CD3OD) 
 12.9, 17.3, 23.6, 53.1, 58.0, 59.7, 68.2, 76.3, 123.7, 123.9, 131.8, 135.1, 135.2, 168.9. 
HRMS (FAB): m/z calcd for C16H15NO5: [M+Na
+
]; 324.0842, found 324.0844. 
 
 (±)-II-58: To a solution of epoxydiol (±)-II-57 (150 mg, 0.497 mmol) in THF (2 mL) 
and deionized water (10 mL) was added a catalytic amount of CBr4 (33 mg, 0.099 mmol). 
The reaction mixture was heated to reflux for 5 h.  The mixture was concentrated and the 
residue was purified by column chromatography (SiO2, hexanes:ethyl acetate gradient = 
11:9 to 3:7) to give (±)-II-58 as a colorless solid (53 mg, 52% based on recovered 
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starting material) followed by the starting material (±)-II-57 (41 mg); mp 215-216 
o
C; 
1
H 
NMR (400 MHz, CD3OD)  1.03 (q, J = 5.1 Hz, 1H), 1.13 (dt, J = 5.1, 8.4 Hz, 1H), 1.52 
(ddt, J = 3.9, 6.3, 8.4 Hz, 1H), 2.09 (dt, J = 4.7, 8.2 Hz, 1H), 4.49 (dd, J = 3.9, 9.8 Hz, 
1H), 5.09 (d, J = 9.8 Hz, 1H), 6.52 (d, J = 1.2 Hz, 1 H), 7.76-7.96 (m, 4H), 9.54 (s, 1H); 
13
C (100 MHz, CD3OD)  10.0, 14.4, 14.9, 54.7, 64.9, 124.2, 133.5, 135.5, 144.6, 148.0, 
170.3, 194.0. HRMS (FAB): m/z calcd for C16H13NO4: [M+Na
+
]; 306.0737, found 
306.0739. 
Materials and Methods: Beta-glucosidase Spectrophotometric Kinetics Assay 
Chemicals: 
 p-Nitrophenyl β-D-glucoside, xylitol. p-nitrophenyl β-D-glucoside and β-
glucosidase were purchased from SigmaAldrich 
Enzyme Assay: 
 To determine the potency of each potential inhibitor, a spectrophotometric 
kinetic assay was utilized. The assay was modified from one developed by Kelemen and 
Whelan at Royal Free Hospital School of Medicine, London, England (Kelemen and 
Whelan 1966). 
144
 
  A 100 mM sodium acetate buffer stock was prepared in double deionized 
water and the pH adjusted to 4.8. A 600 µg/mL stock was prepared of the enzyme, β-
glucosidase (from almonds), in double deionized water. A 33 mM stock was prepared of 
the substrate, p-nitrophenyl β-D-glucoside (F.W. 301.2494 g/mol) in NaOAc buffer, and 
a 1M stock was made in double deionized water of xylitol, a known inhibitor of the 
enzyme. The final concentrations of each reagent in the assay were 70 mM NaOAc, 24 
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µg/mL β-glucosidase and 6.6 mM (2.0 mg/mL) 4-nitrophenyl β-D-glucoside. When 
xylitol was utilized as a positive control for inhibition, the final concentration utilized 
was 100 mM.  
 The assay was monitored directly at 405 nm, the wavelength of light at which 
p-nitrophenolate, the cleavage product of the substrate p-nitrophenyl β-D-glucoside, 
absorbs light. With an increase in concentration of product formed, an increase in 
absorbance at 405 nm was observed, therefore enabling the calculation of rate and 
percent inhibition, relative to full enzyme activity, attributable to each inhibitor at a given 
concentration.  
 Initially, the assay was validated in a 1 mL quartz cuvette.  An aliquot of 
buffer stock was added first, followed by the addition of substrate. The cuvette volume 
was subsequently adjusted with double deionized water, to produce the appropriate 
concentrations of each reagent. The reaction was initiated with enzyme. Directly after the 
addition of enzyme, the cuvette was capped and inverted, to ensure even incorporation of 
reagents throughout the solution.  
 Prior to measuring rates, however, a reading was taken where the cuvette 
contained only buffer and substrate, to ensure the absence of background rate due to 
uncatalyzed substrate dissociation. The results demonstrated a lack of background rate. 
Six readings were then taken, measuring the initial rate of reaction. The concentration of 
enzyme utilized increased linearly with each subsequent reading. The concentrations 
tested were 6, 12, 24, 36, 48 and 60 µmL. The volume of water added to the cuvette was 
adjusted, to accommodate varying enzyme aliquot volumes.  
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 The linear region was consequently selected from each cuvette reading. An 
appropriate and proportional increase in rate was observed with each increase in enzyme 
concentration, and initial rates were therefore plotted against concentration to produce a 
validation curve. From the six readings taken, 24 µg/mL was the concentration of enzyme 
selected to utilize in the 96-well plate assay format. As Keleman and Whelan identified 
xylitol as a known inhibitor of β-glucosidase, this compound was purchased and utilized 
as a positive control for inhibition. According to Keleman and Whelan, xylitol has a 43% 
inhibitory capacity at a concentration of 100 mM.
144
 When a rate was measured in the 
presence of 100 mM xylitol and compared against full activity of enzyme at the utilized 
concentration, a similar inhibitory affect was observed, therefore reproducing previously 
observed effects and further validating the assay.  
 Prior to performing the assay in 96-well plate format, a series of stocks were 
prepared by serial dilution for each potential inhibitor, a 25 mM stock, 5 mmM stock, and 
0.5 mM stock. Incomplete solubility in water was experienced at higher stock 
concentrations. Therefore, each stock was made in 50% DMSO, 50% water, which 
permitted complete solubility. However, as each stock contained DMSO, the enzyme was 
tested for DMSO sensitivity prior to running the IC50 assay. This was accomplished by 
measuring rate in a series of eight wells in the absence of DMSO in the same plate as a 
series of 8 wells containing 10% DMSO. The average rate between the two sets of wells 
was compared, and no notable difference was observed, therefore demonstrating a lack of 
DMSO sensitivity. The assay was subsequently run in 96-well plate format. A 5-point 
IC50 was performed for each potential inhibitor, testing compound concentrations ranging 
from 10 µM-1 mM, equally spaced on a logarithmic scale.  
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 The first column of each plate served as the plate blank, containing solely 
buffer and substrate. Column two served as a negative control for inhibition, containing 
buffer, enzyme and substrate, and reflecting full activity of the enzyme. Column three 
served as a positive control for inhibition, containing buffer, enzyme, substrate, and 100 
mM xylitol. The following columns contained increasing concentrations of inhibitor in 
quadruplate.  
 First, buffer was added to each well utilizing a multi-channel pipette. Substrate 
was then added, also using a multi-channel pipette. Each well volume was adjusted with 
double deionized water, taking into account the volume of inhibitor added to each set of 
wells. Again, this was performed utilizing a multi-channel pipette. The plate was allowed 
to equilibrate in the spectrophotometer at 25 
o
C for 30 min prior to initiation. After 
incubation, the reaction was initiated with enzyme, using a single channel pipette and 
reverse pipetting technique. Enzyme aliquots were hung on the side of each well, directly 
above the meniscus of solution. This was done to ensure uniform initiation of the 
reaction.  
 To initiate the reaction, the plate was tapped gently on the bench top. Prior to 
inserting the plate into the spectrophotometer, the bottom was quickly cleaned with 
laboratory tissue to ensure the removal of dust or particles that could interfere with 
experimental readings. The plate was then placed in the spectrophotometer, shaken for 5 
seconds to promote adequate incorporation of reagents into solution, and a ten-minute 
kinetic read immediately taken.  
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 For each plate assayed, the reduced slope values for all negative control wells 
were averaged and the obtained value considered representative of full enzymatic 
activity. Fractional activity was then calculated by dividing the slope of each well by this 
value and multiplying by 100%. Fractional activity values were used to determine the 
amount of activity observed at each concentration of inhibitor. These values were then 
copied to Graph Pad and plotted as percent activity versus the log of the concentration of 
inhibitor. Data was fit as a nonlinear regression curve, according to the formula y= 
Bottom + ((Top-Bottom)/(1+10x-logIC50)). The fit of the curve permitted the 
determination of the 50% inhibitory concentration of each compound. 
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Table 1 Crystal data and structure refinement for (±)-II-30.  
Identification code  don1v  
Empirical formula  C16H19NO7  
Formula weight  337.32  
Temperature/K  99.95(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.1821(3)  
b/Å  8.3349(4)  
c/Å  11.7398(5)  
α/°  78.776(4)  
β/°  89.260(3)  
γ/°  69.061(4)  
Volume/Å
3
  732.04(5)  
Z  2  
ρcalcmg/mm
3
  1.530  
m/mm
-1
  0.121  
F(000)  356.0  
Crystal size/mm
3
  0.35 × 0.18 × 0.12  
2Θ range for data collection  5.78 to 58.04°  
Index ranges  -11 ≤ h ≤ 10, -11 ≤ k ≤ 11, -14 ≤ l ≤ 15  
Reflections collected  14805  
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Independent reflections  3552[R(int) = 0.0288]  
Data/restraints/parameters  3552/0/252  
Goodness-of-fit on F
2
  1.092  
Final R indexes [I>=2σ (I)]  R1 = 0.0447, wR2 = 0.1058  
Final R indexes [all data]  R1 = 0.0541, wR2 = 0.1123  
Largest diff. peak/hole / e Å
-3
  0.46/-0.32  
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1v. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 3552.5(17) 3001.3(17) 6828.5(12) 25.8(3) 
O2 2479.5(17) 3397.7(16) 4471.9(11) 23.9(3) 
O3 146.2(15) 3610.1(15) 6400(1) 17.6(2) 
O4 -1694.1(15) 1142.3(17) 6170.9(11) 20.8(3) 
O5 -1792.7(15) 888.4(15) 9276.2(10) 21.5(3) 
O6 962.0(15) -3316.7(15) 7182.8(10) 19.9(3) 
N1 -65.3(17) -1019.5(16) 8167.5(11) 14.3(3) 
C1 806(2) 144.1(19) 7566.7(13) 14.4(3) 
C2 2773(2) -749(2) 7820.7(14) 18.1(3) 
C3 4150(2) -114(2) 7227.6(14) 19.3(3) 
C4 3848(2) 1511(2) 6299.0(14) 17.7(3) 
C5 2463(2) 1908(2) 5320.6(13) 16.5(3) 
C6 573(2) 2340.5(19) 5671.8(13) 14.8(3) 
C7 152.8(19) 747(2) 6278.1(13) 14.6(3) 
C8 3985(2) -1784(2) 7023.5(15) 22.7(4) 
C9 -1316.8(19) -511(2) 8972.5(13) 15.1(3) 
C10 51(2) -2625.7(19) 7900.6(13) 14.9(3) 
C11 -1932.7(19) -2001(2) 9344.3(13) 14.6(3) 
C12 -1146.8(19) -3248.0(19) 8676.9(13) 14.5(3) 
C13 -1478(2) -4787(2) 8811.6(14) 17.5(3) 
C14 -2616(2) -5050(2) 9665.5(14) 20.1(3) 
C15 -3384(2) -3813(2) 10345.7(15) 20.3(3) 
C16 -3062(2) -2247(2) 10189.9(14) 18.7(3) 
O1W 6252(4) 3831(4) 7168(3) 36.7(7) 
O2W 4524(4) 5280(5) 4551(3) 43.7(8) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1v. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 20.2(6) 26.8(7) 34.1(7) -14.0(6) -0.1(5) -8.7(5) 
O2 24.5(6) 20.2(6) 22.6(6) 3.0(5) 7.3(5) -6.8(5) 
O3 18.3(6) 14.2(5) 19.7(6) -5.5(4) 3.0(4) -4.2(4) 
O4 15.1(6) 22.0(6) 25.9(7) -2.7(5) -1.7(5) -8.3(5) 
O5 24.1(6) 16.5(6) 26.1(6) -9.4(5) 8.3(5) -7.4(5) 
O6 26.2(6) 18.5(6) 16.8(6) -7.0(4) 5.6(5) -8.6(5) 
N1 18.2(6) 13.1(6) 12.6(6) -3.3(5) 3.1(5) -6.5(5) 
C1 17.6(7) 13.1(7) 13.6(7) -2.1(5) 2.2(6) -7.3(6) 
C2 18.5(8) 19.4(8) 14.4(7) 0.7(6) -0.8(6) -6.6(6) 
C3 13.4(7) 24.3(8) 17.1(8) -0.5(6) -1.0(6) -5.2(6) 
C4 14.5(7) 18.0(7) 20.3(8) -4.1(6) 3.4(6) -5.4(6) 
C5 18.6(7) 14.3(7) 15.4(7) -0.8(6) 3.8(6) -5.8(6) 
C6 15.3(7) 14.1(7) 13.7(7) -1.8(6) 0.1(5) -4.5(6) 
C7 13.9(7) 15.0(7) 14.4(7) -3.0(6) -0.2(5) -4.7(6) 
C8 18.9(8) 17.9(8) 24.1(9) 0.3(6) 2.5(6) -0.4(6) 
C9 14.4(7) 15.5(7) 14.6(7) -2.3(6) 0.3(6) -4.9(6) 
C10 17.9(7) 12.6(7) 13.0(7) -1.3(5) -1.2(6) -4.7(6) 
C11 13.9(7) 14.4(7) 14.0(7) -1.0(6) -1.8(5) -4.0(6) 
C12 14.7(7) 14.8(7) 13.0(7) -1.2(6) -1.2(5) -4.7(6) 
C13 19.0(7) 15.6(7) 17.6(8) -3.1(6) -1.8(6) -5.9(6) 
C14 20.6(8) 18.4(8) 21.8(8) 0.3(6) -3.1(6) -10.1(6) 
C15 15.8(7) 24.6(8) 19.9(8) -0.3(6) 1.8(6) -8.9(6) 
C16 16.3(7) 20.4(8) 19.0(8) -5.1(6) 2.6(6) -5.8(6) 
O1W 26.0(14) 36.1(16) 55.6(19) -17.7(14) 9.0(13) -16.3(13) 
O2W 38.2(18) 39.8(18) 60(2) -6.4(16) 9.5(14) -24.6(15) 
  
Table 4 Bond Lengths for don1v. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.439(2)   C3 C4 1.509(2) 
O2 C5 1.4372(18)   C3 C8 1.509(2) 
O3 C6 1.4328(18)   C4 C5 1.527(2) 
O4 C7 1.4285(18)   C5 C6 1.527(2) 
O5 C9 1.2133(19)   C6 C7 1.530(2) 
O6 C10 1.2098(19)   C9 C11 1.489(2) 
N1 C1 1.4703(18)   C10 C12 1.489(2) 
N1 C9 1.3936(19)   C11 C12 1.391(2) 
N1 C10 1.4041(19)   C11 C16 1.383(2) 
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C1 C2 1.517(2)   C12 C13 1.383(2) 
C1 C7 1.536(2)   C13 C14 1.399(2) 
C2 C3 1.516(2)   C14 C15 1.393(2) 
C2 C8 1.511(2)   C15 C16 1.399(2) 
  
Table 5 Bond Angles for don1v. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C9 N1 C1 122.27(12)   O4 C7 C1 110.01(12) 
C9 N1 C10 111.71(12)   O4 C7 C6 109.62(12) 
C10 N1 C1 125.44(12)   C6 C7 C1 112.65(12) 
N1 C1 C2 109.09(12)   C3 C8 C2 60.24(11) 
N1 C1 C7 109.44(12)   O5 C9 N1 125.38(14) 
C2 C1 C7 116.49(13)   O5 C9 C11 128.52(14) 
C3 C2 C1 125.56(14)   N1 C9 C11 106.09(12) 
C8 C2 C1 123.62(14)   O6 C10 N1 125.24(14) 
C8 C2 C3 59.82(11)   O6 C10 C12 129.04(14) 
C4 C3 C2 127.32(14)   N1 C10 C12 105.72(12) 
C4 C3 C8 124.76(14)   C12 C11 C9 107.91(13) 
C8 C3 C2 59.94(11)   C16 C11 C9 130.28(14) 
O1 C4 C3 109.92(13)   C16 C11 C12 121.81(14) 
O1 C4 C5 111.48(13)   C11 C12 C10 108.24(13) 
C3 C4 C5 117.10(13)   C13 C12 C10 130.09(14) 
O2 C5 C4 108.91(13)   C13 C12 C11 121.64(14) 
O2 C5 C6 106.36(12)   C12 C13 C14 117.01(15) 
C4 C5 C6 116.25(13)   C15 C14 C13 121.38(15) 
O3 C6 C5 110.63(12)   C14 C15 C16 121.16(15) 
O3 C6 C7 109.24(12)   C11 C16 C15 117.00(15) 
C5 C6 C7 114.33(12)           
  
Table 6 Hydrogen Bonds for don1v.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O3 0.88(3) 1.89(3) 2.6841(17) 150(3) 
O2 H2A O2W 0.88(4) 1.87(4) 2.684(3) 153(4) 
O3 H3 O2
1
 0.91(3) 1.76(3) 2.6677(17) 171(3) 
O4 H4 O1W
2
 0.80(3) 1.98(3) 2.738(3) 158(3) 
O1W H1WA O5
3
 0.85 2.30 3.104(4) 156.8 
O1W H1WB O1 0.85 1.77 2.595(3) 163.3 
O2W H2WB O1
4
 0.85 2.06 2.792(3) 143.3 
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1-X,1-Y,1-Z; 2-1+X,+Y,+Z; 31+X,+Y,+Z; 41-X,1-Y,1-Z 
  
 
Table 7 Torsion Angles for don1v. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C4 C5 O2 57.54(16)   C3 C4 C5 C6 65.25(18) 
O1 C4 C5 C6 -62.53(17)   C4 C3 C8 C2 
-
116.81(17) 
O2 C5 C6 O3 -73.73(15)   C4 C5 C6 O3 47.70(17) 
O2 C5 C6 C7 162.45(13)   C4 C5 C6 C7 -76.12(17) 
O3 C6 C7 O4 77.43(15)   C5 C6 C7 O4 
-
158.01(13) 
O3 C6 C7 C1 -45.41(16)   C5 C6 C7 C1 79.15(16) 
O5 C9 C11 C12 173.90(16)   C7 C1 C2 C3 45.9(2) 
O5 C9 C11 C16 -6.6(3)   C7 C1 C2 C8 -28.7(2) 
O6 C10 C12 C11 
-
179.29(16) 
  C8 C2 C3 C4 112.77(19) 
O6 C10 C12 C13 2.7(3)   C8 C3 C4 O1 161.45(14) 
N1 C1 C2 C3 170.33(14)   C8 C3 C4 C5 32.9(2) 
N1 C1 C2 C8 95.81(17)   C9 N1 C1 C2 121.89(15) 
N1 C1 C7 O4 41.01(16)   C9 N1 C1 C7 
-
109.59(15) 
N1 C1 C7 C6 163.63(12)   C9 N1 C10 O6 175.80(15) 
N1 C9 C11 C12 -5.16(16)   C9 N1 C10 C12 -4.50(16) 
N1 C9 C11 C16 174.37(16)   C9 C11 C12 C10 2.51(16) 
N1 C10 C12 C11 1.03(16)   C9 C11 C12 C13 
-
179.30(14) 
N1 C10 C12 C13 
-
176.96(15) 
  C9 C11 C16 C15 
-
179.56(15) 
C1 N1 C9 O5 -1.4(2)   C10 N1 C1 C2 -67.55(18) 
C1 N1 C9 C11 177.73(13)   C10 N1 C1 C7 60.97(18) 
C1 N1 C10 O6 4.4(2)   C10 N1 C9 O5 
-
173.10(15) 
C1 N1 C10 C12 
-
175.91(13) 
  C10 N1 C9 C11 6.00(16) 
C1 C2 C3 C4 1.0(3)   C10 C12 C13 C14 176.61(15) 
C1 C2 C3 C8 
-
111.82(18) 
  C11 C12 C13 C14 -1.1(2) 
C1 C2 C8 C3 114.91(17)   C12 C11 C16 C15 -0.1(2) 
C2 C1 C7 O4 165.30(13)   C12 C13 C14 C15 0.2(2) 
C2 C1 C7 C6 -72.08(17)   C13 C14 C15 C16 0.8(2) 
C2 C3 C4 O1 85.19(19)   C14 C15 C16 C11 -0.9(2) 
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C2 C3 C4 C5 -43.3(2)   C16 C11 C12 C10 
-
177.07(14) 
C3 C4 C5 O2 
-
174.68(13) 
  C16 C11 C12 C13 1.1(2) 
  
Table 8 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1v.  
Atom x y z U(eq) 
H1 2410(40) 3490(40) 6830(30) 63(9) 
H2A 3280(50) 3760(50) 4700(30) 14(9) 
H2B 3350(70) 3120(70) 3970(50) 54(15) 
H3 -740(40) 4600(40) 6030(30) 64(8) 
H4 -2190(30) 2080(40) 6330(20) 46(8) 
H1A 426 1213 7917 17 
H2 3101 -1297 8662 22 
H3A 5176 -358 7775 23 
H4A 4983 1321 5917 21 
H5 2783 873 4938 20 
H6 -209 2883 4944 18 
H7 746 -242 5874 17 
H8A 4914 -2910 7384 27 
H8B 3485 -1763 6255 27 
H13 -956 -5627 8345 21 
H14 -2871 -6095 9784 24 
H15 -4139 -4037 10926 24 
H16 -3594 -1392 10644 22 
H1WA 6718 3283 7842 55 
H1WB 5253 3753 7091 55 
H2WA 4354 5797 5122 66 
H2WB 5447 5334 4232 66 
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Table 1 Crystal data and structure refinement for (±)-II-31.  
Identification code  don1w  
Empirical formula  C16H17NO6  
Formula weight  319.31  
Temperature/K  99.95(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.91018(19)  
b/Å  7.79863(13)  
c/Å  17.1421(3)  
α/°  90.00  
β/°  99.5114(16)  
γ/°  90.00  
Volume/Å
3
  1438.47(4)  
Z  4  
ρcalcmg/mm
3
  1.474  
m/mm
-1
  0.114  
F(000)  672.0  
Crystal size/mm
3
  0.33 × 0.14 × 0.09  
2Θ range for data collection  5.76 to 57.9°  
Index ranges  -13 ≤ h ≤ 14, -9 ≤ k ≤ 10, -23 ≤ l ≤ 23  
Reflections collected  16375  
Independent reflections  3507[R(int) = 0.0298]  
Data/restraints/parameters  3507/0/224  
Goodness-of-fit on F
2
  1.085  
Final R indexes [I>=2σ (I)]  R1 = 0.0510, wR2 = 0.1337  
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Final R indexes [all data]  R1 = 0.0585, wR2 = 0.1394  
Largest diff. peak/hole / e Å
-3
  0.83/-0.26  
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1w. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 4476.4(13) 5722.2(19) 2891.4(8) 24.7(3) 
O2 4381.7(12) 7438.3(17) 4264.2(8) 21.0(3) 
O3 6776.4(12) 10059.9(18) 3549.5(7) 19.9(3) 
O4 7339.6(12) 10398.3(17) 5267.3(7) 17.5(3) 
O5 10502.6(11) 8019.7(18) 5241.0(7) 19.6(3) 
O6 6981.4(12) 6542(2) 6221.4(8) 25.9(3) 
N1 8567.8(13) 7329.0(19) 5532.3(8) 15.3(3) 
C1 7850.4(15) 7692(2) 4736.5(9) 14.8(3) 
C2 7576.2(16) 6022(2) 4295.8(10) 19.2(4) 
C3 6534.0(17) 5634(2) 3619.7(11) 20.7(4) 
C4 5505.2(16) 6787(2) 3220.5(10) 19.2(4) 
C5 5008.7(15) 8206(2) 3695.7(10) 16.5(3) 
C6 5979.4(15) 9505(2) 4078.5(10) 15.1(3) 
C7 6789.6(15) 8919(2) 4840.8(9) 14.2(3) 
C8 6544.0(18) 4824(2) 4420.3(11) 23.8(4) 
C9 9844.6(15) 7602(2) 5716.9(10) 14.9(3) 
C10 8061.8(16) 6882(2) 6207.5(10) 17.9(4) 
C11 10190.0(16) 7304(2) 6584.1(10) 15.2(3) 
C12 9114.1(16) 6914(2) 6880.8(10) 17.1(4) 
C13 9123.8(17) 6663(3) 7680.8(10) 21.7(4) 
C14 10273.3(18) 6799(3) 8177.6(11) 23.5(4) 
C15 11354.1(18) 7165(3) 7877.8(11) 22.8(4) 
C16 11331.4(16) 7427(2) 7066.8(10) 18.5(4) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1w. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 25.0(7) 30.4(8) 17.5(6) -4.8(6) -0.3(5) -8.8(6) 
O2 19.9(6) 24.2(7) 19.8(6) 1.1(5) 6.0(5) -0.9(5) 
O3 17.2(6) 28.3(7) 13.8(6) 5.2(5) 1.6(5) -2.3(5) 
O4 17.4(6) 19.3(6) 15.9(6) -3.6(5) 2.9(5) -3.0(5) 
O5 14.7(6) 29.7(7) 14.8(6) 3.3(5) 3.7(5) 0.1(5) 
O6 15.9(6) 40.3(8) 20.9(6) 9.2(6) 1.6(5) -5.1(6) 
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N1 13.3(7) 20.3(7) 11.6(6) 2.6(5) 0.1(5) 0.2(5) 
C1 13.2(7) 20.7(8) 9.9(7) 1.3(6) 0.5(6) 1.5(6) 
C2 17.9(8) 20.4(9) 18.9(8) -2.1(7) 1.6(7) 5.0(7) 
C3 22.4(9) 20.2(9) 19.2(8) -7.6(7) 2.1(7) 1.8(7) 
C4 18.4(8) 25.4(9) 12.9(7) -3.5(7) 0.3(6) -2.9(7) 
C5 13.7(8) 20.8(9) 14.3(7) 0.0(6) -0.1(6) -0.8(6) 
C6 14.5(8) 17.1(8) 13.5(7) 1.5(6) 1.7(6) 0.5(6) 
C7 14.0(7) 16.2(8) 11.8(7) -1.8(6) 0.1(6) -1.0(6) 
C8 27(1) 17.6(9) 25.6(9) 1.9(7) 0.9(7) -0.3(7) 
C9 13.9(8) 15.9(8) 14.1(7) 0.9(6) 0.5(6) 2.9(6) 
C10 16.1(8) 22.5(9) 14.9(8) 4.6(7) 1.2(6) -0.9(7) 
C11 16.8(8) 15.5(8) 12.7(7) 2.7(6) 0.9(6) 1.8(6) 
C12 15.6(8) 20.0(8) 14.9(8) 2.7(6) 0.0(6) -1.4(7) 
C13 19.7(9) 29.4(10) 16.1(8) 6.9(7) 3.2(7) -0.8(7) 
C14 24.6(9) 31.9(10) 13.2(8) 5.0(7) 0.3(7) -0.3(8) 
C15 20.2(9) 29.7(10) 16.1(8) 4.1(7) -3.8(7) -2.1(7) 
C16 16.3(8) 20.8(9) 17.9(8) 4.3(7) 1.4(6) -0.7(7) 
  
Table 4 Bond Lengths for don1w. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.435(2)   C3 C4 1.511(3) 
O2 C5 1.413(2)   C3 C8 1.509(3) 
O3 C6 1.423(2)   C4 C5 1.525(3) 
O4 C7 1.442(2)   C5 C6 1.533(2) 
O5 C9 1.217(2)   C6 C7 1.522(2) 
O6 C10 1.212(2)   C9 C11 1.490(2) 
N1 C1 1.484(2)   C10 C12 1.488(2) 
N1 C9 1.393(2)   C11 C12 1.388(2) 
N1 C10 1.406(2)   C11 C16 1.380(2) 
C1 C2 1.511(2)   C12 C13 1.384(2) 
C1 C7 1.535(2)   C13 C14 1.399(3) 
C2 C3 1.514(2)   C14 C15 1.392(3) 
C2 C8 1.505(3)   C15 C16 1.401(2) 
  
Table 5 Bond Angles for don1w. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C9 N1 C1 122.38(14)   O4 C7 C1 107.40(13) 
C9 N1 C10 111.40(13)   O4 C7 C6 109.21(14) 
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C10 N1 C1 125.80(14)   C6 C7 C1 115.43(13) 
N1 C1 C2 109.01(14)   C2 C8 C3 60.30(12) 
N1 C1 C7 107.78(13)   O5 C9 N1 124.56(15) 
C2 C1 C7 120.33(14)   O5 C9 C11 129.10(16) 
C1 C2 C3 128.05(15)   N1 C9 C11 106.33(14) 
C8 C2 C1 123.72(16)   O6 C10 N1 125.85(16) 
C8 C2 C3 59.99(12)   O6 C10 C12 128.08(16) 
C4 C3 C2 129.48(16)   N1 C10 C12 106.07(14) 
C8 C3 C2 59.71(12)   C12 C11 C9 108.06(15) 
C8 C3 C4 123.65(16)   C16 C11 C9 129.92(16) 
O1 C4 C3 107.95(15)   C16 C11 C12 121.98(16) 
O1 C4 C5 107.82(14)   C11 C12 C10 108.09(15) 
C3 C4 C5 119.51(14)   C13 C12 C10 130.17(16) 
O2 C5 C4 108.43(15)   C13 C12 C11 121.73(16) 
O2 C5 C6 111.34(13)   C12 C13 C14 116.86(17) 
C4 C5 C6 115.27(14)   C15 C14 C13 121.33(17) 
O3 C6 C5 112.33(14)   C14 C15 C16 121.27(17) 
O3 C6 C7 107.99(13)   C11 C16 C15 116.81(17) 
C7 C6 C5 115.54(14)           
  
Table 6 Hydrogen Bonds for don1w.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O6
1
 0.94(3) 2.08(3) 2.960(2) 156(3) 
O2 H2 O4
2
 1.03(4) 1.71(4) 2.7417(18) 175(3) 
O3 H3 O1
3
 0.85(3) 1.84(3) 2.6684(18) 166(3) 
O4 H4 O5
4
 0.84(3) 2.13(3) 2.9158(18) 155(2) 
11-X,1-Y,1-Z; 21-X,2-Y,1-Z; 31-X,1/2+Y,1/2-Z; 42-X,2-Y,1-Z 
  
Table 7 Torsion Angles for don1w. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C4 C5 O2 55.84(17)   C3 C4 C5 C6 57.8(2) 
O1 C4 C5 C6 
-
178.61(14) 
  C4 C3 C8 C2 
-
119.72(19) 
O2 C5 C6 O3 169.17(14)   C4 C5 C6 O3 45.1(2) 
O2 C5 C6 C7 44.7(2)   C4 C5 C6 C7 -79.37(19) 
O3 C6 C7 O4 72.60(16)   C5 C6 C7 O4 
-
160.68(14) 
O3 C6 C7 C1 -48.49(19)   C5 C6 C7 C1 78.24(19) 
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O5 C9 C11 C12 177.71(18)   C7 C1 C2 C3 30.9(3) 
O5 C9 C11 C16 0.2(3)   C7 C1 C2 C8 -45.1(2) 
O6 C10 C12 C11 177.6(2)   C8 C2 C3 C4 110.5(2) 
O6 C10 C12 C13 -3.8(3)   C8 C3 C4 O1 -77.8(2) 
N1 C1 C2 C3 156.06(17)   C8 C3 C4 C5 45.8(3) 
N1 C1 C2 C8 80.0(2)   C9 N1 C1 C2 102.95(18) 
N1 C1 C7 O4 55.34(17)   C9 N1 C1 C7 
-
124.88(16) 
N1 C1 C7 C6 177.40(14)   C9 N1 C10 O6 
-
178.59(19) 
N1 C9 C11 C12 -1.51(19)   C9 N1 C10 C12 1.3(2) 
N1 C9 C11 C16 
-
179.06(18) 
  C9 C11 C12 C10 2.3(2) 
N1 C10 C12 C11 -2.3(2)   C9 C11 C12 C13 
-
176.40(17) 
N1 C10 C12 C13 176.30(19)   C9 C11 C16 C15 176.26(18) 
C1 N1 C9 O5 -6.2(3)   C10 N1 C1 C2 -85.1(2) 
C1 N1 C9 C11 173.03(15)   C10 N1 C1 C7 47.0(2) 
C1 N1 C10 O6 8.7(3)   C10 N1 C9 O5 
-
179.21(17) 
C1 N1 C10 C12 
-
171.37(16) 
  C10 N1 C9 C11 0.06(19) 
C1 C2 C3 C4 -0.7(3)   C10 C12 C13 C14 
-
179.10(19) 
C1 C2 C3 C8 -111.2(2)   C11 C12 C13 C14 -0.7(3) 
C1 C2 C8 C3 118.05(19)   C12 C11 C16 C15 -1.0(3) 
C2 C1 C7 O4 
-
178.94(14) 
  C12 C13 C14 C15 -0.2(3) 
C2 C1 C7 C6 -56.9(2)   C13 C14 C15 C16 0.6(3) 
C2 C3 C4 O1 
-
154.09(18) 
  C14 C15 C16 C11 0.0(3) 
C2 C3 C4 C5 -30.5(3)   C16 C11 C12 C10 
-
179.92(16) 
C3 C4 C5 O2 -67.8(2)   C16 C11 C12 C13 1.4(3) 
  
Table 8 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1w.  
Atom x y z U(eq) 
H1 4110(30) 5220(40) 3290(18) 55(9) 
H2 3740(40) 8300(50) 4410(20) 86(12) 
H3 6300(30) 10370(40) 3130(17) 39(7) 
H4 7820(20) 10830(30) 4985(14) 25(6) 
H1A 8419 8350 4445 18 
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H2A 8354 5386 4242 23 
H3A 6804 4803 3237 25 
H4A 5816 7351 2767 23 
H5 4375 8856 3322 20 
H6 5513 10538 4213 18 
H7 6245 8333 5174 17 
H8A 5931 5242 4742 29 
H8B 6738 3586 4476 29 
H13 8385 6409 7883 26 
H14 10317 6639 8731 28 
H15 12122 7239 8230 27 
H16 12067 7676 6859 22 
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Table 1 Crystal data and structure refinement for (±)-II-36.  
Identification code  don1q  
Empirical formula  C16H13NO3  
Formula weight  267.27  
Temperature/K  100.00(10)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  10.8711(3)  
b/Å  10.1720(3)  
c/Å  11.3216(4)  
α/°  90.00  
β/°  94.004(3)  
γ/°  90.00  
Volume/Å
3
  1248.90(7)  
Z  4  
ρcalcmg/mm
3
  1.421  
m/mm
-1
  0.811  
F(000)  560  
Crystal size/mm
3
  0.32 × 0.14 × 0.08  
2Θ range for data collection  10.9 to 147.58°  
Index ranges  -13 ≤ h ≤ 13, -12 ≤ k ≤ 12, -13 ≤ l ≤ 14  
Reflections collected  10144  
Independent reflections  2495[R(int) = 0.0288]  
Data/restraints/parameters  2495/0/191  
Goodness-of-fit on F
2
  1.056  
Final R indexes [I>=2σ (I)]  R1 = 0.0418, wR2 = 0.1074  
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Final R indexes [all data]  R1 = 0.0480, wR2 = 0.1126  
Largest diff. peak/hole / e Å
-3
  0.338/-0.316  
 
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1q. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 5310(1) 2871.5(12) -887(1) 31.4(3) 
O2 1719.6(10) 841.2(11) -31.1(10) 31.8(3) 
O3 2460.7(12) -516.7(13) -4027.4(11) 40.9(3) 
N1 3523.2(11) 1663.6(12) -716(1) 23.9(3) 
C1 4137.6(13) 2984.4(14) 874.9(13) 23.5(3) 
C2 3056.0(13) 2349.4(14) 1139.4(13) 23.0(3) 
C3 2519.8(14) 2557.8(16) 2196.8(13) 27.8(3) 
C4 3115.1(16) 3444.1(16) 2986.9(14) 31.6(4) 
C5 4195.9(15) 4078.2(16) 2726.0(14) 31.2(4) 
C6 4730.7(14) 3861.5(16) 1655.1(14) 28.3(3) 
C7 4446.0(13) 2554.6(15) -329.1(13) 24.4(3) 
C8 2636.7(13) 1515.4(14) 109.2(13) 23.8(3) 
C9 3385.3(14) 1079.6(14) -1906.4(12) 24.3(3) 
C12 2994.3(15) 564.4(18) -4641.6(14) 33.2(4) 
C13 3770.5(17) -522.4(17) -4185.1(15) 34.7(4) 
C10 3123.0(14) 2152.0(15) -2823.0(13) 27.4(3) 
C11 2914.2(16) 1880.6(17) -4107.9(14) 32.9(4) 
C14 4631.5(17) -482.6(18) -3107.3(15) 37.7(4) 
C15 4475.6(16) 208.2(17) -2105.0(14) 33.3(4) 
C16 3992.7(19) 2649.0(19) -3679.8(17) 29.5(5) 
C10A 4475.6(16) 208.2(17) -2105.0(14) 33.3(4) 
C11A 4631.5(17) -482.6(18) -3107.3(15) 37.7(4) 
C14A 2914.2(16) 1880.6(17) -4107.9(14) 32.9(4) 
C15A 3123.0(14) 2152.0(15) -2823.0(13) 27.4(3) 
C16A 5402(7) 306(8) -2721(7) 29(2) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1q. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 25.9(6) 42.2(7) 26.8(6) -3.4(5) 5.5(4) -5.0(5) 
O2 31.1(6) 35.7(6) 28.5(6) 0.2(5) 1.4(4) -9.5(5) 
O3 44.6(7) 44.1(7) 34.4(7) -5.2(5) 6.1(5) -17.7(6) 
N1 25.6(6) 27.4(6) 18.5(6) -0.9(5) 0.2(5) -0.8(5) 
C1 24.2(7) 25.5(7) 20.8(7) 0.9(6) 0.7(5) 2.9(6) 
C2 25.4(7) 23.5(7) 19.8(7) 2.5(5) -0.5(5) 2.9(5) 
C3 28.4(8) 32.1(8) 23.2(7) 2.7(6) 3.6(6) 0.7(6) 
C4 38.3(9) 34.8(8) 22.1(7) -1.9(6) 5.1(6) 3.2(7) 
C5 36.1(8) 31.7(8) 25.3(8) -6.8(6) -1.2(6) 0.1(7) 
C6 27.2(7) 30.9(8) 26.8(8) -2.0(6) 1.4(6) -1.4(6) 
C7 24.3(7) 27.1(7) 21.4(7) 1.2(6) -0.4(6) 1.6(6) 
C8 25.8(7) 24.4(7) 20.9(7) 3.7(5) -0.4(5) 1.0(6) 
C9 28.2(7) 26.3(7) 18.1(7) -2.2(6) -0.1(5) -0.7(6) 
C12 34.3(8) 44.8(9) 20.4(7) -0.2(7) 1.1(6) -9.4(7) 
C13 43.6(9) 31.7(8) 29.7(8) -8.5(7) 9.1(7) -6.9(7) 
C10 32.0(8) 27.0(7) 23.0(7) 0.1(6) 0.8(6) 4.5(6) 
C11 34.4(8) 35.4(9) 29.1(8) 8.2(7) 3.9(6) 3.3(7) 
C14 44.9(10) 35.8(9) 33.0(9) 3.0(7) 8.0(7) 15.1(8) 
C15 39.4(9) 32.6(8) 26.8(8) -1.1(6) -5.7(7) 10.3(7) 
C16 34.7(11) 25.6(10) 27.6(10) 2.5(7) -2.3(8) -3.6(8) 
C10A 39.4(9) 32.6(8) 26.8(8) -1.1(6) -5.7(7) 10.3(7) 
C11A 44.9(10) 35.8(9) 33.0(9) 3.0(7) 8.0(7) 15.1(8) 
C14A 34.4(8) 35.4(9) 29.1(8) 8.2(7) 3.9(6) 3.3(7) 
C15A 32.0(8) 27.0(7) 23.0(7) 0.1(6) 0.8(6) 4.5(6) 
C16A 22(4) 34(4) 30(4) -7(3) 5(3) -3(3) 
  
Table 4 Bond Lengths for don1q. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C7 1.2115(18)   C3 C4 1.397(2) 
O2 C8 1.2114(18)   C4 C5 1.390(2) 
O3 C12 1.444(2)   C5 C6 1.398(2) 
O3 C13 1.447(2)   C9 C10 1.519(2) 
N1 C7 1.3994(19)   C9 C15 1.509(2) 
N1 C8 1.3965(18)   C12 C13 1.463(3) 
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N1 C9 1.4709(18)   C12 C11 1.474(2) 
C1 C2 1.392(2)   C13 C14 1.486(3) 
C1 C6 1.383(2)   C10 C11 1.483(2) 
C1 C7 1.492(2)   C10 C16 1.489(2) 
C2 C3 1.384(2)   C11 C16 1.463(3) 
C2 C8 1.488(2)   C14 C15 1.355(2) 
  
Table 5 Bond Angles for don1q. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C12 O3 C13 60.79(11)   N1 C8 C2 105.96(12) 
C7 N1 C9 124.98(12)   N1 C9 C10 109.77(12) 
C8 N1 C7 111.95(12)   N1 C9 C15 110.05(12) 
C8 N1 C9 122.57(12)   C15 C9 C10 115.59(13) 
C2 C1 C7 107.92(13)   O3 C12 C13 59.71(11) 
C6 C1 C2 121.66(14)   O3 C12 C11 117.20(13) 
C6 C1 C7 130.41(14)   C13 C12 C11 126.20(14) 
C1 C2 C8 108.24(12)   O3 C13 C12 59.50(11) 
C3 C2 C1 121.87(14)   O3 C13 C14 117.87(14) 
C3 C2 C8 129.86(14)   C12 C13 C14 125.75(15) 
C2 C3 C4 116.65(15)   C11 C10 C9 123.05(13) 
C5 C4 C3 121.61(15)   C11 C10 C16 58.99(11) 
C4 C5 C6 121.32(15)   C16 C10 C9 126.25(14) 
C1 C6 C5 116.88(14)   C12 C11 C10 124.19(14) 
O1 C7 N1 125.03(14)   C16 C11 C12 123.51(15) 
O1 C7 C1 129.07(14)   C16 C11 C10 60.74(12) 
N1 C7 C1 105.89(12)   C15 C14 C13 126.40(16) 
O2 C8 N1 125.00(14)   C14 C15 C9 125.07(15) 
O2 C8 C2 129.04(14)   C11 C16 C10 60.27(11) 
  
Table 6 Torsion Angles for don1q. 
A B C D Angle/˚ 
O3 C12 C13 C14 -104.14(18) 
O3 C12 C11 C10 41.8(2) 
O3 C12 C11 C16 116.80(18) 
O3 C13 C14 C15 -37.5(3) 
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N1 C9 C10 C11 -178.85(13) 
N1 C9 C10 C16 107.71(17) 
N1 C9 C15 C14 179.60(17) 
C1 C2 C3 C4 0.3(2) 
C1 C2 C8 O2 -177.47(15) 
C1 C2 C8 N1 1.88(16) 
C2 C1 C6 C5 0.2(2) 
C2 C1 C7 O1 -179.87(15) 
C2 C1 C7 N1 -0.58(16) 
C2 C3 C4 C5 -0.4(2) 
C3 C2 C8 O2 0.7(3) 
C3 C2 C8 N1 -179.91(15) 
C3 C4 C5 C6 0.4(3) 
C4 C5 C6 C1 -0.3(2) 
C6 C1 C2 C3 -0.2(2) 
C6 C1 C2 C8 178.16(13) 
C6 C1 C7 O1 1.3(3) 
C6 C1 C7 N1 -179.41(15) 
C7 N1 C8 O2 177.06(14) 
C7 N1 C8 C2 -2.32(16) 
C7 N1 C9 C10 -63.09(18) 
C7 N1 C9 C15 65.20(18) 
C7 C1 C2 C3 -179.18(14) 
C7 C1 C2 C8 -0.80(16) 
C7 C1 C6 C5 178.92(15) 
C8 N1 C7 O1 -178.82(14) 
C8 N1 C7 C1 1.85(16) 
C8 N1 C9 C10 108.16(15) 
C8 N1 C9 C15 -123.55(15) 
C8 C2 C3 C4 -177.71(15) 
C9 N1 C7 O1 -6.8(2) 
C9 N1 C7 C1 173.90(12) 
C9 N1 C8 O2 4.8(2) 
C9 N1 C8 C2 -174.60(12) 
C9 C10 C11 C12 -3.0(2) 
C9 C10 C11 C16 -115.60(17) 
C9 C10 C16 C11 110.38(18) 
C12 O3 C13 C14 117.10(17) 
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C12 C13 C14 C15 33.4(3) 
C12 C11 C16 C10 -113.68(17) 
C13 O3 C12 C11 -117.96(17) 
C13 C12 C11 C10 -29.1(3) 
C13 C12 C11 C16 45.9(2) 
C13 C14 C15 C9 -0.4(3) 
C10 C9 C15 C14 -55.4(2) 
C11 C12 C13 O3 103.21(17) 
C11 C12 C13 C14 -0.9(3) 
C15 C9 C10 C11 56.0(2) 
C15 C9 C10 C16 -17.5(2) 
C16 C10 C11 C12 112.61(19) 
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1q.  
Atom x y z U(eq) 
H3 1784 2120 2376 33 
H4 2773 3618 3721 38 
H5 4579 4671 3287 37 
H6 5467 4296 1472 34 
H9 2641 500 -1929 29 
H12 2812 549 -5520 40 
H13 4022 -1145 -4808 42 
H10 2568 2854 -2545 33 
H11 2244 2433 -4502 39 
H14 5363 -991 -3122 45 
H15 5101 138 -1479 40 
H16A 3988 3603 -3851 35 
H16B 4812 2224 -3682 35 
H10A 4682 -351 -1392 40 
H11A 4912 -1394 -2896 45 
H14A 2716 2601 -4620 39 
H15A 3091 3038 -2561 33 
H16C 5484 1130 -3175 34 
H16D 6194 -53 -2376 34 
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Table 1 Crystal data and structure refinement for (±)-II-38.  
Identification code  don1r5  
Empirical formula  C16.04948H14.82598NO5  
Formula weight  301.71  
Temperature/K  99.9(3)  
Crystal system  monoclinic  
Space group  P21/m  
a/Å  8.4819(5)  
b/Å  7.2208(4)  
c/Å  11.3135(7)  
α/°  90.00  
β/°  106.409(6)  
γ/°  90.00  
Volume/Å
3
  664.68(7)  
Z  2  
ρcalcmg/mm
3
  1.507  
m/mm
-1
  0.946  
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F(000)  316.0  
Crystal size/mm
3
  0.22 × 0.12 × 0.03  
2Θ range for data collection  8.14 to 148.08°  
Index ranges  -10 ≤ h ≤ 10, -8 ≤ k ≤ 8, -14 ≤ l ≤ 14  
Reflections collected  4117  
Independent reflections  4117[R(int) = 0.0000]  
Data/restraints/parameters  4117/80/204  
Goodness-of-fit on F
2
  1.115  
Final R indexes [I>=2σ (I)]  R1 = 0.0937, wR2 = 0.2778  
Final R indexes [all data]  R1 = 0.1028, wR2 = 0.2891  
Largest diff. peak/hole / e Å
-3
  1.03/-0.40  
 
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1r5. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 4232(4) 2932(13) -309(3) 87(3) 
O2 2273(3) 2194(11) 3016(2) 46.0(19) 
O3 5120(4) 5891(4) 2486(3) 53.0(8) 
O4 8548(4) 4110(6) 3036(3) 62.6(9) 
O5 9517(3) 2238(15) 5082(3) 47(2) 
N1 3666(3) 2630(17) 1550(2) 40.6(13) 
C1 1453(4) 2586(10) -173(3) 42.7(9) 
C2 844(4) 2350(7) 832(3) 35.6(7) 
C3 -814(4) 2155(7) 712(4) 44.5(17) 
C4 -1856(4) 2211(13) -489(4) 49(2) 
C5 -1276(4) 2430(20) -1486(3) 53.2(11) 
C6 407(5) 2660(20) -1361(3) 58(2) 
C7 3239(4) 2747(17) 288(3) 49(2) 
C8 2267(4) 2350(20) 1965(3) 38.4(14) 
C9 5407(4) 2609(13) 2310(3) 51.9(13) 
C10 5752(14) 4291(13) 3168(8) 49(2) 
C11 7557(6) 4494(8) 3805(5) 42.3(12) 
C12 8168(17) 3570(20) 4949(15) 42(2) 
C13 7924(15) 1580(20) 5101(12) 33.0(18) 
C14 7105(6) 146(7) 4074(5) 37.1(10) 
C15 5882(14) 777(16) 2823(9) 60(2) 
C16 5279(5) 18(7) 3821(4) 54.4(10) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1r5. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 35.9(12) 181(10) 43.8(13) 32(3) 10.1(10) -29(3) 
O2 45.7(11) 55(6) 39.2(11) 1.1(13) 15.2(9) -8.4(16) 
O3 55.4(17) 50.1(18) 51.5(16) 6.9(12) 11.8(13) 6.1(13) 
O4 42.7(16) 91(3) 54.4(17) 5.2(15) 13.8(13) -17.0(16) 
O5 27.7(10) 41(6) 66.0(13) -1.1(15) 1.3(9) 0.1(14) 
N1 26.1(10) 54(3) 38.5(11) 11(3) 3.7(9) -18(3) 
C1 29.1(13) 55(2) 39.6(13) 7(5) 2.9(11) -7(5) 
C2 25.9(11) 33.4(19) 43.8(13) 3(3) 3.6(10) 4(3) 
C3 28.7(14) 43(5) 62.5(19) -8.8(18) 14.6(13) 0.9(15) 
C4 26.0(13) 36(7) 76(2) -6(2) -3.1(13) 0.3(16) 
C5 37.0(16) 55(3) 54.0(16) -2(7) -8.7(13) -12(7) 
C6 42.6(16) 80(5) 44.0(15) 16(4) -1.8(13) -20(4) 
C7 31.7(14) 71(7) 41.3(14) 18(3) 4.7(12) -15(3) 
C8 33.4(12) 40(4) 39.3(13) 4(3) 5.8(10) -1(3) 
C9 34.6(16) 84(3) 32.9(12) 9(3) 2.4(11) -40(3) 
C10 38(3) 40(3) 55(4) -15(3) -8(3) 10(2) 
C11 31(2) 27(2) 62(3) -10.8(18) 2.4(19) 6.9(17) 
C12 29(4) 43(3) 52(5) 2(3) 10(2) -12(3) 
C13 25(4) 39(3) 31(3) -7.1(19) 2(2) 8(3) 
C14 34(2) 21(2) 51(2) -1.4(16) 3.9(18) -4.1(17) 
C15 36(3) 64(4) 68(5) -26(3) -6(3) 8(3) 
C16 45(2) 59(3) 52(2) -12(2) 1.0(18) 2.7(19) 
  
Table 4 Bond Lengths for don1r5. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C7 1.226(5)   C2 C8 1.492(4) 
O2 C8 1.194(4)   C3 C4 1.397(6) 
O3 C10 1.408(11)   C4 C5 1.361(6) 
O4 C11 1.397(7)   C5 C6 1.404(5) 
O5 C12 1.470(13)   C9 C10 1.531(10) 
O5 C13 1.437(11)   C9 C15 1.455(12) 
N1 C7 1.374(4)   C10 C11 1.503(12) 
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N1 C8 1.407(5)   C11 C12 1.417(15) 
N1 C9 1.484(4)   C12 C13 1.467(7) 
C1 C2 1.386(5)   C13 C14 1.566(12) 
C1 C6 1.387(5)   C14 C15 1.568(12) 
C1 C7 1.461(5)   C14 C16 1.497(7) 
C2 C3 1.381(4)   C15 C16 1.471(10) 
  
Table 5 Bond Angles for don1r5. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C13 O5 C12 60.6(3)   C15 C9 N1 111.0(8) 
C7 N1 C8 110.9(3)   C15 C9 C10 119.1(4) 
C7 N1 C9 122.0(3)   O3 C10 C9 109.1(6) 
C8 N1 C9 126.9(3)   O3 C10 C11 111.2(8) 
C2 C1 C6 121.0(3)   C11 C10 C9 111.6(6) 
C2 C1 C7 107.9(3)   O4 C11 C10 113.1(5) 
C6 C1 C7 131.1(3)   O4 C11 C12 110.2(6) 
C1 C2 C8 107.8(3)   C12 C11 C10 116.9(9) 
C3 C2 C1 122.5(3)   C11 C12 O5 118.3(10) 
C3 C2 C8 129.7(3)   C11 C12 C13 122.7(18) 
C2 C3 C4 116.1(4)   C13 C12 O5 58.6(7) 
C5 C4 C3 122.1(3)   O5 C13 C12 60.8(8) 
C4 C5 C6 121.7(3)   O5 C13 C14 115.4(8) 
C1 C6 C5 116.6(4)   C12 C13 C14 127.5(17) 
O1 C7 N1 124.0(3)   C13 C14 C15 121.2(9) 
O1 C7 C1 128.1(3)   C16 C14 C13 113.7(6) 
N1 C7 C1 107.9(3)   C16 C14 C15 57.3(5) 
O2 C8 N1 125.4(3)   C9 C15 C14 131.5(9) 
O2 C8 C2 129.1(3)   C9 C15 C16 121.8(8) 
N1 C8 C2 105.5(3)   C16 C15 C14 58.9(4) 
N1 C9 C10 109.9(8)   C15 C16 C14 63.8(5) 
  
Table 6 Hydrogen Bonds for don1r5.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O3 H3 O1
1
 0.84 2.05 2.803(5) 149.2 
O4 H4 O5 0.84 2.05 2.604(7) 122.7 
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11-X,1-Y,-Z 
  
Table 7 Torsion Angles for don1r5. 
A B C D Angle/˚ 
O3 C10 C11 O4 -82.1(6) 
O3 C10 C11 C12 148.3(9) 
O4 C11 C12 O5 -7.9(16) 
O4 C11 C12 C13 -77.0(14) 
O5 C12 C13 C14 -100.9(13) 
O5 C13 C14 C15 -94.0(13) 
O5 C13 C14 C16 -158.9(9) 
N1 C9 C10 O3 -47.6(8) 
N1 C9 C10 C11 -170.8(7) 
N1 C9 C15 C14 -146.7(9) 
N1 C9 C15 C16 -71.9(10) 
C1 C2 C3 C4 -0.1(4) 
C1 C2 C8 O2 179.7(12) 
C1 C2 C8 N1 1.0(9) 
C2 C1 C6 C5 -1.8(12) 
C2 C1 C7 O1 178.4(10) 
C2 C1 C7 N1 -0.7(9) 
C2 C3 C4 C5 0.3(11) 
C3 C2 C8 O2 -0.4(17) 
C3 C2 C8 N1 -179.1(5) 
C3 C4 C5 C6 -1.4(17) 
C4 C5 C6 C1 2.1(17) 
C6 C1 C2 C3 0.9(6) 
C6 C1 C2 C8 -179.3(8) 
C6 C1 C7 O1 -2.6(15) 
C6 C1 C7 N1 178.2(8) 
C7 N1 C8 O2 179.7(12) 
C7 N1 C8 C2 -1.5(12) 
C7 N1 C9 C10 118.3(10) 
C7 N1 C9 C15 -107.9(10) 
C7 C1 C2 C3 179.9(5) 
C7 C1 C2 C8 -0.2(7) 
C7 C1 C6 C5 179.4(9) 
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C8 N1 C7 O1 -177.8(11) 
C8 N1 C7 C1 1.5(12) 
C8 N1 C9 C10 -68.6(13) 
C8 N1 C9 C15 65.3(13) 
C8 C2 C3 C4 -179.9(8) 
C9 N1 C7 O1 -3.6(17) 
C9 N1 C7 C1 175.6(9) 
C9 N1 C8 O2 6(2) 
C9 N1 C8 C2 -175.3(10) 
C9 C10 C11 O4 39.9(9) 
C9 C10 C11 C12 -89.7(11) 
C9 C15 C16 C14 -122.4(10) 
C10 C9 C15 C14 -17.6(10) 
C10 C9 C15 C16 57.2(9) 
C10 C11 C12 O5 123.1(11) 
C10 C11 C12 C13 54.0(14) 
C11 C12 C13 O5 105.6(11) 
C11 C12 C13 C14 5(2) 
C12 O5 C13 C14 120.5(19) 
C12 C13 C14 C15 -22.4(17) 
C12 C13 C14 C16 -87.3(14) 
C13 O5 C12 C11 -113(2) 
C13 C14 C15 C9 7.1(14) 
C13 C14 C15 C16 -99.7(7) 
C13 C14 C16 C15 113.1(9) 
C15 C9 C10 O3 -177.2(8) 
C15 C9 C10 C11 59.6(9) 
C16 C14 C15 C9 106.8(11) 
  
Table 8 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1r5.  
Atom x y z U(eq) 
H3 5676 6132 1997 80 
H4 9372 3498 3428 94 
H3A -1221 1993 1406 53 
H4A -3007 2089 -614 59 
H5 -2030 2436 -2286 64 
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H6 808 2857 -2054 70 
H9 6066 2821 1715 62 
H10 5164 4112 3811 59 
H11 7722 5843 4003 51 
H12 8232 4346 5693 50 
H13 7854 1236 5940 40 
H14 7711 -1040 4067 44 
H15 5814 -160 2159 72 
H16A 4782 -1234 3699 65 
H16B 4745 889 4264 65 
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Table 1 Crystal data and structure refinement for (±)-II-40.  
Identification code  don1u  
Empirical formula  C16H13NO4  
Formula weight  283.27  
Temperature/K  99.8(3)  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  22.7463(8)  
b/Å  7.8917(3)  
c/Å  14.3099(6)  
α/°  90.00  
β/°  100.110(4)  
γ/°  90.00  
Volume/Å
3
  2528.85(17)  
Z  8  
ρcalcmg/mm
3
  1.488  
m/mm
-1
  0.897  
F(000)  1184.0  
Crystal size/mm
3
  0.1 × 0.02 × 0.02  
2Θ range for data collection  7.9 to 147.68°  
Index ranges  -27 ≤ h ≤ 28, -8 ≤ k ≤ 9, -17 ≤ l ≤ 17  
Reflections collected  8848  
Independent reflections  2514[R(int) = 0.0286]  
Data/restraints/parameters  2514/0/226  
Goodness-of-fit on F
2
  1.058  
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Final R indexes [I>=2σ (I)]  R1 = 0.0351, wR2 = 0.0875  
Final R indexes [all data]  R1 = 0.0414, wR2 = 0.0930  
Largest diff. peak/hole / e Å
-3
  0.20/-0.21  
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1u. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 3378.6(5) 999.6(14) 2929.5(7) 26.8(3) 
O2 2302.9(4) 1143.0(13) 1413.7(7) 24.9(2) 
O3 3575.7(4) 5558.5(12) 1370.7(7) 22.0(2) 
O4 4812.1(4) 1007.5(12) 1252.3(8) 24.3(2) 
N1 4071.0(5) 3005.1(14) 1323.7(8) 16.8(2) 
C1 3545.8(5) 1911.4(16) 1307.3(9) 16.5(3) 
C2 3654.6(6) 651.7(17) 2111.1(9) 18.1(3) 
C3 3179.3(6) -441.5(18) 2328.9(10) 21.5(3) 
C4 2550.6(6) -432.9(19) 1810.3(11) 23.7(3) 
C5 2390.3(6) -244.4(18) 772.6(10) 22.2(3) 
C6 2803.5(6) 61.4(18) 93.3(10) 21.0(3) 
C7 3372.3(6) 1078.9(17) 338.9(9) 18.4(3) 
C8 3406.0(6) -798.2(18) 185.3(10) 21.4(3) 
C9 4029.7(6) 4773.1(16) 1332.2(9) 16.3(3) 
C10 4651.7(6) 2466.2(16) 1276.7(9) 17.2(3) 
C11 4638.5(6) 5423.0(16) 1288.9(9) 15.5(3) 
C12 5012.5(6) 4037.8(16) 1269.9(9) 16.0(3) 
C13 5614.5(6) 4226.7(17) 1250.0(9) 18.2(3) 
C14 5830.9(6) 5885.0(17) 1238.1(9) 18.8(3) 
C15 5452.9(6) 7276.3(17) 1232.9(9) 18.8(3) 
C16 4845.6(6) 7066.6(17) 1264.8(9) 18.2(3) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1u. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 28.4(5) 34.2(6) 19.0(5) -4.6(4) 7.6(4) -8.8(4) 
O2 18.5(5) 24.2(5) 32.5(6) -0.5(4) 6.1(4) 0.3(4) 
O3 15.6(4) 16.6(5) 33.5(5) 0.3(4) 3.2(4) 2.1(4) 
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O4 22.0(5) 13.2(5) 39.5(6) 0.8(4) 10.5(4) 1.4(4) 
N1 14.1(5) 12.6(5) 23.8(5) 0.3(4) 3.8(4) -1.1(4) 
C1 14.7(5) 13.7(6) 21.5(6) 0.4(5) 4.1(5) -2.5(5) 
C2 17.7(6) 20.3(6) 16.3(6) -0.5(5) 2.8(5) -2.5(5) 
C3 24.0(7) 21.3(7) 19.3(6) 3.1(5) 3.6(5) -4.3(5) 
C4 20.9(7) 22.8(7) 28.4(7) 2.7(6) 7.1(6) -5.7(5) 
C5 17.1(6) 19.5(7) 29.1(7) 0.8(5) 1.2(5) -4.1(5) 
C6 20.2(6) 20.9(7) 20.3(6) 0.2(5) -1.0(5) -3.0(5) 
C7 18.0(6) 18.9(7) 18.0(6) 2.8(5) 2.5(5) -2.3(5) 
C8 22.7(7) 20.3(7) 21.3(7) -4.2(5) 4.1(5) -1.7(5) 
C9 17.1(6) 12.9(6) 18.0(6) 0.6(5) 0.9(5) 0.1(5) 
C10 17.5(6) 14.2(6) 20.4(6) 1.1(5) 4.8(5) -0.2(5) 
C11 15.8(6) 14.7(6) 15.6(6) -0.5(5) 1.6(4) -0.9(5) 
C12 18.1(6) 13.6(6) 16.3(6) 0.5(4) 2.9(5) -0.8(5) 
C13 17.1(6) 17.7(6) 20.3(6) 0.0(5) 4.3(5) 1.6(5) 
C14 15.7(6) 21.8(7) 19.1(6) -1.2(5) 3.5(5) -4.7(5) 
C15 20.1(6) 15.5(6) 20.6(6) -0.1(5) 2.8(5) -4.0(5) 
C16 18.1(6) 14.7(6) 21.1(6) -0.6(5) 1.4(5) 0.4(5) 
  
Table 4 Bond Lengths for don1u. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C2 1.4488(16)   C4 C5 1.473(2) 
O1 C3 1.4494(17)   C5 C6 1.485(2) 
O2 C4 1.4400(18)   C6 C7 1.5109(18) 
O2 C5 1.4642(18)   C6 C8 1.5141(19) 
O3 C9 1.2139(16)   C7 C8 1.5015(19) 
O4 C10 1.2099(16)   C9 C11 1.4883(17) 
N1 C1 1.4705(15)   C10 C12 1.4882(17) 
N1 C9 1.3986(17)   C11 C12 1.3884(18) 
N1 C10 1.4005(16)   C11 C16 1.3825(18) 
C1 C2 1.5075(18)   C12 C13 1.3826(18) 
C1 C7 1.5217(18)   C13 C14 1.3994(18) 
C2 C3 1.4590(18)   C14 C15 1.3938(19) 
C3 C4 1.4911(19)   C15 C16 1.4001(18) 
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Table 5 Bond Angles for don1u. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 O1 C3 60.45(8)   C7 C6 C8 59.52(9) 
C4 O2 C5 60.95(9)   C6 C7 C1 121.06(11) 
C9 N1 C1 122.01(10)   C8 C7 C1 123.20(11) 
C9 N1 C10 111.63(10)   C8 C7 C6 60.35(9) 
C10 N1 C1 126.25(11)   C7 C8 C6 60.14(9) 
N1 C1 C2 110.54(10)   O3 C9 N1 124.66(12) 
N1 C1 C7 110.37(10)   O3 C9 C11 129.13(12) 
C2 C1 C7 113.06(11)   N1 C9 C11 106.21(11) 
O1 C2 C1 117.10(11)   O4 C10 N1 125.60(12) 
O1 C2 C3 59.80(9)   O4 C10 C12 128.55(12) 
C3 C2 C1 121.63(11)   N1 C10 C12 105.85(11) 
O1 C3 C2 59.75(8)   C12 C11 C9 107.89(11) 
O1 C3 C4 117.67(12)   C16 C11 C9 130.39(12) 
C2 C3 C4 124.95(12)   C16 C11 C12 121.72(12) 
O2 C4 C3 118.34(12)   C11 C12 C10 108.40(11) 
O2 C4 C5 60.34(9)   C13 C12 C10 129.74(12) 
C5 C4 C3 123.24(12)   C13 C12 C11 121.86(12) 
O2 C5 C4 58.71(9)   C12 C13 C14 116.93(12) 
O2 C5 C6 117.36(11)   C15 C14 C13 121.25(12) 
C4 C5 C6 127.08(12)   C14 C15 C16 121.20(12) 
C5 C6 C7 123.26(12)   C11 C16 C15 117.01(12) 
C5 C6 C8 122.50(12)           
  
Table 6 Torsion Angles for don1u. 
A B C D Angle/˚ 
O1 C2 C3 C4 104.38(16) 
O1 C3 C4 O2 39.15(18) 
O1 C3 C4 C5 110.56(15) 
O2 C4 C5 C6 102.41(15) 
O2 C5 C6 C7 37.37(19) 
O2 C5 C6 C8 109.82(15) 
O3 C9 C11 C12 179.01(13) 
O3 C9 C11 C16 -1.2(2) 
O4 C10 C12 C11 178.90(14) 
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O4 C10 C12 C13 -1.2(2) 
N1 C1 C2 O1 102.61(12) 
N1 C1 C2 C3 172.21(12) 
N1 C1 C7 C6 -172.46(11) 
N1 C1 C7 C8 114.77(13) 
N1 C9 C11 C12 -0.79(14) 
N1 C9 C11 C16 178.95(13) 
N1 C10 C12 C11 -1.42(14) 
N1 C10 C12 C13 178.49(13) 
C1 N1 C9 O3 3.5(2) 
C1 N1 C9 C11 -176.66(10) 
C1 N1 C10 O4 -3.0(2) 
C1 N1 C10 C12 177.28(11) 
C1 C2 C3 O1 -105.09(14) 
C1 C2 C3 C4 -0.7(2) 
C1 C7 C8 C6 109.69(14) 
C2 O1 C3 C4 -116.29(14) 
C2 C1 C7 C6 63.15(16) 
C2 C1 C7 C8 -9.62(17) 
C2 C3 C4 O2 -31.7(2) 
C2 C3 C4 C5 39.7(2) 
C3 O1 C2 C1 112.57(13) 
C3 C4 C5 O2 -106.26(15) 
C3 C4 C5 C6 -3.9(2) 
C4 O2 C5 C6 -118.69(14) 
C4 C5 C6 C7 -32.6(2) 
C4 C5 C6 C8 39.8(2) 
C5 O2 C4 C3 114.18(14) 
C5 C6 C7 C1 -2.0(2) 
C5 C6 C7 C8 111.07(15) 
C5 C6 C8 C7 -112.31(15) 
C7 C1 C2 O1 -133.09(11) 
C7 C1 C2 C3 -63.49(16) 
C8 C6 C7 C1 -113.11(14) 
C9 N1 C1 C2 -126.07(12) 
C9 N1 C1 C7 108.11(13) 
C9 N1 C10 O4 -179.38(13) 
C9 N1 C10 C12 0.92(14) 
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C9 C11 C12 C10 1.35(14) 
C9 C11 C12 C13 -178.57(12) 
C9 C11 C16 C15 179.46(12) 
C10 N1 C1 C2 57.93(16) 
C10 N1 C1 C7 -67.89(15) 
C10 N1 C9 O3 -179.94(12) 
C10 N1 C9 C11 -0.13(14) 
C10 C12 C13 C14 179.33(12) 
C11 C12 C13 C14 -0.77(19) 
C12 C11 C16 C15 -0.82(19) 
C12 C13 C14 C15 -0.88(19) 
C13 C14 C15 C16 1.7(2) 
C14 C15 C16 C11 -0.82(19) 
C16 C11 C12 C10 -178.42(11) 
C16 C11 C12 C13 1.7(2) 
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1u.  
Atom x y z U(eq) 
H1 3216(7) 2690(20) 1402(11) 16(4) 
H2 4057(8) 250(20) 2258(11) 17(4) 
H3 3300(8) -1530(20) 2612(13) 28(4) 
H4 2281(8) -1070(20) 2153(12) 24(4) 
H5 1997(7) -740(20) 496(11) 17(4) 
H6 2587(8) 210(20) -555(13) 27(4) 
H7 3462(8) 1800(20) -188(12) 25(4) 
H8A 3530(8) -1170(20) -403(13) 24(4) 
H8B 3523(8) -1510(20) 747(13) 27(4) 
H13 5869 3275 1245 22 
H14 6243 6066 1233 23 
H15 5610 8387 1207 23 
H16 4587 8011 1270 22 
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Table 1 Crystal data and structure refinement for (±)-II-42.  
Identification code  don1x  
Empirical formula  C16.75H20NO6.75  
Formula weight  343.34  
Temperature/K  100.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  10.4024(3)  
b/Å  12.8740(4)  
c/Å  14.1877(4)  
α/°  95.258(2)  
β/°  108.218(3)  
γ/°  111.130(3)  
Volume/Å
3
  1638.06(8)  
Z  4  
ρcalcmg/mm
3
  1.392  
m/mm
-1
  0.108  
F(000)  726.0  
Crystal size/mm
3
  0.32 × 0.1 × 0.03  
2Θ range for data collection  5.9 to 58.14°  
Index ranges  -14 ≤ h ≤ 14, -17 ≤ k ≤ 16, -18 ≤ l ≤ 19  
Reflections collected  28946  
Independent reflections  7852[R(int) = 0.0284]  
Data/restraints/parameters  7852/0/493  
Goodness-of-fit on F
2
  1.135  
Final R indexes [I>=2σ (I)]  R1 = 0.0434, wR2 = 0.1146  
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Final R indexes [all data]  R1 = 0.0530, wR2 = 0.1199  
Largest diff. peak/hole / e Å
-3
  0.40/-0.25  
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1x. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 10200.2(12) 3048.6(10) 4490.2(8) 15.9(2) 
O2 6479.7(13) 1980.6(11) 11.1(9) 19.8(3) 
O3 5097.0(12) 2008.3(10) 1509.1(9) 17.9(2) 
O4 8973.4(12) 3997.7(10) 2941.1(9) 15.8(2) 
O5 6199.3(13) 737.1(10) 4483.2(10) 22.1(3) 
O6 8386.4(12) 4610.5(9) 4838.9(9) 18.3(2) 
N1 7278.9(14) 2620.4(11) 4396(1) 14.4(3) 
C1 7535.4(16) 2336.4(13) 3460.9(11) 13.9(3) 
C2 8939.7(17) 2088.1(13) 3774.1(12) 14.8(3) 
C3 9298.2(17) 1687.7(14) 2876.3(12) 17.6(3) 
C4 7956.6(18) 734.6(14) 2073.4(12) 18.8(3) 
C5 7012.7(18) 913.0(14) 1293.9(12) 18.1(3) 
C6 7213.8(17) 2077.1(14) 1085.3(12) 16.2(3) 
C7 6598.5(16) 2720.4(13) 1651.4(12) 14.8(3) 
C8 7504.1(16) 3226.5(13) 2804.4(11) 14.0(3) 
C9 6637.2(17) 1744.6(14) 4843.5(12) 16.6(3) 
C10 7750.0(16) 3705.0(13) 5010.6(12) 14.9(3) 
C11 6653.9(17) 2322.7(14) 5808.7(12) 17.2(3) 
C12 7299.3(16) 3497.3(14) 5898.5(12) 16.1(3) 
C13 7459.9(17) 4271.4(15) 6713.6(13) 19.0(3) 
C14 6965.2(18) 3824.3(16) 7458.2(13) 22.4(4) 
C15 6335.1(18) 2647.4(16) 7374.5(14) 23.6(4) 
C16 6162.1(18) 1869.5(15) 6543.5(13) 21.5(3) 
O1A 9078.5(12) 6121.5(10) 3500.6(9) 16.2(2) 
O2A 6356.9(13) 6635.7(10) -791.6(9) 19.4(2) 
O3A 6180.1(14) 7898.8(10) 971.0(9) 22.3(3) 
O4A 6212.7(12) 5311.1(9) 1788.4(9) 17.5(2) 
O5A 6189.5(12) 5645.8(10) 3749.6(9) 19.5(2) 
O6A 8615.9(14) 9489.8(10) 4034.0(9) 23.4(3) 
N1A 7544.9(14) 7513.5(11) 3696.5(10) 15.4(3) 
C1A 7828.5(16) 7323.6(13) 2756.7(11) 13.7(3) 
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C2A 9216.1(16) 7051.2(13) 3012.2(12) 14.7(3) 
C3A 9578.8(17) 6750.0(14) 2089.7(12) 17.4(3) 
C4A 9697.8(18) 7631.5(15) 1461.8(13) 20.1(3) 
C5A 8573.0(18) 7577.4(15) 659.0(13) 20.2(3) 
C6A 7044.0(17) 6623.8(14) 260.9(12) 16.6(3) 
C7A 6072.8(17) 6758.8(13) 839.7(12) 15.9(3) 
C8A 6372.4(16) 6474.7(13) 1894.4(12) 14.4(3) 
C9A 6770.4(17) 6673.1(14) 4113.2(12) 16.7(3) 
C10A 7972.8(17) 8623.6(14) 4257.4(12) 17.6(3) 
C11A 6760.9(17) 7298.0(15) 5044.9(12) 19.2(3) 
C12A 7453.7(18) 8462.7(15) 5121.5(12) 19.6(3) 
C13A 7573(2) 9265.9(17) 5902.9(13) 25.7(4) 
C14A 6982(2) 8850.3(19) 6614.2(14) 30.6(4) 
C15A 6309(2) 7682.2(19) 6548.5(14) 30.1(4) 
C16A 6176.5(18) 6875.2(17) 5751.7(13) 24.4(4) 
O1S 3172.7(14) -285.3(11) 1086(1) 23.7(3) 
C1S 1898(2) -99.3(17) 518.5(15) 27.3(4) 
O2S 7838(3) 4284(2) -108(2) 29.8(6) 
C2S 9368(5) 4666(4) 107(4) 48.3(12) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1x. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 14.8(5) 12.5(5) 13.9(5) 0.5(4) -0.4(4) 4.2(4) 
O2 25.3(6) 21.5(6) 12.3(5) 2.0(5) 2.3(5) 13.8(5) 
O3 12.7(5) 16.7(6) 19.6(6) 4.0(5) 1.3(4) 5.0(4) 
O4 14.0(5) 11.6(5) 17.5(6) 1.5(4) 3.3(4) 3.3(4) 
O5 22.2(6) 13.3(6) 28.2(7) 4.1(5) 9.4(5) 4.5(5) 
O6 19.5(6) 13.1(5) 17.9(6) 2.8(4) 4.4(4) 4.3(4) 
N1 13.4(6) 11.7(6) 14.7(6) 2.0(5) 2.7(5) 4.0(5) 
C1 13.8(7) 11.3(7) 12.9(7) 1.2(6) 1.5(5) 4.6(6) 
C2 14.8(7) 11.5(7) 13.3(7) 0.7(6) 0.1(6) 5.2(6) 
C3 18.0(7) 18.3(8) 15.3(7) 0.8(6) 1.7(6) 10.6(6) 
C4 23.8(8) 14.0(8) 16.5(8) -0.4(6) 3.1(6) 9.9(6) 
C5 19.0(7) 14.1(8) 16.0(8) -1.8(6) 2.4(6) 5.8(6) 
C6 16.4(7) 16.2(8) 12.4(7) 1.6(6) 0.7(6) 7.2(6) 
C7 13.0(7) 12.9(7) 14.4(7) 1.8(6) 1.1(6) 4.6(6) 
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C8 12.3(7) 12.6(7) 13.8(7) 1.2(6) 1.8(5) 4.4(6) 
C9 12.3(7) 16.2(8) 19.7(8) 5.4(6) 4.2(6) 5.2(6) 
C10 11.8(7) 15.3(7) 15.4(7) 2.2(6) 1.4(6) 6.7(6) 
C11 12.8(7) 17.9(8) 18.8(8) 4.0(6) 3.9(6) 5.9(6) 
C12 10.7(7) 19.3(8) 16.5(7) 4.8(6) 2.4(6) 6.4(6) 
C13 14.7(7) 20.3(8) 19.8(8) 2.6(6) 4.1(6) 7.2(6) 
C14 17.5(8) 30.3(10) 19.4(8) 2.0(7) 6.0(6) 11.4(7) 
C15 18.2(8) 32.3(10) 23.4(9) 9.2(7) 10.8(7) 10.5(7) 
C16 16.3(7) 23.3(9) 25.4(9) 8.6(7) 8.5(7) 7.4(7) 
O1A 20.7(6) 15.9(6) 13.6(5) 4.9(4) 5.1(4) 10.0(5) 
O2A 17.5(6) 18.9(6) 15.2(6) 3.8(5) 0.7(4) 4.8(5) 
O3A 20.8(6) 15.5(6) 24.1(6) 1.9(5) -1.6(5) 9.6(5) 
O4A 18.9(5) 12.6(5) 16.1(6) 2.3(4) 2.6(4) 4.6(4) 
O5A 17.4(5) 17.4(6) 21.3(6) 4.5(5) 6.1(5) 5.6(5) 
O6A 29.1(6) 15.2(6) 20.7(6) 2.4(5) 4.2(5) 8.3(5) 
N1A 16.1(6) 13.5(6) 15.1(6) 1.8(5) 3.2(5) 6.9(5) 
C1A 14.5(7) 12.6(7) 12.7(7) 2.3(6) 3.1(6) 5.8(6) 
C2A 12.9(7) 13.3(7) 14.9(7) 3.2(6) 2.3(6) 4.6(6) 
C3A 13.9(7) 22.4(8) 16.3(8) 5.1(6) 4.3(6) 8.8(6) 
C4A 14.4(7) 22.3(8) 20.6(8) 6.8(7) 5.7(6) 4.5(6) 
C5A 17.3(7) 18.9(8) 21.1(8) 7.4(7) 5.8(6) 4.4(6) 
C6A 14.8(7) 16.6(8) 15.0(7) 4.7(6) 1.1(6) 6.3(6) 
C7A 12.5(7) 12.8(7) 16.9(7) 1.3(6) 0.1(6) 4.3(6) 
C8A 11.7(7) 12.8(7) 16.5(7) 1.9(6) 2.9(6) 5.0(6) 
C9A 14.2(7) 19.9(8) 16.6(7) 4.9(6) 3.5(6) 9.5(6) 
C10A 17.4(7) 18.4(8) 14.9(7) 1.5(6) -0.3(6) 11.0(6) 
C11A 15.3(7) 27.2(9) 15.5(7) 3.1(7) 2.7(6) 12.2(7) 
C12A 17.8(7) 25.6(9) 15.4(7) 2.2(6) 1.3(6) 13.7(7) 
C13A 28.0(9) 29.4(10) 19.5(8) -0.5(7) 2.1(7) 18.9(8) 
C14A 30.2(9) 48.4(12) 16.9(8) -1.2(8) 4.2(7) 26.2(9) 
C15A 23.2(9) 52.5(13) 18.1(8) 5.9(8) 8.1(7) 19.6(9) 
C16A 16.7(8) 36.1(10) 19.8(8) 5.5(7) 5.6(6) 11.6(7) 
O1S 22.5(6) 19.0(6) 25.4(6) 2.1(5) 5.9(5) 7.1(5) 
C1S 24.7(9) 30.1(10) 28.4(9) 6.9(8) 10.6(7) 11.9(8) 
O2S 34.4(14) 27.8(15) 31.3(14) 9.0(12) 15.4(12) 14.0(12) 
C2S 36(2) 49(3) 54(3) -5(2) 19(2) 13(2) 
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Table 4 Bond Lengths for don1x. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C2 1.4312(18)   O2A C6A 1.4441(18) 
O2 C6 1.4459(18)   O3A C7A 1.4212(19) 
O3 C7 1.4343(18)   O4A C8A 1.4346(19) 
O4 C8 1.4299(18)   O5A C9A 1.218(2) 
O5 C9 1.208(2)   O6A C10A 1.205(2) 
O6 C10 1.2054(19)   N1A C1A 1.471(2) 
N1 C1 1.472(2)   N1A C9A 1.398(2) 
N1 C9 1.405(2)   N1A C10A 1.409(2) 
N1 C10 1.402(2)   C1A C2A 1.549(2) 
C1 C2 1.546(2)   C1A C8A 1.545(2) 
C1 C8 1.544(2)   C2A C3A 1.526(2) 
C2 C3 1.530(2)   C3A C4A 1.500(2) 
C3 C4 1.505(2)   C4A C5A 1.328(2) 
C4 C5 1.331(2)   C5A C6A 1.503(2) 
C5 C6 1.507(2)   C6A C7A 1.531(2) 
C6 C7 1.524(2)   C7A C8A 1.536(2) 
C7 C8 1.545(2)   C9A C11A 1.488(2) 
C9 C11 1.489(2)   C10A C12A 1.489(2) 
C10 C12 1.490(2)   C11A C12A 1.386(2) 
C11 C12 1.390(2)   C11A C16A 1.383(2) 
C11 C16 1.385(2)   C12A C13A 1.387(2) 
C12 C13 1.381(2)   C13A C14A 1.390(3) 
C13 C14 1.396(2)   C14A C15A 1.391(3) 
C14 C15 1.394(3)   C15A C16A 1.400(3) 
C15 C16 1.395(3)   O1S C1S 1.436(2) 
O1A C2A 1.4226(19)   O2S C2S 1.405(5) 
  
Table 5 Bond Angles for don1x. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C9 N1 C1 119.97(13)   C9A N1A C1A 126.61(13) 
C10 N1 C1 128.20(13)   C9A N1A C10A 111.62(13) 
C10 N1 C9 111.41(13)   C10A N1A C1A 121.65(13) 
N1 C1 C2 107.52(12)   N1A C1A C2A 108.60(12) 
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N1 C1 C8 112.38(12)   N1A C1A C8A 109.40(12) 
C8 C1 C2 116.86(13)   C8A C1A C2A 118.68(13) 
O1 C2 C1 111.33(12)   O1A C2A C1A 112.26(12) 
O1 C2 C3 110.56(13)   O1A C2A C3A 106.41(12) 
C3 C2 C1 114.24(12)   C3A C2A C1A 114.35(12) 
C4 C3 C2 111.62(13)   C4A C3A C2A 113.05(14) 
C5 C4 C3 123.21(15)   C5A C4A C3A 123.63(15) 
C4 C5 C6 123.92(15)   C4A C5A C6A 124.38(15) 
O2 C6 C5 110.47(13)   O2A C6A C5A 106.54(13) 
O2 C6 C7 106.54(12)   O2A C6A C7A 108.91(12) 
C5 C6 C7 114.53(13)   C5A C6A C7A 113.39(13) 
O3 C7 C6 110.56(12)   O3A C7A C6A 109.87(13) 
O3 C7 C8 108.77(12)   O3A C7A C8A 107.01(13) 
C6 C7 C8 116.17(12)   C6A C7A C8A 117.71(13) 
O4 C8 C1 111.21(12)   O4A C8A C1A 113.14(12) 
O4 C8 C7 108.71(12)   O4A C8A C7A 108.80(12) 
C1 C8 C7 115.16(12)   C7A C8A C1A 116.07(13) 
O5 C9 N1 124.10(15)   O5A C9A N1A 125.75(15) 
O5 C9 C11 129.65(15)   O5A C9A C11A 128.28(15) 
N1 C9 C11 106.25(13)   N1A C9A C11A 105.93(14) 
O6 C10 N1 126.07(15)   O6A C10A N1A 124.18(16) 
O6 C10 C12 127.99(15)   O6A C10A C12A 130.08(16) 
N1 C10 C12 105.94(13)   N1A C10A C12A 105.73(14) 
C12 C11 C9 107.87(14)   C12A C11A C9A 108.43(15) 
C16 C11 C9 130.53(15)   C16A C11A C9A 129.68(16) 
C16 C11 C12 121.59(16)   C16A C11A C12A 121.89(16) 
C11 C12 C10 108.45(14)   C11A C12A C10A 108.21(14) 
C13 C12 C10 129.69(15)   C11A C12A C13A 121.61(17) 
C13 C12 C11 121.86(15)   C13A C12A C10A 130.17(17) 
C12 C13 C14 117.06(16)   C12A C13A C14A 116.98(18) 
C15 C14 C13 121.08(16)   C13A C14A C15A 121.50(17) 
C14 C15 C16 121.56(16)   C14A C15A C16A 121.27(18) 
C11 C16 C15 116.84(16)   C11A C16A C15A 116.75(18) 
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Table 6 Hydrogen Bonds for don1x.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O4 0.81(2) 2.16(2) 2.7955(16) 135(2) 
O1 H1 O6
1
 0.81(2) 2.21(2) 2.7486(16) 124(2) 
O2 H2 O1S
2
 0.85(3) 1.90(3) 2.7595(18) 178(3) 
O3 H3 O2A
3
 0.86(2) 1.91(2) 2.7636(17) 169(2) 
O4 H4 O1A 0.85(3) 1.88(3) 2.7294(17) 176(2) 
O1A H1A O1
1
 0.86(3) 1.86(3) 2.7124(16) 176(2) 
O2A H2A O4A
3
 0.89(3) 1.87(3) 2.7537(16) 168(2) 
O3A H3A O2
3
 0.90(3) 1.86(3) 2.7496(17) 171(2) 
O4A H4A O5A 0.86(3) 2.02(3) 2.7854(17) 147(2) 
O1S H1S O3 0.89(3) 1.92(3) 2.7837(17) 163(2) 
O2S H2S O2 1.00(7) 1.84(7) 2.835(3) 172(6) 
12-X,1-Y,1-Z; 21-X,-Y,-Z; 31-X,1-Y,-Z 
  
Table 7 Torsion Angles for don1x. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C2 C3 C4 
-
175.73(13) 
  O1A C2A C3A C4A 177.58(12) 
O2 C6 C7 O3 71.96(15)   O2A C6A C7A O3A -72.06(15) 
O2 C6 C7 C8 
-
163.48(12) 
  O2A C6A C7A C8A 165.18(13) 
O3 C7 C8 O4 
-
176.05(12) 
  O3A C7A C8A O4A 177.60(11) 
O3 C7 C8 C1 58.42(16)   O3A C7A C8A C1A -53.45(17) 
O5 C9 C11 C12 178.72(16)   O5A C9A C11A C12A 
-
174.97(16) 
O5 C9 C11 C16 -0.8(3)   O5A C9A C11A C16A 4.2(3) 
O6 C10 C12 C11 
-
177.37(15) 
  O6A C10A C12A C11A 179.58(16) 
O6 C10 C12 C13 1.8(3)   O6A C10A C12A C13A -0.2(3) 
N1 C1 C2 O1 -58.30(16)   N1A C1A C2A O1A 54.50(16) 
N1 C1 C2 C3 175.60(12)   N1A C1A C2A C3A 175.86(12) 
N1 C1 C8 O4 101.06(14)   N1A C1A C8A O4A -94.55(15) 
N1 C1 C8 C7 
-
134.71(13) 
  N1A C1A C8A C7A 138.63(13) 
N1 C9 C11 C12 -0.30(16)   N1A C9A C11A C12A 2.69(17) 
N1 C9 C11 C16 -   N1A C9A C11A C16A -
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179.86(16) 178.18(16) 
N1 C10 C12 C11 2.75(16)   N1A C10A C12A C11A 0.14(17) 
N1 C10 C12 C13 
-
178.05(15) 
  N1A C10A C12A C13A 
-
179.61(16) 
C1 N1 C9 O5 -3.8(2)   C1A N1A C9A O5A -1.1(2) 
C1 N1 C9 C11 175.31(12)   C1A N1A C9A C11A 
-
178.81(13) 
C1 N1 C10 O6 4.6(2)   C1A N1A C10A O6A -1.5(2) 
C1 N1 C10 C12 
-
175.49(13) 
  C1A N1A C10A C12A 178.01(12) 
C1 C2 C3 C4 -49.22(18)   C1A C2A C3A C4A 53.06(18) 
C2 C1 C8 O4 -23.93(18)   C2A C1A C8A O4A 30.76(19) 
C2 C1 C8 C7 100.30(15)   C2A C1A C8A C7A -96.06(16) 
C2 C3 C4 C5 90.4(2)   C2A C3A C4A C5A -93.3(2) 
C3 C4 C5 C6 3.6(3)   C3A C4A C5A C6A -1.0(3) 
C4 C5 C6 O2 153.48(16)   C4A C5A C6A O2A 
-
158.02(17) 
C4 C5 C6 C7 -86.2(2)   C4A C5A C6A C7A 82.2(2) 
C5 C6 C7 O3 -50.49(17)   C5A C6A C7A O3A 46.37(17) 
C5 C6 C7 C8 74.07(17)   C5A C6A C7A C8A -76.40(18) 
C6 C7 C8 O4 58.48(17)   C6A C7A C8A O4A -58.20(17) 
C6 C7 C8 C1 -67.05(17)   C6A C7A C8A C1A 70.76(18) 
C8 C1 C2 O1 69.10(17)   C8A C1A C2A O1A -71.20(17) 
C8 C1 C2 C3 -57.00(18)   C8A C1A C2A C3A 50.16(18) 
C9 N1 C1 C2 -77.83(16)   C9A N1A C1A C2A -83.61(17) 
C9 N1 C1 C8 152.20(13)   C9A N1A C1A C8A 47.33(19) 
C9 N1 C10 O6 177.11(15)   C9A N1A C10A O6A 
-
177.85(15) 
C9 N1 C10 C12 -3.00(16)   C9A N1A C10A C12A 1.64(16) 
C9 C11 C12 C10 -1.50(17)   C9A C11A C12A C10A -1.72(17) 
C9 C11 C12 C13 179.22(14)   C9A C11A C12A C13A 178.05(14) 
C9 C11 C16 C15 179.98(15)   C9A C11A C16A C15A 
-
178.60(16) 
C10 N1 C1 C2 94.09(17)   C10A N1A C1A C2A 100.59(15) 
C10 N1 C1 C8 -35.9(2)   C10A N1A C1A C8A 
-
128.46(14) 
C10 N1 C9 O5 
-
176.96(15) 
  C10A N1A C9A O5A 175.08(15) 
C10 N1 C9 C11 2.12(16)   C10A N1A C9A C11A -2.66(16) 
C10 C12 C13 C14 
-
178.13(15) 
  C10A C12A C13A C14A 
-
179.54(16) 
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C11 C12 C13 C14 1.0(2)   C11A C12A C13A C14A 0.7(2) 
C12 C11 C16 C15 0.5(2)   C12A C11A C16A C15A 0.4(2) 
C12 C13 C14 C15 -0.2(2)   C12A C13A C14A C15A 0.4(3) 
C13 C14 C15 C16 -0.5(3)   C13A C14A C15A C16A -1.1(3) 
C14 C15 C16 C11 0.3(2)   C14A C15A C16A C11A 0.7(3) 
C16 C11 C12 C10 178.12(14)   C16A C11A C12A C10A 179.06(14) 
C16 C11 C12 C13 -1.2(2)   C16A C11A C12A C13A -1.2(2) 
  
Table 8 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1x.  
Atom x y z U(eq) 
H1 10300(20) 3610(20) 4253(17) 28(6) 
H2 6570(30) 1450(20) -340(20) 45(7) 
H3 4550(30) 2350(20) 1242(18) 34(6) 
H4 9050(30) 4670(20) 3128(19) 42(7) 
H1B 6685 1598 3044 17 
H2B 8744 1449 4134 18 
H3B 9665 2341 2570 21 
H3C 10097 1420 3127 21 
H4B 7775 -32 2126 23 
H5 6161 268 842 22 
H6 8300 2551 1284 19 
H7 6571 3377 1331 18 
H8 7035 3691 3054 17 
H13 7888 5073 6766 23 
H14 7060 4331 8031 27 
H15 6016 2368 7896 28 
H16 5728 1067 6484 26 
H1A 9270(30) 6350(20) 4140(20) 40(7) 
H2A 5600(30) 5950(20) -1083(19) 43(7) 
H3A 5300(30) 7890(20) 595(19) 40(7) 
H4A 6350(30) 5210(20) 2400(20) 48(7) 
H1AA 8102 8072 2551 16 
H2AA 10087 7744 3492 18 
H3AA 10530 6666 2327 21 
H3AB 8795 6004 1655 21 
H4AA 10629 8264 1649 24 
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H5A 8747 8182 313 24 
H6A 7127 5877 295 20 
H7A 5020 6245 402 19 
H8A 5548 6500 2103 17 
H13A 8038 10064 5950 31 
H14A 7039 9376 7158 37 
H15A 5931 7427 7054 36 
H16A 5708 6076 5699 29 
H1S 3930(30) 400(20) 1275(19) 42(7) 
H1SA 2134 364 35 41 
H1SB 1621 303 989 41 
H1SC 1067 -838 144 41 
H2S 7430(70) 3460(60) -80(50) 73(19) 
H2SA 9529 4234 -419 72 
H2SB 9855 4548 775 72 
H2SC 9789 5483 113 72 
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Table 1 Crystal data and structure refinement for (±)-II-54.  
Identification code  don2a  
Empirical formula  C16H13NO5  
Formula weight  299.27  
Temperature/K  100.00(10)  
Crystal system  orthorhombic  
Space group  Pbca  
a/Å  15.3092(4)  
b/Å  7.2876(2)  
c/Å  23.3953(6)  
α/°  90.00  
β/°  90.00  
γ/°  90.00  
Volume/Å
3
  2610.17(12)  
Z  8  
ρcalcmg/mm
3
  1.523  
m/mm
-1
  0.962  
F(000)  1248.0  
Crystal size/mm
3
  0.2135 × 0.0449 × 0.0185  
2Θ range for data collection  7.56 to 141.94°  
Index ranges  -18 ≤ h ≤ 18, -8 ≤ k ≤ 8, -28 ≤ l ≤ 22  
Reflections collected  11665  
Independent reflections  2444[R(int) = 0.0364]  
Data/restraints/parameters  2444/0/199  
Goodness-of-fit on F
2
  1.028  
Final R indexes [I>=2σ (I)]  R1 = 0.0361, wR2 = 0.0898  
Final R indexes [all data]  R1 = 0.0438, wR2 = 0.0942  
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Largest diff. peak/hole / e Å
-3
  0.23/-0.26  
 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don2a. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 
6456.8(7
) 
5304.9(17) 
7284.1(
5) 
26.0(
3) 
O2 
4759.3(7
) 
4653.6(14) 
7006.5(
5) 
18.3(
2) 
O3 
5167.6(7
) 
5725.8(14) 
6528.9(
5) 
19.7(
2) 
O4 
5034.2(6
) 
2702.5(15) 
4739.9(
5) 
19.8(
2) 
O5 
7569.8(7
) 
2834.3(16) 
5779.3(
5) 
23.3(
3) 
N1 
6181.7(8
) 
3009.7(16) 
5378.5(
5) 
14.4(
3) 
C1 
5607.2(9
) 
3385.2(19) 
5870.1(
6) 
14.3(
3) 
C2 
5281.5(9
) 
1611.9(19) 
6132.7(
6) 
17.0(
3) 
C3 
5069.2(1
0) 
1445(2) 
6761.4(
7) 
19.8(
3) 
C4 
5229.6(1
0) 
3035(2) 
7167.1(
6) 
18.5(
3) 
C5 
6197.4(1
0) 
3414(2) 
7227.6(
7) 
23.0(
3) 
C6 
6575.9(1
0) 
4376(2) 
6741.1(
7) 
22.3(
3) 
C7 
5928.4(9
) 
4909.8(19) 
6278.3(
6) 
17.0(
3) 
C8 
5817.1(1
1) 
362(2) 
6501.5(
7) 
23.7(
3) 
C9 
5808.9(9
) 
2628.1(18) 
4843.2(
6) 
15.0(
3) 
C10 
7084.7(9
) 
2703.7(18) 
5373.3(
6) 
15.7(
3) 
C11 
6542.0(9
) 
2139.6(18) 
4457.6(
6) 
14.9(
3) 
C12 
7308.2(9
) 
2206.5(18) 
4772.6(
6) 
15.3(
3) 
C13 
8114.1(9
) 
1867.2(19) 
4527.7(
6) 
17.2(
3) 
C14 
8120.1(9
) 
1401(2) 
3946.8(
7) 
18.4(
3) 
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C15 
7348.3(1
0) 
1310.1(19) 
3632.5(
6) 
18.1(
3) 
C16 
6540.7(9
) 
1706.5(19) 
3882.2(
6) 
16.5(
3) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don2a. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 23.4(5) 32.7(6) 21.9(6) -12.6(5) -0.8(4) -5.1(4) 
O2 18.8(5) 18.8(5) 17.3(5) 1.5(4) 5.5(4) 0.3(4) 
O3 24.8(5) 16.7(5) 17.7(5) 2.9(4) 7.5(4) 3.0(4) 
O4 12.6(5) 28.4(5) 18.4(5) -1.5(4) -1.4(4) 0.4(4) 
O5 16.6(5) 35.7(6) 17.6(6) -4.7(4) -3.0(4) 5.2(4) 
N1 12.1(5) 18.0(5) 13.2(6) -0.3(4) 0.6(5) 0.2(4) 
C1 13.4(6) 16.4(6) 13.1(7) -0.9(5) 0.5(5) 0.8(5) 
C2 20.4(7) 15.8(6) 14.7(7) -2.4(5) 2.2(5) -2.5(5) 
C3 26.1(7) 16.8(7) 16.6(7) 0.9(5) 3.2(6) -2.3(5) 
C4 22.3(7) 18.2(7) 15.0(7) 1.3(5) 0.6(6) 1.2(6) 
C5 24.2(8) 26.2(8) 18.6(7) -5.6(6) -5.8(6) 3.9(6) 
C6 17.2(7) 27.7(7) 22.0(8) -11.7(6) -1.7(6) -1.9(6) 
C7 18.2(7) 15.0(6) 17.8(7) -2.8(5) 5.5(5) -2.1(5) 
C8 33.3(8) 16.3(7) 21.4(8) 0.0(6) 3.2(7) 3.1(6) 
C9 15.6(6) 13.3(6) 16.1(7) 0.9(5) 0.6(5) 0.2(5) 
C10 14.0(6) 16.0(6) 17.1(7) 0.2(5) -0.1(6) 1.3(5) 
C11 14.1(7) 12.7(6) 17.9(7) 0.3(5) 1.0(5) 0.5(5) 
C12 16.2(7) 13.4(5) 16.2(7) 0.3(5) 0.1(5) -0.2(5) 
C13 14.1(7) 17.5(6) 20.0(7) 0.3(5) 0.1(5) 0.8(5) 
C14 16.5(7) 17.5(6) 21.2(7) 0.8(6) 4.6(6) 1.4(5) 
C15 21.2(7) 17.4(6) 15.9(7) -0.8(5) 1.9(6) 0.5(5) 
C16 16.5(7) 15.7(6) 17.2(7) -0.4(5) -1.3(5) -0.2(5) 
  
Table 4 Bond Lengths for don2a. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C5 1.440(2)   C3 C4 1.518(2) 
O1 C6 1.4512(18)   C3 C8 1.518(2) 
O2 O3 1.4999(14)   C4 C5 1.514(2) 
O2 C4 1.4319(18)   C5 C6 1.457(2) 
O3 C7 1.4331(17)   C6 C7 1.518(2) 
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O4 C9 1.2116(18)   C9 C11 1.4833(19) 
O5 C10 1.2095(19)   C10 C12 1.491(2) 
N1 C1 1.4736(18)   C11 C12 1.386(2) 
N1 C9 1.4040(18)   C11 C16 1.383(2) 
N1 C10 1.4004(18)   C12 C13 1.383(2) 
C1 C2 1.5152(19)   C13 C14 1.401(2) 
C1 C7 1.5454(19)   C14 C15 1.393(2) 
C2 C3 1.511(2)   C15 C16 1.398(2) 
C2 C8 1.499(2)         
  
Table 5 Bond Angles for don2a. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C5 O1 C6 60.52(10)   O1 C6 C7 115.00(13) 
C4 O2 O3 114.52(10)   C5 C6 C7 114.88(13) 
C7 O3 O2 115.29(10)   O3 C7 C1 107.01(11) 
C9 N1 C1 119.37(11)   O3 C7 C6 110.19(12) 
C10 N1 C1 128.72(12)   C6 C7 C1 117.65(12) 
C10 N1 C9 111.22(12)   C2 C8 C3 60.13(10) 
N1 C1 C2 110.76(11)   O4 C9 N1 124.53(13) 
N1 C1 C7 115.21(11)   O4 C9 C11 129.06(14) 
C2 C1 C7 117.87(12)   N1 C9 C11 106.41(12) 
C3 C2 C1 122.27(12)   O5 C10 N1 125.93(14) 
C8 C2 C1 124.86(13)   O5 C10 C12 128.20(13) 
C8 C2 C3 60.55(10)   N1 C10 C12 105.87(12) 
C2 C3 C4 120.80(13)   C12 C11 C9 107.96(13) 
C2 C3 C8 59.32(10)   C16 C11 C9 130.23(13) 
C8 C3 C4 121.69(14)   C16 C11 C12 121.80(13) 
O2 C4 C3 112.55(12)   C11 C12 C10 108.39(12) 
O2 C4 C5 111.51(12)   C13 C12 C10 129.70(13) 
C5 C4 C3 110.86(13)   C13 C12 C11 121.91(14) 
O1 C5 C4 116.93(13)   C12 C13 C14 116.82(13) 
O1 C5 C6 60.11(10)   C15 C14 C13 121.20(13) 
C6 C5 C4 113.81(13)   C14 C15 C16 121.31(14) 
O1 C6 C5 59.36(10)   C11 C16 C15 116.93(13) 
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Table 6 Torsion Angles for don2a. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C5 C6 C7 
-
105.48(14) 
  C3 C4 C5 C6 76.44(16) 
O1 C6 C7 O3 -19.91(17)   C4 O2 O3 C7 4.25(16) 
O1 C6 C7 C1 
-
142.90(13) 
  C4 C3 C8 C2 
-
109.48(16) 
O2 O3 C7 C1 78.54(14)   C4 C5 C6 O1 108.50(14) 
O2 O3 C7 C6 -50.48(15)   C4 C5 C6 C7 3.02(19) 
O2 C4 C5 O1 17.44(19)   C5 O1 C6 C7 105.26(15) 
O2 C4 C5 C6 -49.81(18)   C5 C6 C7 O3 46.29(17) 
O3 O2 C4 C3 -79.05(14)   C5 C6 C7 C1 -76.70(17) 
O3 O2 C4 C5 46.26(16)   C6 O1 C5 C4 
-
103.32(15) 
O4 C9 C11 C12 
-
178.67(14) 
  C7 C1 C2 C3 14.18(19) 
O4 C9 C11 C16 2.4(2)   C7 C1 C2 C8 -60.23(18) 
O5 C10 C12 C11 177.19(14)   C8 C2 C3 C4 110.94(16) 
O5 C10 C12 C13 -3.6(2)   C8 C3 C4 O2 129.60(14) 
N1 C1 C2 C3 149.88(13)   C8 C3 C4 C5 3.9(2) 
N1 C1 C2 C8 75.47(17)   C9 N1 C1 C2 81.89(15) 
N1 C1 C7 O3 151.02(11)   C9 N1 C1 C7 
-
141.15(13) 
N1 C1 C7 C6 -84.39(16)   C9 N1 C10 O5 
-
176.30(14) 
N1 C9 C11 C12 1.25(14)   C9 N1 C10 C12 4.01(15) 
N1 C9 C11 C16 
-
177.63(14) 
  C9 C11 C12 C10 1.15(14) 
N1 C10 C12 C11 -3.13(14)   C9 C11 C12 C13 
-
178.16(12) 
N1 C10 C12 C13 176.11(14)   C9 C11 C16 C15 179.68(13) 
C1 N1 C9 O4 5.3(2)   C10 N1 C1 C2 -87.71(16) 
C1 N1 C9 C11 
-
174.66(11) 
  C10 N1 C1 C7 49.26(19) 
C1 N1 C10 O5 -6.0(2)   C10 N1 C9 O4 176.57(13) 
C1 N1 C10 C12 174.29(12)   C10 N1 C9 C11 -3.35(15) 
C1 C2 C3 C4 -3.9(2)   C10 C12 C13 C14 179.17(13) 
C1 C2 C3 C8 
-
114.81(16) 
  C11 C12 C13 C14 -1.7(2) 
C1 C2 C8 C3 110.74(16)   C12 C11 C16 C15 0.9(2) 
C2 C1 C7 O3 -75.19(15)   C12 C13 C14 C15 0.8(2) 
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C2 C1 C7 C6 49.40(18)   C13 C14 C15 C16 1.0(2) 
C2 C3 C4 O2 58.88(18)   C14 C15 C16 C11 -1.8(2) 
C2 C3 C4 C5 -66.79(18)   C16 C11 C12 C10 
-
179.86(12) 
C3 C4 C5 O1 143.69(13)   C16 C11 C12 C13 0.8(2) 
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don2a.  
Atom x y z U(eq) 
H1 5072 3925 5692 17 
H2 4860 939 5882 20 
H3 4536 704 6848 24 
H4 5010 2654 7552 22 
H5 6564 2465 7422 28 
H6 7184 4047 6623 27 
H7 6214 5872 6038 20 
H8A 6420 749 6596 28 
H8B 5738 -977 6453 28 
H13 8639 1946 4743 21 
H14 8660 1142 3764 22 
H15 7371 972 3241 22 
H16 6015 1680 3667 20 
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Table 1 Crystal data and structure refinement for (±)-II-56.  
Identification code  don2b4  
Empirical formula  C17H21NO7  
Formula weight  351.35  
Temperature/K  100.00(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  14.4945(17)  
b/Å  10.6522(10)  
c/Å  11.1524(14)  
α/°  90.00  
β/°  108.353(13)  
γ/°  90.00  
Volume/Å
3
  1634.3(3)  
Z  4  
ρcalcmg/mm
3
  1.428  
m/mm
-1
  0.941  
F(000)  744.0  
Crystal size/mm
3
  0.32 × 0.06 × 0.05  
2Θ range for data collection  10.5 to 141.98°  
Index ranges  -13 ≤ h ≤ 17, -12 ≤ k ≤ 10, -13 ≤ l ≤ 13  
Reflections collected  6895  
Independent reflections  3035[R(int) = 0.0290]  
Data/restraints/parameters  3035/0/247  
Goodness-of-fit on F
2
  1.029  
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Final R indexes [I>=2σ (I)]  R1 = 0.0377, wR2 = 0.0966  
Final R indexes [all data]  R1 = 0.0453, wR2 = 0.1012  
Largest diff. peak/hole / e Å
-3
  0.32/-0.19  
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don2b4. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 4424.5(8) 711.1(11) 5815.9(10) 21.9(3) 
O2 5162.9(9) -352.6(11) 8203.9(11) 23.0(3) 
O3 4726.1(8) 1564.2(11) 9544.4(10) 19.7(2) 
O4 3804.8(8) 3721.3(10) 8311.1(10) 17.9(2) 
O5 2744.4(9) 4729.8(11) 4688.6(11) 24.8(3) 
O6 1397.4(8) 3195.9(13) 7587.4(11) 29.0(3) 
N1 2255.9(9) 3707.7(13) 6218.7(12) 17.8(3) 
C1 2921.7(11) 2620.9(14) 6409.4(14) 16.2(3) 
C2 2336.6(11) 1506.3(16) 5736.7(14) 20.1(3) 
C3 2779.0(12) 231.9(16) 5731.1(15) 21.6(3) 
C4 3840.6(12) -15.6(15) 6383.1(14) 19.2(3) 
C5 4227.1(11) 238.4(15) 7791.9(14) 17.2(3) 
C6 4365.9(11) 1615.7(15) 8193.6(13) 15.7(3) 
C7 3477.7(11) 2495.9(14) 7835.1(14) 15.1(3) 
C8 2039.4(12) 428.4(17) 6411.5(16) 24.9(4) 
C9 2246.5(11) 4679.9(15) 5372.1(14) 18.5(3) 
C10 1572.6(11) 3902.4(17) 6839.7(14) 21.1(3) 
C11 1504.2(11) 5599.3(16) 5491.9(15) 21.3(3) 
C12 1109.6(11) 5137.3(17) 6379.8(15) 23.1(4) 
C13 418.2(12) 5813(2) 6729.0(17) 31.8(4) 
C14 136.5(13) 6967(2) 6142(2) 38.6(5) 
C15 521.8(14) 7409.5(19) 5233(2) 36.9(5) 
C16 1220.3(13) 6734.3(17) 4888.5(18) 29.2(4) 
O7 6104.2(9) 1784.5(13) 5855.6(12) 29.6(3) 
C17 6828.8(14) 2087(2) 6986.8(19) 37.3(5) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don2b4. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 26.2(6) 29.6(6) 12.5(5) 2.7(4) 9.6(4) -1.1(5) 
O2 29.0(6) 29.0(7) 13.5(5) 4.9(5) 10.1(5) 10.9(5) 
O3 24.5(6) 22.9(6) 10.7(5) 1.0(4) 4.0(4) -2.2(5) 
O4 25.3(6) 16.9(6) 13.3(5) -1.7(4) 8.7(4) -2.6(4) 
O5 30.2(6) 27.7(7) 21.6(6) 7.1(5) 15.3(5) 5.7(5) 
O6 23.6(6) 48.0(8) 19.2(6) 5.8(5) 12.0(5) 2.0(5) 
N1 19.1(6) 23.2(7) 13.5(6) 1.0(5) 8.7(5) 3.4(5) 
C1 18.4(7) 18.5(8) 13.4(7) 0.5(6) 7.4(6) 2.8(6) 
C2 20.0(7) 24.7(9) 14.6(7) -2.1(6) 3.9(6) 0.5(6) 
C3 27.4(8) 21.7(8) 15.9(7) -4.9(6) 7.0(6) -3.0(7) 
C4 27.2(8) 18.7(8) 14.3(7) -1.1(6) 10.4(6) -0.1(6) 
C5 21.8(7) 18.6(8) 13.5(7) 1.9(6) 8.7(6) 2.6(6) 
C6 19.1(7) 19.7(8) 9.2(7) 0.8(5) 5.6(5) -0.8(6) 
C7 19.1(7) 15.4(7) 12.2(7) -0.9(5) 7.0(6) -1.7(6) 
C8 22.6(8) 27.8(9) 25.5(8) -5.1(7) 9.4(7) -8.3(7) 
C9 20.2(7) 20.3(8) 14.9(7) -1.4(6) 5.1(6) 1.8(6) 
C10 17.0(7) 33.7(10) 13.7(7) -3.6(6) 6.5(6) 0.6(7) 
C11 18.6(7) 22.8(8) 20.6(8) -6.0(6) 3.3(6) 2.0(6) 
C12 17.6(7) 31.3(9) 19.1(7) -8.8(7) 3.9(6) 2.7(7) 
C13 20.2(8) 47.9(12) 26.7(9) -14.5(8) 6.7(7) 5.1(8) 
C14 23.0(9) 42.4(12) 44.1(12) -22.4(9) 1.3(8) 10.5(8) 
C15 29.8(10) 27.3(10) 44.8(12) -10.4(8) -1.0(8) 8.5(8) 
C16 26.7(8) 24.2(9) 32.0(9) -2.0(7) 2.6(7) 3.2(7) 
O7 30.5(6) 34.9(7) 21.4(6) 2.6(5) 5.4(5) -0.5(5) 
C17 30.9(9) 43.5(12) 31.6(10) -11.0(9) 1.4(8) 7.7(8) 
  
Table 4 Bond Lengths for don2b4. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.4328(19)   C3 C8 1.510(2) 
O2 C5 1.4334(19)   C4 C5 1.517(2) 
O3 C6 1.4317(17)   C5 C6 1.529(2) 
O4 C7 1.4324(18)   C6 C7 1.540(2) 
O5 C9 1.205(2)   C9 C11 1.492(2) 
O6 C10 1.208(2)   C10 C12 1.492(2) 
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N1 C1 1.4791(19)   C11 C12 1.381(2) 
N1 C9 1.399(2)   C11 C16 1.382(2) 
N1 C10 1.3912(19)   C12 C13 1.386(2) 
C1 C2 1.514(2)   C13 C14 1.393(3) 
C1 C7 1.545(2)   C14 C15 1.385(3) 
C2 C3 1.502(2)   C15 C16 1.391(3) 
C2 C8 1.508(2)   O7 C17 1.401(2) 
C3 C4 1.504(2)         
  
Table 5 Bond Angles for don2b4. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C9 N1 C1 122.95(12)   O4 C7 C1 107.90(12) 
C10 N1 C1 125.43(13)   O4 C7 C6 107.85(12) 
C10 N1 C9 111.63(13)   C6 C7 C1 116.23(12) 
N1 C1 C2 107.72(12)   C2 C8 C3 59.69(11) 
N1 C1 C7 108.70(12)   O5 C9 N1 125.41(14) 
C2 C1 C7 118.14(13)   O5 C9 C11 128.35(15) 
C3 C2 C1 122.52(13)   N1 C9 C11 106.24(13) 
C3 C2 C8 60.23(11)   O6 C10 N1 126.02(16) 
C8 C2 C1 123.60(14)   O6 C10 C12 128.09(15) 
C2 C3 C4 121.97(14)   N1 C10 C12 105.89(14) 
C2 C3 C8 60.08(11)   C12 C11 C9 107.67(15) 
C4 C3 C8 124.15(14)   C12 C11 C16 122.27(16) 
O1 C4 C3 110.40(13)   C16 C11 C9 130.05(16) 
O1 C4 C5 106.50(12)   C11 C12 C10 108.52(14) 
C3 C4 C5 117.23(13)   C11 C12 C13 121.08(18) 
O2 C5 C4 104.91(12)   C13 C12 C10 130.38(17) 
O2 C5 C6 107.67(12)   C12 C13 C14 117.21(19) 
C4 C5 C6 116.50(13)   C15 C14 C13 121.24(17) 
O3 C6 C5 104.03(12)   C14 C15 C16 121.51(19) 
O3 C6 C7 107.13(11)   C11 C16 C15 116.67(19) 
C5 C6 C7 119.08(13)           
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Table 6 Torsion Angles for don2b4. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C4 C5 O2 -69.45(15)   C3 C4 C5 C6 -74.66(18) 
O1 C4 C5 C6 49.49(17)   C4 C3 C8 C2 110.36(17) 
O2 C5 C6 O3 -62.81(14)   C4 C5 C6 O3 179.76(12) 
O2 C5 C6 C7 178.09(11)   C4 C5 C6 C7 60.66(17) 
O3 C6 C7 O4 62.94(14)   C5 C6 C7 O4 
-
179.57(12) 
O3 C6 C7 C1 
-
175.82(12) 
  C5 C6 C7 C1 -58.33(18) 
O5 C9 C11 C12 179.10(16)   C7 C1 C2 C3 -56.3(2) 
O5 C9 C11 C16 -1.9(3)   C7 C1 C2 C8 17.2(2) 
O6 C10 C12 C11 
-
177.52(17) 
  C8 C2 C3 C4 
-
113.85(16) 
O6 C10 C12 C13 4.0(3)   C8 C3 C4 O1 
-
136.50(16) 
N1 C1 C2 C3 
-
179.88(13) 
  C8 C3 C4 C5 -14.4(2) 
N1 C1 C2 C8 
-
106.35(16) 
  C9 N1 C1 C2 
-
104.18(16) 
N1 C1 C7 O4 -45.32(15)   C9 N1 C1 C7 126.71(14) 
N1 C1 C7 C6 
-
166.54(12) 
  C9 N1 C10 O6 177.23(16) 
N1 C9 C11 C12 -0.39(17)   C9 N1 C10 C12 -2.21(17) 
N1 C9 C11 C16 178.66(16)   C9 C11 C12 C10 -0.92(18) 
N1 C10 C12 C11 1.91(17)   C9 C11 C12 C13 177.71(15) 
N1 C10 C12 C13 
-
176.55(17) 
  C9 C11 C16 C15 
-
177.93(17) 
C1 N1 C9 O5 2.3(2)   C10 N1 C1 C2 75.95(17) 
C1 N1 C9 C11 
-
178.21(13) 
  C10 N1 C1 C7 -53.16(19) 
C1 N1 C10 O6 -2.9(3)   C10 N1 C9 O5 
-
177.84(15) 
C1 N1 C10 C12 177.67(13)   C10 N1 C9 C11 1.67(17) 
C1 C2 C3 C4 -0.8(2)   C10 C12 C13 C14 178.70(17) 
C1 C2 C3 C8 113.04(17)   C11 C12 C13 C14 0.4(2) 
C1 C2 C8 C3 
-
111.32(16) 
  C12 C11 C16 C15 1.0(3) 
C2 C1 C7 O4 
-
168.38(12) 
  C12 C13 C14 C15 1.0(3) 
218 
 
C2 C1 C7 C6 70.41(17)   C13 C14 C15 C16 -1.4(3) 
C2 C3 C4 O1 -63.19(18)   C14 C15 C16 C11 0.4(3) 
C2 C3 C4 C5 59.0(2)   C16 C11 C12 C10 179.94(15) 
C3 C4 C5 O2 166.41(13)   C16 C11 C12 C13 -1.4(3) 
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don2b4.  
Atom x y z U(eq) 
H1 4141(17) 790(20) 4980(30) 48(7) 
H2 5316(19) -540(20) 8960(30) 53(8) 
H3 5159(16) 2060(20) 9800(20) 28(6) 
H4 4132(17) 3990(20) 7920(20) 39(7) 
H1A 3412 2818 5975 19 
H2A 1837 1729 4917 24 
H3A 2513 -221 4909 26 
H4A 3963 -921 6251 23 
H5 3793 -175 8215 21 
H6 4879 1988 7877 19 
H7 3012 2190 8268 18 
H8A 1383 67 6028 30 
H8B 2274 430 7347 30 
H13 148 5501 7343 38 
H14 -329 7460 6369 46 
H15 304 8192 4836 44 
H16 1489 7038 4269 35 
H7A 5580(20) 1240(30) 6050(30) 74(9) 
H17A 6540 2154 7669 56 
H17B 7127 2890 6890 56 
H17C 7326 1428 7192 56 
 
 
219 
 
 
Table 1 Crystal data and structure refinement for (±)-II-57. 
Identification code  don1y5  
Empirical formula  C16H15NO5  
Formula weight  301.29  
Temperature/K  100.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  7.40297(16)  
b/Å  10.1453(2)  
c/Å  18.2027(3)  
α/°  82.2109(16)  
β/°  85.4289(16)  
γ/°  84.8574(17)  
Volume/Å
3
  1345.90(5)  
Z  4  
ρcalcmg/mm
3
  1.487  
m/mm
-1
  0.934  
F(000)  632.0  
Crystal size/mm
3
  0.32 × 0.15 × 0.03  
2Θ range for data collection  8.82 to 141.9°  
Index ranges  -9 ≤ h ≤ 9, -12 ≤ k ≤ 12, -22 ≤ l ≤ 22  
Reflections collected  9087  
Independent reflections  9087[R(int) = 0.0000]  
Data/restraints/parameters  9087/0/414  
Goodness-of-fit on F
2
  1.067  
Final R indexes [I>=2σ (I)]  R1 = 0.0507, wR2 = 0.1441  
Final R indexes [all data]  R1 = 0.0516, wR2 = 0.1452  
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Largest diff. peak/hole / e Å
-3
  0.34/-0.29  
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1y5. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 535.8(16) 1754.9(11) -2247.3(6) 29.5(3) 
O2 4886.3(14) 1517.9(11) -1877.0(6) 24.3(2) 
O3 5698.3(14) 1575.8(11) -122.0(6) 25.1(2) 
O4 2030.7(14) 512.8(10) 751.5(6) 23.7(2) 
O5 3459.2(15) 4778.7(10) 881.5(6) 27.5(2) 
N1 2778.9(17) 2713.6(12) 617.0(7) 20.4(3) 
C1 2985.1(19) 3027.4(14) -195.5(7) 19.8(3) 
C2 1133.3(19) 3443.3(15) -504.3(8) 22.7(3) 
C3 415(2) 3002.8(15) -1188.9(8) 23.3(3) 
C4 1493(2) 2011.7(15) -1643.0(8) 22.9(3) 
C5 3335(2) 2506.1(15) -1893.9(8) 23.4(3) 
C6 4674(2) 2462.2(14) -1342.2(8) 21.4(3) 
C7 4156.8(19) 1917.5(14) -545.5(8) 19.7(3) 
C8 -395(2) 2539.0(17) -423.6(9) 27.5(3) 
C9 2345.1(19) 1497.3(14) 1017.2(8) 20.1(3) 
C10 3081.0(19) 3644.8(14) 1087.5(8) 20.1(3) 
C11 2355.0(18) 1667.6(14) 1815.4(8) 19.8(3) 
C12 2814.3(19) 2955.1(15) 1859.2(8) 19.8(3) 
C13 2965.5(19) 3402.6(16) 2533.4(8) 23.9(3) 
C14 2647(2) 2501.7(17) 3172.1(8) 27.0(3) 
C15 2180(2) 1216.7(17) 3125.2(8) 27.6(3) 
C16 2021(2) 769.6(15) 2442.9(8) 24.4(3) 
O1A 9365.3(16) 3924.7(11) 6819.5(6) 25.8(2) 
O2A 5165.6(14) 4214.3(11) 6336.3(6) 25.9(2) 
O3A 4439.5(15) 3475.8(12) 4691.4(7) 27.8(2) 
O4A 6342.8(16) 28.7(11) 4020.7(6) 28.7(2) 
O5A 8522.3(14) 4147.8(10) 3838.9(6) 23.2(2) 
N1A 7456.3(17) 2053.7(12) 4124.1(7) 19.9(3) 
C1A 7148(2) 1992.4(15) 4936.8(8) 20.6(3) 
C2A 8912(2) 1632.0(15) 5318.4(8) 22.4(3) 
C3A 9561(2) 2283.9(15) 5945.2(8) 22.5(3) 
C4A 8518(2) 3501.0(14) 6222.1(8) 21.4(3) 
C5A 6624(2) 3169.9(14) 6492.1(8) 22.6(3) 
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C6A 5344(2) 3045.1(15) 5937.1(8) 22.9(3) 
C7A 5978.2(19) 3264.1(15) 5125.0(8) 20.6(3) 
C8A 10565(2) 2429.6(17) 5188.5(8) 27.3(3) 
C9A 6912.9(19) 1068.0(14) 3731.7(8) 20.4(3) 
C10A 8017.8(18) 3146.6(14) 3644.6(8) 18.6(3) 
C11A 7195.8(18) 1584.8(14) 2930.5(8) 19.5(3) 
C12A 7844.6(18) 2840.5(14) 2877.2(8) 18.9(3) 
C13A 8172(2) 3604.7(15) 2197.3(8) 23.8(3) 
C14A 7828(2) 3058.2(17) 1563.6(9) 27.7(3) 
C15A 7191(2) 1793.5(17) 1616.3(8) 26.9(3) 
C16A 6861(2) 1034.2(15) 2306.9(8) 23.7(3) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1y5. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 37.1(6) 28.3(6) 25.3(5) -3.7(5) -12.9(5) -4.4(5) 
O2 26.7(5) 27.8(5) 19.3(5) -8.0(4) -0.2(4) -1.6(4) 
O3 21.4(5) 31.9(6) 23.2(5) -7.2(4) -4.5(4) -0.4(4) 
O4 28.0(5) 22.1(5) 22.2(5) -5.0(4) 0.2(4) -7.6(4) 
O5 36.4(6) 22.6(5) 24.9(5) -5.3(4) 0.2(5) -8.6(4) 
N1 24.7(6) 22.0(6) 15.2(6) -3.8(5) 0.9(5) -5.5(5) 
C1 24.1(7) 20.9(6) 14.9(6) -1.8(5) 1.0(5) -7.0(5) 
C2 22.7(7) 24.9(7) 20.4(7) -4.3(6) 0.3(6) -1.0(6) 
C3 21.4(7) 27.0(7) 21.2(7) -0.5(6) -3.7(6) -3.3(6) 
C4 27.0(7) 24.2(7) 18.6(7) -1.2(5) -7.3(6) -4.7(6) 
C5 31.1(8) 22.2(7) 16.8(6) -2.9(5) 0.0(6) -2.6(6) 
C6 23.7(7) 21.8(7) 19.5(7) -5.4(6) 3.0(5) -5.1(5) 
C7 19.1(6) 24.4(7) 16.7(6) -3.1(5) -1.9(5) -5.7(5) 
C8 23.1(7) 36.1(8) 22.7(7) -0.5(6) -1.1(6) -4.9(6) 
C9 18.6(7) 23.7(7) 18.3(7) -3.4(5) 1.1(5) -4.2(5) 
C10 18.3(6) 23.0(7) 19.9(7) -6.1(5) 0.7(5) -3.6(5) 
C11 16.1(6) 25.6(7) 18.1(7) -2.8(5) -0.8(5) -3.2(5) 
C12 15.1(6) 25.2(7) 19.5(7) -5.0(6) 0.1(5) -2.2(5) 
C13 19.5(7) 31.1(8) 22.9(7) -9.1(6) -0.6(5) -4.1(6) 
C14 19.7(7) 43.7(9) 18.5(7) -8.0(6) 0.4(5) -3.7(6) 
C15 22.0(7) 40.0(9) 19.2(7) 2.3(6) 0.9(6) -5.3(6) 
C16 21.6(7) 27.7(8) 23.0(7) 0.5(6) 1.3(6) -4.5(6) 
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O1A 31.9(6) 27.5(5) 19.4(5) -1.3(4) -5.4(4) -9.2(4) 
O2A 26.2(5) 29.2(6) 22.8(5) -8.1(4) -0.2(4) 1.3(4) 
O3A 23.2(5) 34.6(6) 26.0(5) -3.7(5) -5.2(4) -2.9(4) 
O4A 40.9(6) 21.2(5) 25.7(5) -3.2(4) -0.5(5) -12.0(5) 
O5A 26.4(5) 21.9(5) 22.8(5) -4.8(4) 0.6(4) -8.4(4) 
N1A 25.4(6) 19.4(6) 15.6(6) -2.3(5) 0.3(5) -7.1(5) 
C1A 25.6(7) 22.0(7) 14.6(6) -2.0(5) 0.8(5) -6.8(6) 
C2A 25.5(7) 23.0(7) 17.9(7) -2.4(5) 0.5(6) 0.4(6) 
C3A 22.2(7) 27.4(7) 17.7(7) -2.2(5) -1.3(5) -2.1(5) 
C4A 24.8(7) 23.2(7) 16.8(6) -0.9(5) -3.6(5) -5.4(6) 
C5A 29.1(8) 21.3(7) 17.7(6) -3.1(5) 0.2(6) -4.0(6) 
C6A 21.5(7) 24.2(7) 24.0(7) -6.5(6) 1.8(6) -4.9(5) 
C7A 19.1(7) 24.9(7) 18.5(7) -4.4(5) -2.0(5) -3.1(5) 
C8A 20.8(7) 39.9(9) 19.8(7) -0.8(6) -0.9(6) -0.4(6) 
C9A 22.5(7) 20.1(7) 19.6(7) -5.3(5) -2.7(5) -2.7(5) 
C10A 17.6(6) 20.2(7) 18.2(6) -2.2(5) -0.7(5) -3.5(5) 
C11A 16.8(6) 22.2(7) 20.0(7) -4.7(5) -1.2(5) -1.5(5) 
C12A 16.6(6) 22.3(7) 18.0(7) -3.4(5) -0.7(5) -2.1(5) 
C13A 21.9(7) 27.3(8) 21.6(7) -0.5(6) 1.0(6) -4.7(6) 
C14A 24.9(7) 37.6(9) 19.2(7) -0.3(6) 0.1(6) -1.2(6) 
C15A 22.6(7) 40.4(9) 19.1(7) -9.7(6) -3.9(6) 0.3(6) 
C16A 21.9(7) 27.2(7) 23.9(7) -9.2(6) -2.4(6) -2.8(6) 
  
Table 4 Bond Lengths for don1y5. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.4197(17)   O1A C4A 1.4298(17) 
O2 C5 1.4543(18)   O2A C5A 1.4598(18) 
O2 C6 1.4461(17)   O2A C6A 1.4637(17) 
O3 C7 1.4191(17)   O3A C7A 1.4213(17) 
O4 C9 1.2149(18)   O4A C9A 1.2086(18) 
O5 C10 1.2110(18)   O5A C10A 1.2177(17) 
N1 C1 1.4688(17)   N1A C1A 1.4724(17) 
N1 C9 1.3952(18)   N1A C9A 1.4084(18) 
N1 C10 1.4014(18)   N1A C10A 1.3880(18) 
C1 C2 1.526(2)   C1A C2A 1.520(2) 
C1 C7 1.5354(19)   C1A C7A 1.5506(19) 
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C2 C3 1.528(2)   C2A C3A 1.523(2) 
C2 C8 1.505(2)   C2A C8A 1.513(2) 
C3 C4 1.519(2)   C3A C4A 1.520(2) 
C3 C8 1.504(2)   C3A C8A 1.508(2) 
C4 C5 1.511(2)   C4A C5A 1.500(2) 
C5 C6 1.460(2)   C5A C6A 1.464(2) 
C6 C7 1.5124(19)   C6A C7A 1.508(2) 
C9 C11 1.4869(19)   C9A C11A 1.4865(19) 
C10 C12 1.489(2)   C10A C12A 1.4890(18) 
C11 C12 1.393(2)   C11A C12A 1.3899(19) 
C11 C16 1.382(2)   C11A C16A 1.380(2) 
C12 C13 1.381(2)   C12A C13A 1.385(2) 
C13 C14 1.396(2)   C13A C14A 1.396(2) 
C14 C15 1.394(2)   C14A C15A 1.395(2) 
C15 C16 1.396(2)   C15A C16A 1.398(2) 
  
Table 5 Bond Angles for don1y5. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C6 O2 C5 60.43(9)   C5A O2A C6A 60.09(9) 
C9 N1 C1 126.54(12)   C9A N1A C1A 122.32(12) 
C9 N1 C10 111.75(12)   C10A N1A C1A 125.45(12) 
C10 N1 C1 121.68(12)   C10A N1A C9A 111.44(12) 
N1 C1 C2 110.07(11)   N1A C1A C2A 111.34(12) 
N1 C1 C7 111.15(12)   N1A C1A C7A 109.18(11) 
C2 C1 C7 116.76(11)   C2A C1A C7A 117.62(12) 
C1 C2 C3 126.85(12)   C1A C2A C3A 126.93(13) 
C8 C2 C1 123.39(13)   C8A C2A C1A 125.13(13) 
C8 C2 C3 59.44(9)   C8A C2A C3A 59.56(10) 
C4 C3 C2 122.50(12)   C4A C3A C2A 121.61(12) 
C8 C3 C2 59.53(10)   C8A C3A C2A 59.89(10) 
C8 C3 C4 120.10(13)   C8A C3A C4A 119.24(13) 
O1 C4 C3 111.98(12)   O1A C4A C3A 111.72(12) 
O1 C4 C5 112.22(12)   O1A C4A C5A 108.49(12) 
C5 C4 C3 109.38(12)   C5A C4A C3A 109.37(12) 
O2 C5 C4 117.18(12)   O2A C5A C4A 116.90(12) 
O2 C5 C6 59.51(9)   O2A C5A C6A 60.09(9) 
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C6 C5 C4 118.55(12)   C6A C5A C4A 118.03(12) 
O2 C6 C5 60.06(9)   O2A C6A C7A 116.89(12) 
O2 C6 C7 116.76(12)   C5A C6A O2A 59.82(9) 
C5 C6 C7 118.52(12)   C5A C6A C7A 118.87(13) 
O3 C7 C1 107.48(11)   O3A C7A C1A 109.62(12) 
O3 C7 C6 112.19(11)   O3A C7A C6A 109.18(12) 
C6 C7 C1 107.34(11)   C6A C7A C1A 108.00(12) 
C3 C8 C2 61.03(10)   C3A C8A C2A 60.56(10) 
O4 C9 N1 125.76(13)   O4A C9A N1A 124.42(13) 
O4 C9 C11 128.17(13)   O4A C9A C11A 129.57(13) 
N1 C9 C11 106.07(12)   N1A C9A C11A 106.01(12) 
O5 C10 N1 124.98(13)   O5A C10A N1A 124.87(13) 
O5 C10 C12 128.95(13)   O5A C10A C12A 128.63(13) 
N1 C10 C12 106.07(12)   N1A C10A C12A 106.49(11) 
C12 C11 C9 108.26(12)   C12A C11A C9A 108.05(12) 
C16 C11 C9 129.81(13)   C16A C11A C9A 130.37(13) 
C16 C11 C12 121.93(14)   C16A C11A C12A 121.54(14) 
C11 C12 C10 107.85(13)   C11A C12A C10A 108.00(12) 
C13 C12 C10 130.40(14)   C13A C12A C10A 130.25(13) 
C13 C12 C11 121.75(14)   C13A C12A C11A 121.72(13) 
C12 C13 C14 116.94(14)   C12A C13A C14A 117.12(14) 
C15 C14 C13 121.08(14)   C15A C14A C13A 121.19(14) 
C14 C15 C16 121.82(14)   C14A C15A C16A 121.08(14) 
C11 C16 C15 116.48(14)   C11A C16A C15A 117.35(14) 
  
Table 6 Hydrogen Bonds for don1y5.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O1A
1
 0.96(2) 1.79(2) 2.7132(16) 161(2) 
O3 H3 O4
2
 0.91(3) 1.98(3) 2.8883(15) 179(2) 
O1A H1AA O5A
3
 0.96(3) 1.76(3) 2.7056(15) 171(3) 
O3A H3AA O2A
4
 0.88(3) 1.94(3) 2.8150(16) 176(2) 
1-1+X,+Y,-1+Z; 21-X,-Y,-Z; 32-X,1-Y,1-Z; 41-X,1-Y,1-Z 
  
Table 7 Torsion Angles for don1y5. 
A B C D Angle/˚   A B C D Angle/˚ 
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O1 C4 C5 O2 -94.95(15)   O1A C4A C5A O2A 95.88(14) 
O1 C4 C5 C6 
-
163.23(12) 
  O1A C4A C5A C6A 164.57(12) 
O2 C5 C6 C7 
-
106.17(14) 
  O2A C5A C6A C7A 106.08(14) 
O2 C6 C7 O3 94.26(14)   O2A C6A C7A O3A -94.77(15) 
O2 C6 C7 C1 
-
147.89(12) 
  O2A C6A C7A C1A 146.09(12) 
O4 C9 C11 C12 179.08(14)   O4A C9A C11A C12A 178.84(15) 
O4 C9 C11 C16 0.2(3)   O4A C9A C11A C16A 1.1(3) 
O5 C10 C12 C11 178.61(14)   O5A C10A C12A C11A 
-
179.30(14) 
O5 C10 C12 C13 -1.7(3)   O5A C10A C12A C13A -1.3(3) 
N1 C1 C2 C3 
-
136.32(14) 
  N1A C1A C2A C3A 135.43(14) 
N1 C1 C2 C8 -61.81(18)   N1A C1A C2A C8A 59.68(19) 
N1 C1 C7 O3 -45.62(15)   N1A C1A C7A O3A 49.05(15) 
N1 C1 C7 C6 
-
166.49(11) 
  N1A C1A C7A C6A 167.91(11) 
N1 C9 C11 C12 -0.85(15)   N1A C9A C11A C12A -1.22(15) 
N1 C9 C11 C16 
-
179.78(14) 
  N1A C9A C11A C16A 
-
178.92(14) 
N1 C10 C12 C11 -0.55(15)   N1A C10A C12A C11A -0.15(15) 
N1 C10 C12 C13 179.12(14)   N1A C10A C12A C13A 177.84(14) 
C1 N1 C9 O4 -1.7(2)   C1A N1A C9A O4A -8.5(2) 
C1 N1 C9 C11 178.23(13)   C1A N1A C9A C11A 171.53(12) 
C1 N1 C10 O5 2.9(2)   C1A N1A C10A O5A 8.5(2) 
C1 N1 C10 C12 
-
177.84(12) 
  C1A N1A C10A C12A 
-
170.66(12) 
C1 C2 C3 C4 2.5(2)   C1A C2A C3A C4A -5.3(2) 
C1 C2 C3 C8 110.86(16)   C1A C2A C3A C8A 
-
113.16(17) 
C1 C2 C8 C3 
-
116.42(15) 
  C1A C2A C8A C3A 116.02(16) 
C2 C1 C7 O3 
-
173.00(11) 
  C2A C1A C7A O3A 177.15(12) 
C2 C1 C7 C6 66.13(15)   C2A C1A C7A C6A -63.99(16) 
C2 C3 C4 O1 179.57(13)   C2A C3A C4A O1A 179.07(12) 
C2 C3 C4 C5 -55.38(17)   C2A C3A C4A C5A 58.94(17) 
C3 C4 C5 O2 140.15(12)   C3A C4A C5A O2A 
-
142.04(12) 
C3 C4 C5 C6 71.86(16)   C3A C4A C5A C6A -73.35(16) 
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C4 C3 C8 C2 112.31(15)   C4A C3A C8A C2A 
-
111.70(15) 
C4 C5 C6 O2 106.45(14)   C4A C5A C6A O2A 
-
106.56(14) 
C4 C5 C6 C7 0.3(2)   C4A C5A C6A C7A -0.5(2) 
C5 O2 C6 C7 109.06(14)   C5A O2A C6A C7A 
-
109.34(14) 
C5 C6 C7 O3 163.03(12)   C5A C6A C7A O3A 
-
163.42(13) 
C5 C6 C7 C1 -79.11(15)   C5A C6A C7A C1A 77.44(16) 
C6 O2 C5 C4 
-
108.72(14) 
  C6A O2A C5A C4A 108.43(14) 
C7 C1 C2 C3 -8.4(2)   C7A C1A C2A C3A 8.4(2) 
C7 C1 C2 C8 66.10(18)   C7A C1A C2A C8A -67.38(19) 
C8 C2 C3 C4 
-
108.36(15) 
  C8A C2A C3A C4A 107.82(15) 
C8 C3 C4 O1 108.58(15)   C8A C3A C4A O1A 
-
110.24(14) 
C8 C3 C4 C5 
-
126.38(14) 
  C8A C3A C4A C5A 129.64(14) 
C9 N1 C1 C2 84.47(17)   C9A N1A C1A C2A 107.20(15) 
C9 N1 C1 C7 -46.48(18)   C9A N1A C1A C7A 
-
121.27(14) 
C9 N1 C10 O5 
-
179.20(14) 
  C9A N1A C10A O5A 178.54(13) 
C9 N1 C10 C12 0.01(15)   C9A N1A C10A C12A -0.66(16) 
C9 C11 C12 C10 0.86(15)   C9A C11A C12A C10A 0.84(15) 
C9 C11 C12 C13 
-
178.85(13) 
  C9A C11A C12A C13A 
-
177.36(13) 
C9 C11 C16 C15 178.38(14)   C9A C11A C16A C15A 177.06(14) 
C10 N1 C1 C2 -98.01(15)   C10A N1A C1A C2A -83.82(17) 
C10 N1 C1 C7 131.04(13)   C10A N1A C1A C7A 47.71(18) 
C10 N1 C9 O4 
-
179.43(14) 
  C10A N1A C9A O4A 
-
178.90(14) 
C10 N1 C9 C11 0.50(15)   C10A N1A C9A C11A 1.15(16) 
C10 C12 C13 C14 
-
179.27(14) 
  C10A C12A C13A C14A 
-
177.97(14) 
C11 C12 C13 C14 0.4(2)   C11A C12A C13A C14A -0.2(2) 
C12 C11 C16 C15 -0.4(2)   C12A C11A C16A C15A -0.4(2) 
C12 C13 C14 C15 -0.7(2)   C12A C13A C14A C15A -0.3(2) 
C13 C14 C15 C16 0.4(2)   C13A C14A C15A C16A 0.5(2) 
C14 C15 C16 C11 0.1(2)   C14A C15A C16A C11A -0.2(2) 
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C16 C11 C12 C10 179.89(13)   C16A C11A C12A C10A 178.78(13) 
C16 C11 C12 C13 0.2(2)   C16A C11A C12A C13A 0.6(2) 
  
Table 8 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1y5.  
Atom x y z U(eq) 
H1 210(30) 2630(20) -2501(13) 47(6) 
H3 6420(30) 930(20) -327(14) 50(6) 
H1A 3689 3836 -298 24 
H2 698 4384 -437 27 
H3A -358 3708 -1484 28 
H4 1692 1151 -1309 28 
H5 3368 3259 -2309 28 
H6 5522 3190 -1419 26 
H7 3446 1121 -532 24 
H8A -123 1593 -219 33 
H8B -1629 2922 -279 33 
H13 3272 4283 2561 29 
H14 2750 2769 3646 32 
H15 1963 629 3570 33 
H16 1700 -106 2412 29 
H1AA 10220(40) 4550(30) 6614(17) 78(9) 
H3AA 4600(30) 4180(30) 4359(15) 56(7) 
H1AB 6376 1231 5099 25 
H2A 9254 649 5374 27 
H3AB 10188 1656 6334 27 
H4A 8457 4247 5803 26 
H5A 6488 2576 6975 27 
H6A 4423 2377 6083 28 
H7A 6718 4054 5023 25 
H8AA 11771 1933 5133 33 
H8AB 10445 3312 4881 33 
H13A 8611 4464 2164 29 
H14A 8031 3557 1088 33 
H15A 6978 1442 1176 32 
H16A 6425 173 2345 28 
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Table 1 Crystal data and structure refinement for (±)-II-58.  
Identification code  don1z  
Empirical formula  C16H13NO4  
Formula weight  283.27  
Temperature/K  100.00(10)  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  14.7396(2)  
b/Å  8.13114(12)  
c/Å  21.9186(3)  
α/°  90.00  
β/°  104.2876(16)  
γ/°  90.00  
Volume/Å
3
  2545.69(7)  
Z  8  
ρcalcmg/mm
3
  1.478  
m/mm
-1
  0.107  
F(000)  1184.0  
Crystal size/mm
3
  0.2983 × 0.1942 × 0.1143  
2Θ range for data collection  6.04 to 58°  
Index ranges  -19 ≤ h ≤ 20, -10 ≤ k ≤ 10, -29 ≤ l ≤ 29  
Reflections collected  14590  
Independent reflections  3106[R(int) = 0.0264]  
Data/restraints/parameters  3106/0/195  
Goodness-of-fit on F
2
  1.085  
Final R indexes [I>=2σ (I)]  R1 = 0.0404, wR2 = 0.0942  
Final R indexes [all data]  R1 = 0.0466, wR2 = 0.0982  
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Largest diff. peak/hole / e Å
-3
  0.38/-0.24  
 
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for don1z. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 1235.1(7) 2548.0(15) 3312.2(5) 23.8(3) 
O2 4301.5(7) -1803.5(13) 3186.5(5) 17.7(2) 
O3 6019.3(7) 2399.6(14) 3282.7(5) 21.7(3) 
O4 5646.3(7) -1276.0(13) 4788.5(5) 17.3(2) 
N1 5571.9(8) 612.2(15) 3984.1(5) 12.5(2) 
C1 4546.9(9) 746.4(17) 3792.9(6) 12.2(3) 
C2 4234.2(9) 2498.5(17) 3839.7(7) 13.7(3) 
C3 3216.2(10) 2852.6(18) 3530.6(7) 15.2(3) 
C4 2669.8(10) 1476.8(18) 3180.5(6) 14.5(3) 
C5 3076.7(10) 151.0(18) 2994.9(6) 15.4(3) 
C6 4122.6(9) -80.2(17) 3153.3(7) 14.1(3) 
C7 3995.1(10) 3626.0(18) 3282.8(7) 17.3(3) 
C8 1644.6(10) 1505.7(19) 3082.8(7) 17.3(3) 
C9 6212(1) 1533.6(17) 3746.1(7) 14.3(3) 
C10 6027.4(9) -326.4(17) 4506.4(6) 12.9(3) 
C11 7149.4(10) 1208.0(17) 4178.9(7) 14.5(3) 
C12 7035.7(9) 100.8(17) 4635.7(7) 13.5(3) 
C13 7779.1(10) -422.8(19) 5112.8(7) 17.6(3) 
C14 8658.9(10) 224.1(19) 5119.2(8) 21.0(3) 
C15 8778.8(10) 1323.9(19) 4660.1(8) 21.4(3) 
C16 8020.3(10) 1836.2(18) 4177.4(7) 18.9(3) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for don1z. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
O1 15.0(5) 28.5(6) 27.2(6) -7.8(5) 3.8(4) 5.6(4) 
O2 13.2(5) 13.6(5) 25.8(6) -4.2(4) 3.9(4) 2.6(4) 
O3 20.5(5) 25.3(6) 20.3(5) 7.9(5) 7.1(4) 0.2(4) 
O4 15.6(5) 17.7(5) 19.1(5) 5.2(4) 5.1(4) 0.1(4) 
N1 10.1(5) 13.9(6) 13.5(6) 0.9(4) 2.7(4) -0.2(4) 
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C1 9.4(6) 13.9(6) 12.9(6) 0.1(5) 2.3(5) 0.6(5) 
C2 12.4(6) 13.3(7) 14.5(6) -0.5(5) 1.9(5) 0.8(5) 
C3 13.5(6) 14.4(7) 17.3(7) -1.7(5) 3.1(5) 3.1(5) 
C4 13.2(6) 17.4(7) 12.3(6) -0.4(5) 1.7(5) 2.5(5) 
C5 12.1(6) 18.4(7) 14.2(6) -2.5(5) 0.6(5) 0.3(5) 
C6 13.4(6) 14.2(7) 14.5(6) -2.3(5) 3.1(5) 2.0(5) 
C7 17.5(7) 14.8(7) 19.1(7) 2.6(6) 3.6(5) 1.5(5) 
C8 14.5(6) 20.5(7) 15.2(7) -1.8(6) 0.1(5) 2.1(6) 
C9 13.5(6) 13.9(7) 16.6(7) -1.6(5) 5.7(5) -0.7(5) 
C10 12.7(6) 12.5(6) 13.5(6) -1.7(5) 2.8(5) 1.7(5) 
C11 13.7(6) 12.5(6) 17.5(7) -3.6(5) 4.4(5) 0.7(5) 
C12 12.4(6) 11.6(6) 16.6(7) -3.7(5) 3.8(5) 0.2(5) 
C13 15.6(7) 16.3(7) 18.8(7) -3.3(6) 0.7(5) 2.4(5) 
C14 13.9(7) 18.7(7) 26.9(8) -7.6(6) -1.8(6) 2.9(6) 
C15 11.6(6) 18.3(7) 34.0(9) -8.7(6) 5.3(6) -2.2(6) 
C16 16.7(7) 14.8(7) 26.7(8) -3.6(6) 8.5(6) -2.0(6) 
  
Table 4 Bond Lengths for don1z. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C8 1.2187(18)   C3 C7 1.522(2) 
O2 C6 1.4243(17)   C4 C5 1.345(2) 
O3 C9 1.2107(18)   C4 C8 1.4732(19) 
O4 C10 1.2107(17)   C5 C6 1.5061(19) 
N1 C1 1.4689(17)   C9 C11 1.4941(19) 
N1 C9 1.4023(17)   C10 C12 1.4839(19) 
N1 C10 1.4015(17)   C11 C12 1.387(2) 
C1 C2 1.5087(19)   C11 C16 1.382(2) 
C1 C6 1.5413(19)   C12 C13 1.382(2) 
C2 C3 1.5139(19)   C13 C14 1.396(2) 
C2 C7 1.4975(19)   C14 C15 1.390(2) 
C3 C4 1.478(2)   C15 C16 1.400(2) 
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Table 5 Bond Angles for don1z. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C9 N1 C1 126.38(12)   C2 C7 C3 60.17(9) 
C10 N1 C1 121.68(11)   O1 C8 C4 123.08(14) 
C10 N1 C9 111.36(11)   O3 C9 N1 125.65(13) 
N1 C1 C2 111.14(11)   O3 C9 C11 128.64(13) 
N1 C1 C6 112.65(11)   N1 C9 C11 105.70(12) 
C2 C1 C6 114.29(11)   O4 C10 N1 125.13(12) 
C1 C2 C3 115.78(12)   O4 C10 C12 128.38(13) 
C7 C2 C1 122.49(12)   N1 C10 C12 106.49(11) 
C7 C2 C3 60.72(9)   C12 C11 C9 108.42(12) 
C2 C3 C7 59.11(9)   C16 C11 C9 130.30(14) 
C4 C3 C2 116.19(12)   C16 C11 C12 121.28(13) 
C4 C3 C7 119.33(12)   C11 C12 C10 107.92(12) 
C5 C4 C3 122.51(13)   C13 C12 C10 129.95(13) 
C5 C4 C8 119.14(13)   C13 C12 C11 122.13(13) 
C8 C4 C3 118.12(12)   C12 C13 C14 116.90(14) 
C4 C5 C6 122.54(13)   C15 C14 C13 121.27(14) 
O2 C6 C1 110.74(11)   C14 C15 C16 121.21(14) 
O2 C6 C5 107.49(11)   C11 C16 C15 117.20(14) 
C5 C6 C1 108.53(11)           
  
Table 6 Hydrogen Bonds for don1z.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O2 H2 O1
1
 0.91(2) 1.94(2) 2.8442(14) 174(2) 
11/2+X,-1/2+Y,+Z 
  
Table 7 Torsion Angles for don1z. 
A B C D Angle/˚   A B C D Angle/˚ 
O3 C9 C11 C12 
-
178.35(15) 
  C4 C5 C6 C1 31.07(19) 
O3 C9 C11 C16 2.4(3)   C5 C4 C8 O1 169.66(14) 
O4 C10 C12 C11 178.34(14)   C6 C1 C2 C3 38.99(16) 
O4 C10 C12 C13 -2.3(3)   C6 C1 C2 C7 -31.36(18) 
N1 C1 C2 C3 167.85(11)   C7 C2 C3 C4 109.99(14) 
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N1 C1 C2 C7 97.51(15)   C7 C3 C4 C5 50.1(2) 
N1 C1 C6 O2 63.26(15)   C7 C3 C4 C8 
-
135.43(14) 
N1 C1 C6 C5 
-
178.97(11) 
  C8 C4 C5 C6 
-
171.63(13) 
N1 C9 C11 C12 1.52(15)   C9 N1 C1 C2 -53.34(17) 
N1 C9 C11 C16 
-
177.76(14) 
  C9 N1 C1 C6 76.40(17) 
N1 C10 C12 C11 -2.35(15)   C9 N1 C10 O4 
-
177.24(13) 
N1 C10 C12 C13 177.00(14)   C9 N1 C10 C12 3.43(15) 
C1 N1 C9 O3 -11.9(2)   C9 C11 C12 C10 0.51(15) 
C1 N1 C9 C11 168.21(12)   C9 C11 C12 C13 
-
178.91(13) 
C1 N1 C10 O4 11.0(2)   C9 C11 C16 C15 178.41(14) 
C1 N1 C10 C12 
-
168.36(11) 
  C10 N1 C1 C2 117.14(14) 
C1 C2 C3 C4 -4.41(18)   C10 N1 C1 C6 
-
113.11(14) 
C1 C2 C3 C7 
-
114.40(14) 
  C10 N1 C9 O3 176.77(14) 
C1 C2 C7 C3 103.53(14)   C10 N1 C9 C11 -3.10(15) 
C2 C1 C6 O2 
-
168.63(11) 
  C10 C12 C13 C14 
-
178.84(14) 
C2 C1 C6 C5 -50.86(15)   C11 C12 C13 C14 0.4(2) 
C2 C3 C4 C5 -17.6(2)   C12 C11 C16 C15 -0.8(2) 
C2 C3 C4 C8 156.90(13)   C12 C13 C14 C15 -0.9(2) 
C3 C4 C5 C6 2.8(2)   C13 C14 C15 C16 0.6(2) 
C3 C4 C8 O1 -5.0(2)   C14 C15 C16 C11 0.3(2) 
C4 C3 C7 C2 
-
104.70(14) 
  C16 C11 C12 C10 179.86(13) 
C4 C5 C6 O2 150.88(13)   C16 C11 C12 C13 0.4(2) 
  
Table 8 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for don1z.  
Atom x y z U(eq) 
H2 4921(15) -1960(30) 3207(9) 33(5) 
H1 4309 109 4112 15 
H2A 4488 3046 4255 16 
H3 2879 3595 3765 18 
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H5 2690 -672 2754 18 
H6 4388 427 2819 17 
H7A 4090 3213 2878 21 
H7B 4117 4815 3358 21 
H8 1286 673 2829 21 
H13 7695 -1187 5422 21 
H14 9186 -94 5444 25 
H15 9387 1736 4674 26 
H16 8101 2584 3862 23 
 
